

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2002210917 B2**

(54) Title
Degraded TPO agonist antibody

(51) International Patent Classification(s)
C12N 15/09 (2006.01) **C07K 16/28** (2006.01)
C07K 16/24 (2006.01)

(21) Application No: **2002210917** (22) Date of Filing: **2001.10.22**

(87) WIPO No: **WO02/33072**

(30) Priority Data

(31) Number	(32) Date	(33) Country
2000-321821	2000.10.20	JP
2001-277314	2001.09.12	JP
JP01/03288	2001.04.17	WO

(43) Publication Date: **2002.04.29**

(43) Publication Journal Date: **2002.07.04**

(44) Accepted Journal Date: **2006.05.18**

(71) Applicant(s)
Chugai Seiyaku Kabushiki Kaisha

(72) Inventor(s)
Ohtomo, Toshihiko;Tsunoda, Hiroyuki;Tsuchiya, Masayuki;Orita, Tetsuro;Yabuta, Naohiro

(74) Agent / Attorney
Griffith Hack, Level 29 Northpoint Tower 100 Miller Street, North Sydney, NSW, 2060

(56) Related Art
Int. J. Cancer, 77(5): 763-72, 1988
WO 99/03495
Blood, 92(6): 1981-88, 1998

(12)特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2002年4月25日 (25.04.2002)

PCT

(10) 国際公開番号
WO 02/33072 A1

- (51) 国際特許分類: C12N 15/09, 15/62, [JP/JP]; 〒300-4101 茨城県新治郡新治村永井153-2 中外製薬株式会社内 Ibaraki (JP).
C07K 16/28, A61K 39/395
- (21) 国際出願番号: PCT/JP01/09259 (74) 代理人: 高木千嘉, 外(TAKAGI, Chiyoshi et al.); 〒102-0083 東京都千代田区麹町一丁目10番地 麹町広洋ビル Tokyo (JP).
- (22) 国際出願日: 2001年10月22日 (22.10.2001)
- (25) 国際出願の言語: 日本語 (81) 指定国 (国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (26) 国際公開の言語: 日本語 (84) 指定国 (広域): ARIPO 特許 (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), ユーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (30) 優先権データ:
特願2000-321821 2000年10月20日 (20.10.2000) JP
PCT/JP01/03288 2001年4月17日 (17.04.2001) JP
特願2001-277314 2001年9月12日 (12.09.2001) JP
- (71) 出願人 (米国を除く全ての指定国について): 中外製薬株式会社 (CHUGAI SEIYAKU KABUSHIKI KAISHA) [JP/JP]; 〒115-8543 東京都北区浮間5丁目5番1号 Tokyo (JP).
- (72) 発明者; および
(75) 発明者/出願人 (米国についてのみ): 土屋政幸 (TSUCHIYA, Masayuki) [JP/JP], 大友俊彦 (OHTOMO, Toshihiko) [JP/JP]; 〒412-8513 静岡県御殿場市駒門1丁目135番地 中外製薬株式会社内 Shizuoka (JP), 藪田尚弘 (YABUTA, Naohiro) [JP/JP], 角田浩行 (TSUNODA, Hiroyuki) [JP/JP], 織田哲郎 (ORITA, Tetsuro)
- 添付公開書類:
— 国際調査報告書
- 2文字コード及び他の略語については、定期発行される各PCTガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。



WO 02/33072 A1

(54) Title: DEGRADED TPO AGONIST ANTIBODY

(54) 発明の名称: 低分子化TPOアゴニスト抗体

(57) Abstract: A modified antibody containing at least two H chain V domains and at least two L chain V domains of a monoclonal antibody which transduces a signal into cells by crosslinking a TPO receptor to thereby exert TPO agonism. Because of being usable as a TPO signal transduction agonist, this modified antibody is useful as a preventive and/or a remedy for blood diseases in which platelet reduction participates, thrombopenia following chemotherapy for cancer or leukemia, etc.

(57) 要約:

本発明は、TPOレセプターを架橋することにより細胞内にシグナル伝達してTPOアゴニスト作用を奏しうる、モノクローナル抗体のH鎖V領域を2つ以上及びL鎖V領域を2つ以上含む改変抗体に関する。この改変抗体は、TPOによるシグナル伝達のアゴニストとして使用することができ、血小板減少が関与する血液疾患、癌や白血病等の化学治療後の血小板減少症などの予防及び/又は治療薬等として有用である

VERIFICATION OF TRANSLATION

I, **Shoji MIWA**, a patent attorney of c/o Subaru Patent Office of Kojimachi Koyo Bldg., 10, Kojimachi 1-chome Chiyoda-ku, Tokyo, Japan, hereby certify that I know well both the Japanese and English languages, that to the best of my knowledge and belief the attached English translation is a true translation, made by me and for which I accept responsibility, of the description, claims, abstract and drawing of **International Application No. PCT/JP01/09259** filed on **October 22, 2001**, annexed hereto.

Signature of translator:



Shoji MIWA

Dated this 10th day of March, 2003.

DEGRADED TPO AGONIST ANTIBODY**TECHNICAL FIELD**

This invention relates to modified antibodies
5 containing two or more H chain V regions and two or more L
chain V regions of an antibody which show TPO agonist
activity by crosslinking TPO receptor. The modified
antibodies have TPO agonist activity of transducing a signal
into cells by crosslinking TPO receptor and are useful as a
10 medicine for various purposes.

BACKGROUND ART

Thrombopoietin (TPO) is a platelet production
regulation factor found in 1994 and is known to be composed
15 of a glycoprotein having a molecular weight of 70-80
thousands produced mainly in liver. Thrombopoietin is a
cytokine which in bone marrow promotes platelet precursor
cells to survive, proliferate, differentiate and mature,
namely promotes megakaryocytes to differentiate and
20 proliferate. Thrombopoietin (TPO) receptor was identified
earlier than TPO as c-Mpl, a receptor of a specific factor
to regulate platelet production (M. Souyri et al., Cell 63:
1137 (1990)). It was reported that c-Mpl is distributed
mainly in platelet precursor cells, megakaryocytes and
25 platelet cells and that the suppression of c-Mpl expression
inhibits selectively megakaryocyte formation (M. Methia et
al., Blood 82: 1395 (1993)). It was reported that the ligand

to c-Mpl is TPO based on the results of proliferation assay of cells specific to c-Mpl ligand and purification of the ligand using c-Mpl (F. de Sauvage et al., Nature 369: 533 (1994); TD. Bartley et al., Cell 77: 1117 (1994)). At present Mpl is called TPO receptor. Therefore TPO and TPO receptor agonists have been expected to work as a therapeutic agent for thrombocytopenia, for example, as a medicine alleviating thrombocytopenia caused by bone marrow inhibition or bone marrow resection therapy for cancer patients.

On the other hand modified antibodies, especially antibodies with lowered molecular size, for example, single chain Fvs were developed to improve permeability into tissues and tumors by lowering molecular size and to produce by a recombinant method. Recently the dimers of single chain Fvs, especially bispecific-dimers have been used for crosslinking cells. Typical examples of such dimers are hetero-dimers of single chain Fvs recognizing antigens of cancer cells and antigens of host cells like NK cells and neutrophils (Kipriyanov et al., Int. J. Cancer, 77, 9763-9772, 1998). They were produced by construction technique of single chain Fv as modified antibodies, which are more effective in treating cancers by inducing intercellular crosslinking. It has been thought that the intercellular crosslinking is induced by antibodies and their fragments (e.g. Fab fragment), bispecific modified antibodies and even dimers of single chain Fvs, which are monospecific.

As antibodies capable of transducing a signal by crosslinking a cell surface molecule(s), there are known an antibody against EPO receptor involved in cell differentiation and proliferation (JP-A 2000-95800), an antibody against MuSK receptor (Xie et al., Nature Biotech. 15, 768-771, 1997) and others. There are also known an agonist antibody to TPO receptor, its fragments and single chain Fvs (WO99/17364). However there have been no reports on single chain Fv dimers and modified antibodies such as single chain bivalent antibodies having agonist activity.

Noticing that single chain Fv monomers derived from monoclonal antibodies (antibody MABL-1 and antibody MABL-2 produced by the inventors) which induce apoptosis of IAP-containing cells do not induce apoptosis of cells and that dimers induce apoptosis, the inventors discovered that dimers crosslink (dimerize) IAP receptor on cell surface, thereby a signal is transduced into the cells and, as a result, apoptosis is induced. This suggests that monospecific single chain Fv dimers crosslink a cell surface molecule(s) (e.g. receptor) and transduce a signal like a ligand, thereby serving as an agonist.

Focusing on the intercellular crosslinking, it was discovered that the above-mentioned single chain Fv dimers do not cause hemagglutination while the above-mentioned monoclonal antibodies do. The same result was also observed with single chain bivalent antibodies (single chain polypeptides containing two H chain V regions and two L

chain V regions). This suggests that monoclonal antibodies may form intercellular crosslinking while modified antibodies like single chain Fv dimers and single chain bivalent antibodies crosslink a cell surface molecule(s) but do not form intercellular crosslinking.

Based on those observations the inventors have newly discovered that modified antibodies such as single chain Fv dimers and single chain bivalent antibodies crosslink a cell surface molecule(s) or intracellular molecule(s) of the same cell, in addition to known intercellular crosslinking, and are suitable as a ligand to the molecule(s) (especially as a ligand which mimics the action of natural ligand).

Discovering further that an antibody molecule (whole IgG) can be modified into single chain Fv dimers, single chain bivalent antibodies and the like which crosslink a cell surface molecule(s), thereby reducing side effects caused by intercellular crosslinking and providing new medicines inducing only desired effect on the cell, the inventors completed the invention. The modified antibodies of the invention have remarkably high activity compared with whole antibodies (IgG) having the same V region as the modified antibodies. They have an improved permeability into tissues due to the lowered molecular size compared with antibody molecules and the lack of constant regions.

DISCLOSURE OF INVENTION

It would be advantageous if at least preferred
embodiments of the present invention were to provide low
molecular-sized agonistic modified antibodies which
contain two or more H chain V regions and two or more L
5 chain V regions of a monoclonal antibody and have TPO
agonist action by crosslinking TPO receptor.

In a first aspect, the present invention provides a
modified antibody comprising two or more H chain V regions
and two or more L chain V regions of antibody and showing
10 TPO agonist action by crosslinking TPO receptor, wherein
the modified antibody is:

- (i) a multimer of single chain Fv comprising an H
chain V region and an L chain V region; or
- (ii) a single chain polypeptide comprising two or
15 more H chain V regions and two or more L chain V regions.

Therefore, this invention relates the modified
antibodies which contain two or more H chain V regions and
two or more L chain V regions, preferably 2 to 6 each,
especially preferably 2 to 4 each, most preferably two
20 each, and show TPO agonist activity by crosslinking TPO
receptor.

The "modified antibodies" in the specification mean
any substances which contain two or more H chain V regions
and two or more L chain V regions, wherein said V regions
25 are combined directly or via linker through covalent bond
or non-covalent bond. For example, polypeptides and
compounds produced by combining each V region of antibody
through a peptide linker or a chemical crosslinking agent
and the like. Two or more H chain V regions and two or
30 more L chain V regions used in the invention can be
derived from the same antibody or from different
antibodies.

Modified antibodies of the invention can be any

things as long as they comprise two or more H chain V regions and two or more L chain V regions of antibody, when the modified antibody is: (i) a multimer of single chain Fv comprising an H chain V region and an L chain V region; or (ii) a single chain polypeptide comprising two or more H chain V regions and two or more L chain V regions, and specifically recognize and crosslink TPO receptor and thereby can transduce a signal into cells. They include modified antibodies produced by further modifying a part of the amino acid sequence of V region of the modified antibodies.

The modified antibodies of the invention may be multimers such as dimers, trimers or tetramers of single chain Fv containing an H chain V region and an L chain V region, or single chain polypeptides containing two or more H chain V regions and two or more L chain V regions. When the modified antibodies of the invention are multimers of single chain Fv such as dimers, trimers, tetramers and the like containing an H chain V region and an L chain V region, it is preferable that the H chain V region and L chain V region existing in the same chain are not associated to form an antigen-binding site.

More preferable examples are dimers of the single chain Fv which contains an H chain V region and an L chain V region, or a single chain polypeptide containing two H chain V regions and two L chain V regions. The H chain V region and L chain V region are connected preferably through a linker in the modified antibodies.

The above-mentioned single chain Fv multimer includes a multimer by non-covalent bond, a multimer by a covalent bond through a crosslinking radical and a multimer through a crosslinking reagent (an antibody, an antibody fragment,

2002210917 10 Mar 2006

5

-6a-

or bivalent modified antibody). Conventional crosslinking radicals used for crosslinking peptides can be used as the crosslinking radicals to form the multimers. Examples are disulfide crosslinking by cysteine residue, other crosslinking radicals such as C₄ - C₁₀ alkylene (e.g. tetramethylene, pentamethylene, hexamethylene,

heptamethylene and octamethylene, etc.) or C₄ - C₁₀ alkenylene (cis/trans -3-butenylene, cis/trans-2-pentenylene, cis/trans-3-pentenylene, cis/trans-3-hexenylene, etc.).

Moreover, the crosslinking reagent which can combine with a single chain Fv is, for example, an amino acid sequence which can optionally be introduced into Fv, for example, an antibody against FLAG sequence and the like or a fragment thereof, or a modified antibody originated from the antibody, for example, single chain Fv.

"TPO agonist action" in the specification means a biological action occurring in the cell(s) into which a signal is transduced by crosslinking TPO receptor, for example, proliferation, differentiation or growth stimulation of megakaryocytes, or platelet production.

ED50 of the TPO agonist action in the invention is determined by known methods for measuring agonist action. Examples for measurement are cell proliferation assay using TPO sensitive cell lines such as BaF/mpl or UT7/TPO, measurement of phosphorylation of MPL protein, megakaryocyte colony assay by differentiation from bone marrow cells, in vivo mouse platelet recovery synthesis assay, measurement of expression induction of platelet antigen GPIIbIIIa (anti GPIIbIIIa) using human leukemia megakaryoblastic cell line (CMK) or measurement of polyploidy induction of megakaryoblastic cell line (DAMI). ED50 is a dose needed for achieving 50% reaction of the maximum activity set as 100% in the dose-reaction curve.

Preferable modified antibodies of the invention have TPO agonist action (ED50) equivalent to or better than that of an antibody having the same antigen-binding region as the modified antibody, namely the whole antibody (hereinafter "parent antibody") like IgG having the same pair of H chain V region and L chain V region as the pair of H chain V region and L chain V region forming antigen-binding region of the modified antibody. More preferable are those having TPO agonist action (ED50) more than two times higher than that of parent antibody, further preferably more than 5 times, most preferably more than 10 times. The invention includes modified antibodies with TPO agonist action containing H chain V region and L chain V region forming the same antigen-binding region as the parent antibody which binds to TPO receptor but has no TPO agonist action to the molecule.

In a second aspect, the present invention provides a compound comprising two or more H chain V regions and two or more L chain V regions of monoclonal antibody and showing an equivalent or better agonist action (ED50) compared with thrombopoietin (TPO).

The compounds containing two or more H chain V regions and two or more L chain V regions of the invention can be any compounds which contain two or more H chain V regions and two or more L chain V regions of antibody and show TPO agonist action (ED50) equivalent to or better than that of thrombopoietin (TPO). Preferable are those having TPO agonist action (ED50) more than two times higher than that of TPO, more preferably more than 5 times, most preferably more than 10 times.

The "compounds" mentioned here include not only modified antibodies of the invention but also any compounds containing two or more, preferably from 2 to 6,

more preferably from 2 to 4, most preferably 2 antigen-binding regions such as whole antibodies or F(ab')₂.

5 Preferable modified antibodies or compounds of the invention containing two or more H chain V regions and two or more L chain V regions of antibody have an intercellular adhesion action (ED50) not more than 1/10 compared with the parent antibody, more preferably have no substantial intercellular adhesion action.

10 ED50 of the intercellular adhesion action mentioned in the above is determined by known methods for measuring intercellular adhesion action, for example, by the measurement of agglomeration of cells expressing TPO receptor.

15 The invention also relates to DNAs which encode for the modified antibodies or compounds.

In a third aspect, the invention provides a DNA which encodes the modified antibody of the first aspect, or compound of the second aspect.

20 The invention relates to animal cells or microorganisms which produce the modified antibodies or compounds.

In a fourth aspect, the invention provides an animal cell which produces a modified antibody of the first aspect, or a compound of the second aspect.

25 In a fifth aspect, the invention provides a microorganism which produces a modified antibody of the first aspect, or a compound of the second aspect.

The invention relates to use of the modified antibody or compound as TPO agonist.

30 In a sixth aspect, the invention provides use of a modified antibody of the first aspect, or a compound of the second aspect, as TPO agonist.

The invention also relates to a method of causing

agonist action to cells by crosslinking TPO receptor using the modified antibody or compound and thereby transducing a signal into cells.

5 In a seventh aspect, the invention provides a method of causing an agonist action to cells by crosslinking TPO receptor using the modified antibody of the first aspect or the compound of the second aspect, thereby transducing a signal into cells.

10 Examples of agonist action are proliferation, differentiation-induction or growth stimulation of megakaryocytes, platelet production, phosphorylation of TPO receptor protein and the like.

15 In an eighth aspect, the invention provides a medicine comprising as active ingredient the modified antibody of the first aspect or compound of the second aspect.

The medicine may be for treating thrombocytopenia etc. containing the modified antibody as active component.

20 The invention also relates to use of the modified antibody or compound as a medicine.

In a ninth aspect, the invention provides use of the modified antibody of the first aspect, or the compound of the second aspect, as medicine.

25 In a tenth aspect, the invention provides a method of screening a modified antibody comprising two or more H chain V regions and two or more L chain V regions of antibody and showing an agonist action by crosslinking TPO receptor, wherein the modified antibody is: (i) a multimer of single chain Fv comprising an H chain V region and an L chain V region; or (ii) a single chain polypeptide
30 comprising two or more H chain V regions and two or more L chain V regions, that comprises the steps 1) to produce a modified antibody containing two or more H chain V regions

and two or more L chain V regions of antibody and binding specifically to TPO receptor, 2) to subject cells expressing TPO receptor to react with the modified antibody and 3) to measure TPO agonist action in the cells caused by crosslinking TPO receptor. The method of measurement is useful for the quality control in producing the modified antibodies of the invention as a medicine and other purposes.

In an eleventh aspect, the invention provides a method of measuring an agonist action of a modified antibody comprising two or more H chain V regions and two or more L chain V regions of antibody and showing an agonist action by crosslinking TPO receptor, wherein the modified antibody is: (i) a multimer of single chain Fv comprising an H chain V region and an L chain V region; or (ii) a single chain polypeptide comprising two or more H chain V regions and two or more L chain V regions, which comprises the steps 1) to produce a modified antibody comprising two or more H chain V regions and two or more L chain V regions of antibody and binding specifically to TPO receptor, 2) to subject cells expressing said TPO receptor to react with the modified antibody and 3) to measure TPO agonist action in the cells caused by crosslinking TPO receptor.

The modified antibodies of the invention can be mono-specific modified antibodies or multi-specific modified antibodies like bi-specific modified antibodies. Preferable are mono-specific modified antibodies.

In one embodiment, the H chain V region and/or L chain V region is H chain V region derived from human antibody and/or L chain V region derived from human antibody. The H chain V region and/or L chain V region derived from human antibody can be obtained by screening

2002210917 10 Mar 2006

human monoclonal antibody library as described in WO99/10494. The H chain V region and L chain V region derived from human monoclonal antibodies produced by transgenic mouse and the like are also included.

5 In another embodiment, the H chain V regions and/or L chain V regions are humanized H chain V regions and/or humanized L chain V regions. Specifically, the humanized modified antibodies consist of the humanized L chain V region which comprises framework regions (FR) derived from
10 an L chain V region of human monoclonal antibody and complementarity determining regions (hereinafter "CDR") derived from an L chain V region of non-human mammalian (e.g. mouse, rat, bovine, sheep, ape) monoclonal antibody and/or the humanized H chain V region which comprises FR
15 derived from an H chain V region of human monoclonal antibody and CDR derived from an H chain V region of non-human mammalian (e.g. mouse, rat, bovine, sheep, ape) monoclonal antibody. In this case, the amino acid sequences of CDR and FR may be partially altered, e.g.
20 deleted, replaced or added.

H chain V regions and/or L chain V regions of the modified antibodies of the invention can be H chain V regions and/or L chain V regions derived from monoclonal antibodies of animals other than human (such as mouse,
25 rat, bovine, sheep, ape, chicken and the like). In this case, the amino acid sequence of CDR and FR may be partially altered, e.g. deleted, replaced or added.

Described herein are DNAs encoding the various modified antibodies as mentioned above and genetic
30 engineering techniques for producing recombinant vectors comprising the DNAs.

Described herein are host cells transformed with the recombinant vectors. Examples of host cells are animal

cells such as human cells, mouse cells or the like and microorganisms such as E. coli, Bacillu subtilis, yeast or the like.

5 Also described herein is a process for producing the modified antibodies, which comprises culturing the above-mentioned hosts and extracting the modified antibodies from the culture thereof.

10 Also described herein is a process for producing a dimer of the single chain Fv which comprises culturing host animal cells producing the single chain Fv in a serum-free medium to secrete the single chain Fv into the medium and isolating the dimer of the single chain Fv formed in the medium.

15 The present invention also relates to the use of the modified antibodies as TPO agonist. That is, it relates to a signal-transduction agonist which comprises as an active ingredient the modified antibody obtained as mentioned in the above.

20 Therefore, pharmaceutical preparations containing TPO agonist modified antibodies of the invention as an active ingredient are useful as preventatives and/or

remedies for platelet-reduction-related blood diseases, thrombocytopenia caused by chemotherapy of cancers or leukemia, and the like.

The modified antibodies of the present invention
5 comprise two or more H chain V regions and two or more L chain V regions derived from antibodies. The structure of the modified antibodies may be a dimer of single chain Fv comprising one H chain V region and one L chain V region or a polypeptide comprising two H chain V regions and two L
10 chain V regions. In the modified antibodies of the invention, the V regions of H chain and L chain are preferably linked through a peptide linker which consists of one or more amino acids. The resulting modified antibodies contain variable regions of antibodies and bind to the
15 antigen with the same specificity as that of the original monoclonal antibodies.

H chain V region

In the present invention, the H chain V region derived from an antibody recognizes TPO receptor and
20 oligomerizes, for example, dimerizes through crosslinking said molecule, and thereby transduces a signal into the cells. The H chain V region of the invention includes H chain V regions derived from a mammal (e.g. human, mouse, rat, bovine, sheep, ape etc.) and H chain V regions having
25 partially modified amino acid sequences of the H chain V regions. More preferable is a humanized H chain V region containing FR of H chain V region of a human monoclonal

antibody and CDR of H chain V region of a mouse monoclonal antibody. Also preferable is an H chain V region having an amino acid sequence derived from a human, which can be produced by recombination technique. The H chain V region of the invention may be a fragment of aforementioned H chain V region, which fragment preserves the antigen binding capacity.

L chain V region

In the present invention, the L chain V region recognizes TPO receptor and oligomerizes, for example, dimerizes through crosslinking said molecule, and thereby transduces a signal into the cells. The L chain V region of the invention includes L chain V regions derived from a mammal (e.g. human, mouse, rat, bovine, sheep, ape etc.) and L chain V regions having partially modified amino acid sequences of the L chain V regions. More preferable is a humanized L chain V region containing FR of L chain V region of human monoclonal antibody and CDR of L chain V region of mouse monoclonal antibodies. Also preferable is an L chain V region having an amino acid sequence derived from a human, which can be produced by recombination technique. The L chain V regions of the invention may be fragments of L chain V region, which fragments preserve the antigen binding capacity.

25 Complementarity determining region (CDR)

Each V region of L chain and H chain forms an antigen-binding site. The variable region of the L and H

chains is composed of comparatively conserved four common framework regions linked to three hypervariable regions or complementarity determining regions (CDR) (Kabat, E.A. et al., "Sequences of Protein of Immunological Interest", US Dept. Health and Human Services, 1983).

Major portions in the four framework regions (FRs) form β -sheet structures and thus three CDRs form a loop. CDRs may form a part of the β -sheet structure in certain cases. The three CDRs are held sterically close position to each other by FR, which contributes to the formation of the antigen-binding site together with three CDRs.

These CDRs can be identified by comparing the amino acid sequence of V region of the obtained antibody with known amino acid sequences of V regions of known antibodies according to the empirical rule in Kabat, E.A. et al., "Sequences of Protein of Immunological Interest".

Single chain Fv

A single chain Fv is a polypeptide monomer comprising an H chain V region and an L chain V region linked each other which are derived from antibodies. The resulting single chain Fvs contain variable regions of the original antibodies and preserve the complementarity determining region thereof, and therefore the single chain Fvs bind to the antigen by the same specificity as that of the original antibodies (JP-Appl. 11-63557). A part of the variable region and/or CDR of the single chain Fv of the invention or a part of the amino acid sequence thereof may

be partially altered, for example, deleted, replaced or added. The H chain V region and L chain V region composing the single chain Fv of the invention are mentioned before and may be linked directly or through a linker, preferably a peptide linker. The constitution of the single chain Fv may be [H chain V region]-[L chain V region] or [L chain V region]-[H chain V region]. In the present invention, it is possible to make the single chain Fv to form a dimer, a trimer or a tetramer, from which the modified antibody of the invention can be formed.

Single chain modified antibody

The single chain modified antibodies of the present invention comprising two or more H chain V regions and two or more L chain V regions, preferably each two to four, especially preferable each two, comprise two or more H chain V regions and L chain V regions as mentioned above. Each region of the peptide should be arranged such that the modified single chain antibody forms a specific steric structure, concretely mimicking a steric structure formed by the dimer of single chain Fv. For instance, the V regions are arranged in the order of the following manner:

[H chain V region]-[L chain V region]-[H chain V region]-[L chain V region]; or

[L chain V region]-[H chain V region]-[L chain V region]-[H chain V region],

wherein these regions are connected through a peptide linker, respectively.

Linker

In this invention, the linkers for the connection between the H chain V region and the L chain V region may be any peptide linker which can be introduced by the genetic engineering procedure or any linker chemically synthesized. For instance, linkers disclosed in literatures, e.g. Protein Engineering, 9(3), 299-305, 1996 may be used in the invention. These linkers can be the same or different in the same molecule. If peptide linkers are required, the following are cited as example linkers:

Ser

Gly-Ser

Gly-Gly-Ser

Ser-Gly-Gly

Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly-Gly-Gly-Gly

(Gly-Gly-Gly-Gly-Ser)_n and

(Ser-Gly-Gly-Gly-Gly)_n

wherein n is an integer not less than one. Preferable length of the linker peptide varies dependent upon the receptor to be the antigen, in the case of single chain Fvs,

the range of 1 to 20 amino acids is normally preferable. In the case of single chain modified antibodies comprising two or more H chain V regions and two or more L chain V regions, the peptide linkers connecting those forming the same antigen binding site comprising [H chain V region]-[L chain V region] (or [L chain V region]-[H chain V region]) have lengths of 1 - 30 amino acids, preferably 1 - 20 amino acids, more preferably 3 - 18 amino acids. The peptide linkers connecting those not forming the same antigen binding site comprising [H chain V region]-[L chain V region] or ([L chain V region]-[H chain V region]) have lengths of 1 - 40 amino acids, preferably 3 - 30 amino acids, more preferably 5 - 20 amino acids. The method for introducing those linkers will be described in the explanation for DNA construction coding for modified antibodies of the invention.

The chemically synthesized linkers, i.e. the chemical crosslinking agents, according to the invention can be any linkers conventionally employed for the linkage of peptides. Examples of the linkers may include N-hydroxy succinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl)suberate (BS³), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycolbis(succinimidyl succinate) (EGS), ethylene glycolbis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimido oxycarbonyloxy)ethyl]sulfone (BSOCOES), bis[2-(sulfosuccinimido oxycarbonyloxy)

ethyl)sulfone (sulfo-BSOCOES) or the like. These are commercially available. It is preferable for the chemically synthesized linkers to have the length equivalent to that of peptide linkers.

5 To form a dimer of the single chain Fv it is preferable to select a linker suitable to dimerize in the solution such as culture medium more than 20%, preferably more than 50%, more preferably more than 80%, most preferably more than 90% of the single chain Fv produced in
10 the host cells. Specifically, preferable is a linker composed of 2 to 12 amino acids, preferably 3 to 10 amino acids or other linkers corresponding thereto.

Preparation of modified antibodies

The modified antibodies can be produced by
15 connecting, through the aforementioned linker, an H chain V region and an L chain V region derived from known or novel antibodies specifically binding to TPO receptor. As examples of the single chain Fvs are cited those having H chain V region and L chain V region of antibody 12B5 and antibody
20 12E10 described in WO99/10494. As examples of the modified antibodies of the invention having two or more H chain V regions and two or more L chain V regions are cited sc12B5 dimer (linker: 15 amino acids), sc12E10 dimer (linker: 15 amino acids), db12B5 dimer (linker: 5 amino acids), db12E10
25 dimer (linker: 5 amino acids), sc12B5sc(FV)₂ and sc12E10sc(FV)₂ which contain H chain V regions and L chain V

regions derived from the above-mentioned monoclonal antibodies.

For the preparation of the modified antibodies, a signal peptide may be attached to its N-terminal if the polypeptide is desired to be a secretory peptide. A well-known amino acid sequence useful for the purification of polypeptide such as the FLAG sequence may be attached for the efficient purification of the polypeptide. In this case a dimer can be formed by using anti-FLAG antibody.

For the preparation of the modified antibody of the invention, it is necessary to obtain a DNA, i.e. a DNA encoding the single chain Fv or a DNA encoding reconstructed single chain polypeptide. These DNAs, especially for sc12B5, db12B5, sc12E10 and/or db12E10 are obtainable from the DNAs encoding the H chain V regions and the L chain V regions derived from said Fvs. They are also obtainable by polymerase chain reaction (PCR) method using those DNAs as a template and amplifying the part of DNA contained therein encoding desired amino acid sequence with the aid of a pair of primers corresponding to both ends thereof.

In the case where each V region having partially modified amino acid sequence is desired, the V regions in which one or some amino acids are modified, i.e. deleted, replaced or added can be obtained by a procedure known in the art using PCR. A part of the amino acid sequence in the V region is preferably modified by the PCR known in the art

in order to prepare the modified antibody which is sufficiently active against the specific antigen.

For the determination of primers for the PCR amplification, the types of H chain and L chain, if a
5 monoclonal antibody is used as a starting material, are determined by a typing method known in the technical field.

For the amplification of the L chain V regions of antibody 12B5 and antibody 12E10 by PCR, 5'-end and 3'-end oligonucleotide primers are decided as aforementioned. In
10 the same manner, 5'-end and 3'-end oligonucleotide primers are decided for the amplification of the H chain V regions of antibody 12B5 and antibody 12E10.

In embodiments of the invention, the 5'-end primers which contain a sequence "GATC" providing the
15 restriction enzyme Hinf I recognition site at the neighborhood of 5'-terminal thereof are used and the 3'-end primers which contain a nucleotide sequence "CCCGG" providing the XmaI recognition site at the neighborhood of 5'-terminal thereof are used. Other restriction enzyme
20 recognition site may be used instead of these sites as long as they are used for subcloning a desired DNA fragment into a cloning vector.

Specifically designed PCR primers are employed to provide suitable nucleotide sequences at 5'-end and 3'-end
25 of the cDNAs encoding the V regions of the antibodies 12B5 and 12E10 so that the cDNAs are readily inserted into an expression vector and appropriately function in the

expression vector (e.g. this invention devises to increase transcription efficiency by inserting Kozak sequence). The V regions of the antibodies 12B5 and 12E10 obtained by amplifying by PCR using these primers are inserted into HEF
5 expression vector containing the desired human C region (see W092/19759). The cloned DNAs can be sequenced by using any conventional process, for example, by the automatic DNA sequencer (Applied Biosystems).

A linker such as a peptide linker can be
10 introduced into the modified antibody of the invention in the following manner. Primers which have partially complementary sequence with the primers for the H chain V regions and the L chain V regions as described above and which code for the N-terminal or the C-terminal of the
15 linker are designed. Then, the PCR procedure can be carried out using these primers to prepare a DNA encoding the peptide linker having desired amino acid sequence and length. The DNAs encoding the H chain V region and the L chain V region can be connected through the resulting DNA to
20 produce the DNA encoding the modified antibody of the invention which has the desired peptide linker. Once the DNA encoding one of the modified antibodies is prepared, the DNAs encoding the modified antibodies with or without the desired peptide linker can readily be produced by designing
25 various primers for the linker and then carrying out the PCR using the primers and the aforementioned DNA as a template.

Each V region of the modified antibody of the present invention can be humanized by using conventional techniques (e.g. Sato, K. et al., Cancer Res., 53, 1-6 (1993)). Once a DNA encoding each of humanized Fvs is prepared, a humanized single chain Fv, a fragment of the humanized single chain Fv, a humanized monoclonal antibody and a fragment of the humanized monoclonal antibody can readily be produced according to conventional methods. Preferably, amino acid sequences of the V regions thereof may be partially modified, if necessary.

Furthermore, a DNA derived from other mammalian origin, for example a DNA encoding each of V regions of human antibody, can be produced in the same manner as used to produce DNA encoding the H chain V region and the L chain V region derived from mouse by conventional methods as mentioned in the above. The resulting DNA can be used to prepare an H chain V region and an L chain V region of other mammal, especially derived from human antibody, a single chain Fv derived from human and a fragment thereof, and a monoclonal antibody of human origin and a fragment thereof.

When the modified antibodies of the invention is bi-specific modified antibodies, they can be produced by known methods (for example, the method described in WO9413804).

As mentioned above, when the aimed DNAs encoding the V regions of the modified antibodies and the V regions of the humanized modified antibodies are prepared, the

expression vectors containing them and hosts transformed with the vectors can be obtained according to conventional methods. Further, the hosts can be cultured according to a conventional method to produce the reconstructed single chain Fv, the reconstructed humanized single chain Fv, the humanized monoclonal antibodies and fragments thereof. They can be isolated from cells or a medium and can be purified into a homogeneous mass. For this purpose any isolation and purification methods conventionally used for proteins, e.g. chromatography, ultra-filtration, salting-out and dialysis, may be employed in combination, if necessary, without limitation thereto.

When the reconstructed single chain Fv of the present invention is produced by culturing an animal cell such as COS7 cells or CHO cells, preferably CHO cells, in a serum-free medium, the dimer of said single chain Fv formed in the medium can be stably recovered and purified in a high yield. Thus purified dimer can be stably preserved for a long period. The serum-free medium employed in the invention may be any medium conventionally used for the production of a recombinant protein without limit thereto.

For the production of the modified antibodies of the present invention, any expression systems can be employed, for example, eukaryotic cells such as animal cells, e.g., established mammalian cell lines, filamentous fungi and yeast, and prokaryotic cells such as bacterial cells e.g., E. coli. Preferably, the modified antibodies of

the invention are expressed in mammalian cells, for example COS7 cells or CHO cells.

In these cases, conventional promoters useful for the expression in mammalian cells can be used. Preferably, human cytomegalovirus (HCMV) immediate early promoter is used. Expression vectors containing the HCMV promoter include HCMV-VH-HC γ 1, HCMV-VL-HCK and the like which are derived from pSV2neo (WO92/19759).

Additionally, other promoters for gene expression in mammal cell which may be used in the invention include virus promoters derived from retrovirus, polyoma virus, adenovirus and simian virus 40 (SV40) and promoters derived from mammal such as human polypeptide-chain elongation factor-1 α (HEF-1 α). SV40 promoter can easily be used according to the method of Mulligan, R.C., et al. (Nature 277, 108-114 (1979)) and HEF-1 α promoter can also be used according to the methods of Mizushima, S. et al. (Nucleic Acids Research, 18, 5322 (1990)).

Replication origin (ori) which can be used in the invention includes ori derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV) and the like. An expression vector may contain, as a selection marker, phosphotransferase APH (3') II or I (neo) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyl transferase (Ecogpt) gene or dihydrofolate reductase (DHFR) gene.

The antigen-binding activity of the modified antibody prepared in the above can be evaluated by a conventional method such as radio immunoassay (RIA), enzyme-linked immunosorbent assay (ELISA) or surface plasmon resonance. It can also be evaluated using the binding-inhibitory ability of original antibody as an index, for example in terms of the absence or presence of concentration-dependent inhibition of the binding of said monoclonal antibody to the antigen.

More in detail, animal cells transformed with an expression vector containing a DNA encoding the modified antibody of the invention, e.g., COS7 cells or CHO cells, are cultured. The cultured cells and/or the supernatant of the medium or the modified antibody purified from them are used to determine the binding to antigen. As a control is used a supernatant of the culture medium in which cells transformed only with the expression vector were cultured. In the case of an antigen, for example, the antibody 12B5 and the antibody 12E10, a test sample of the modified antibody of the invention or a supernatant of the control is added to Ba/F3 cells expressing human MPL and then an assay such as the flow cytometry is carried out to evaluate the antigen-binding activity.

In vitro evaluation of the signal transduction effect (for example, proliferation, differentiation-induction or growth stimulation of megakaryocyte, platelet production, or phosphorylation of TPO receptor protein) is

2002210917 10 Mar 2006

-27-

performed in the following manner. A test sample of the above-mentioned modified antibody is added to the cells which are expressing the antibody or cells into which the gene for the antibody has been introduced, and is
5 evaluated by the change caused by the signal transduction (for example, human MPL antigen-specific proliferation, measurement of protein phosphorylation, or expression of platelet-specific antigen) using conventional methods.

In vivo evaluation is carried out by
10 administering a monoclonal antibody recognizing MPL, a modified antibody of the invention and PBS as control to mice, and evaluating the strength of the activity by the change of the amount of platelet in mouse serum.

As mentioned above the modified antibodies of
15 the invention can be obtained by preparing modified antibodies which contain two or more H chain V regions and two or more L chain V regions and specifically bind to TPO receptor, wherein the modified antibody is: (i) a multimer of single chain Fv comprising an H chain V region and an L
20 chain V region; or (ii) a single chain polypeptide comprising two or more H chain V regions and two or more L chain V regions and screening the modified antibodies by in vivo or in vitro evaluation as mentioned in the above.

The modified antibodies of the invention, which
25 comprises two or more H chain V regions and two or more L chain V regions, preferably each two to four, more preferably each two, may be a dimer of the single chain Fv comprising one H chain V region and one L chain V region, or a single chain polypeptide in which two or more H chain
30 V regions and two or more L chain V regions are connected. It is considered that owing to such construction the peptide

mimics three dimensional structure of TPO and therefore retains an excellent antigen-binding property and TPO agonist activity.

5 The modified antibodies of the invention have a remarkably lowered molecular size compared with parent antibody molecule (e.g. IgG), and, therefore, have a superior permeability into tissues and tumors and a higher activity than parent monoclonal antibody molecule. Therefore, the modified antibodies of the invention can
10 efficiently transduce TPO signal into cells. The pharmaceutical preparations containing them are useful for treating platelet-reduction-related blood diseases and thrombocytopenia caused by chemotherapy for cancers or leukemia. It is further expected that the antibody of the
15 invention can be used as a contrast agent by RI-labeling. The effect can be enhanced by attaching to a RI-compound or a toxin.

BEST MODE FOR WORKING THE INVENTION

20 The present invention will concretely be illustrated in reference to the following examples, which in no way limit the scope of the invention.

For illustrating the production process of the modified antibodies of the invention, examples of producing
25 single chain Fvs are shown below. Mouse antibodies against human IAP, MABL-1 and MABL-2 were used in the examples of producing the modified antibodies. Hybridomas MABL-1 and

MABL-2 producing them respectively were internationally deposited as FERM BP-6100 and FERM BP-6101 with the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Minister of International Trade and Industry (1-3 Higasi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan), an authorized depository for microorganisms, on September 11, 1997.

Examples

Example 1 (Cloning of DNAs encoding V region of mouse monoclonal antibodies to human IAP)

DNAs encoding variable regions of the mouse monoclonal antibodies to human IAP, MABL-1 and MABL-2, were cloned as follows.

1.1 Preparation of messenger RNA (mRNA)

mRNAs of the hybridomas MABL-1 and MABL-2 were obtained by using mRNA Purification Kit (Pharmacia Biotech).

1.2 Synthesis of double-stranded cDNA

Double-stranded cDNA was synthesized from about 1 µg of the mRNA using Marathon cDNA Amplification Kit (CLONTECH) and an adapter was linked thereto.

1.3 PCR Amplification of genes encoding variable regions of an antibody by

PCR was carried out using Thermal Cycler (PERKIN ELMER).

(1) Amplification of a gene coding for L chain V region of MABL-1

Primers used for the PCR method are Adapter Primer-1 (CLONTECH) shown in SEQ ID No. 1, which hybridizes to a partial sequence of the adapter, and MKC (Mouse Kappa Constant) primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No. 2, which hybridizes to the mouse kappa type L chain V region.

50 μ l of the PCR solution contains 5 μ l of 10 \times PCR Buffer II, 2 mM MgCl₂, 0.16 mM dNTPs (dATP, dGTP, dCTP and dTTP), 2.5 units of a DNA polymerase, AmpliTaq Gold (PERKIN ELMER), 0.2 μ M of the adapter primer of SEQ ID No. 1, 0.2 μ M of the MKC primer of SEQ ID No. 2 and 0.1 μ g of the double-stranded cDNA derived from MABL-1. The solution was preheated at 94°C of the initial temperature for 9 minutes and then heated at 94°C for 1 minute, at 60°C for 1 minute and at 72°C for 1 minute 20 seconds in order. This temperature cycle was repeated 35 times and then the reaction mixture was further heated at 72°C for 10 minutes.

(2) Amplification of cDNA encoding H chain V region of MABL-

1

The Adapter Primer-1 shown in SEQ ID No. 1 and MHC- γ 1 (Mouse Heavy Constant) primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No. 3 were used as primers for PCR.

The amplification of cDNA was performed according to the method of the amplification of the L chain V region gene, which was described in Example 1.3-(1), except for

using 0.2 μM of the MHC- $\gamma 1$ primer instead of 0.2 μM of the MKC primer.

(3) Amplification of cDNA encoding L chain V region of MABL-2

5 The Adapter Primer-1 of SEQ ID No. 1 and the MKC primer of SEQ ID No. 2 were used as primers for PCR.

 The amplification of cDNA was carried out according to the method of the amplification of the L chain V region gene of MABL-1 which was described in Example 1.3-
10 (1), except for using 0.1 μg of the double-stranded cDNA derived from MABL-2 instead of 0.1 μg of the double-stranded cDNA from MABL-1.

(4) Amplification of cDNA encoding H chain V region of MABL-2

15 The Adapter Primer-1 of SEQ ID No. 1 and MHC- $\gamma 2a$ primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No. 4 were used as primers for PCR.

 The amplification of cDNA was performed according to the method of the amplification of the L chain V region
20 gene, which was described in Example 1.3-(3), except for using 0.2 μM of the MHC- $\gamma 2a$ primer instead of 0.2 μM of the MKC primer.

1.4 Purification of PCR products

 The DNA fragment amplified by PCR as described
25 above was purified using the QIAquick PCR Purification Kit (QIAGEN) and dissolved in 10 mM Tris-HCl (pH 8.0) containing 1 mM EDTA.

1.5 Ligation and Transformation

About 140 ng of the DNA fragment comprising the gene encoding the mouse kappa type L chain V region derived from MABL-1 as prepared above was ligated with 50 ng of
5 pGEM-T Easy vector (Promega) in the reaction buffer comprising 30 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 10 mM dithiothreitol, 1 mM ATP and 3 units of T4 DNA Ligase (Promega) at 15°C for 3 hours.

Then, 1 µl of the reaction mixture was added to 50
10 µl of E. coli DH5α competent cells (Toyobo Inc.) and the cells were stored on ice for 30 minutes, incubated at 42°C for 1 minute and stored on ice for 2 minutes again. 100 µl of SOC medium (GIBCO BRL) was added. The cells of E. coli were plated on LB (Molecular Cloning: A Laboratory Manual,
15 Sambrook et al., Cold Spring Harbor Laboratory Press, 1989) agar medium containing 100 µg/ml of ampicillin (SIGMA) and cultured at 37°C overnight to obtain the transformant of E. coli.

The transformant was cultured in 3 ml of LB medium
20 containing 50 µg/ml of ampicillin at 37°C overnight and the plasmid DNA was prepared from the culture using the QIAprep Spin Miniprep Kit (QIAGEN).

The resulting plasmid comprising the gene encoding the mouse kappa type L chain V region derived from the
25 hybridoma MABL-1 was designated as pGEM-M1L.

According to the same manner as described above, a plasmid comprising the gene encoding the mouse H chain V

region derived from the hybridoma MABL-1 was prepared from the purified DNA fragment and designated as pGEM-M1H.

A plasmid comprising the gene encoding the mouse kappa type L chain V region derived from the hybridoma MABL-2 was prepared from the purified DNA fragment and designated as pGEM-M2L.

A plasmid comprising the gene encoding the mouse H chain V region derived from the hybridoma MABL-2 was prepared from the purified DNA fragment and designated as pGEM-M2H.

Example 2 (DNA Sequencing)

The nucleotide sequence of the cDNA encoding region in the aforementioned plasmids was determined using Auto DNA Sequencer (Applied Biosystem) and ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystem) according to the manufacturer's protocol.

The nucleotide sequence of the gene encoding the L chain V region from the mouse antibody MABL-1, which is included in the plasmid pGEM-M1L, is shown in SEQ ID No. 5.

The nucleotide sequence of the gene encoding the H chain V region from the mouse antibody MABL-1, which is included in the plasmid pGEM-M1H, is shown in SEQ ID No. 6.

The nucleotide sequence of the gene encoding the L chain V region from the mouse antibody MABL-2, which is included in the plasmid pGEM-M2L, is shown in SEQ ID No. 7.

The nucleotide sequence of the gene encoding the H chain V region from the mouse antibody MABL-2, which is included in the plasmid pGEM-M2H, is shown in SEQ ID No. 8.

5 Example 3 (Determination of CDR)

The V regions of L chain and H chain generally have a similarity in their structures and each four framework regions therein are linked by three hypervariable regions, i.e., complementarity determining regions (CDR). An amino acid sequence of the framework is relatively well conserved, while an amino acid sequence of CDR has extremely high variation (Kabat, E.A., et al., "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services, 1983).

15 On the basis of these facts, the amino acid sequences of the variable regions from the mouse monoclonal antibodies to human IAP were applied to the database of amino acid sequences of the antibodies made by Kabat et al. to investigate the homology. The CDR regions were determined based on the homology as shown in Table 1.

Table 1

	<u>Plasmid</u>	<u>SEQ ID No.</u>	<u>CDR (1)</u>	<u>CDR (2)</u>	<u>CDR (3)</u>
	pGEM-M1L	5	43-58	74-80	113-121
25	pGEM-M1H	6	50-54	69-85	118-125
	pGEM-M2L	7	43-58	74-80	113-121

pGEM-M2H 8 50-54 69-85 118-125

Example 4 (Identification of Cloned cDNA Expression

(Preparation of Chimera MABL-1 antibody and Chimera MABL-2
5 antibody.)

4.1 Preparation of vectors expressing chimera MABL-1
antibody

 cDNA clones, pGEM-M1L and pGEM-M1H, encoding the V
regions of the L chain and the H chain of the mouse antibody
10 MABL-1, respectively, were modified by the PCR method and
introduced into the HEF expression vector (WO92/19759) to
prepare vectors expressing chimera MABL-1 antibody.

 A forward primer MLS (SEQ ID No. 9) for the L
chain V region and a forward primer MHS (SEQ ID No. 10) for
15 the H chain V region were designed to hybridize to a DNA
encoding the beginning of the leader sequence of each V
region and to contain the Kozak consensus sequence (J. Mol.
Biol., 196, 947-950, 1987) and HindIII restriction enzyme
site. A reverse primer MLAS (SEQ ID No. 11) for the L chain
20 V region and a reverse primer MHAS (SEQ ID No. 12) for the H
chain V region were designed to hybridize to a DNA encoding
the end of the J region and to contain the splice donor
sequence and BamHI restriction enzyme site.

 100 µl of a PCR solution comprising 10 µl of 10 ×
25 PCR Buffer II, 2 mM MgCl₂, 0.16 mM dNTPs (dATP, dGTP, dCTP
and dTTP), 5 units of DNA polymerase AmpliTaq Gold, 0.4 µM
each of primers and 8 ng of the template DNA (pGEM-M1L or

pGEM-M1H) was preheated at 94°C of the initial temperature for 9 minutes and then heated at 94°C for 1 minute, at 60°C for 1 minute and at 72°C for 1 minute 20 seconds in order. This temperature cycle was repeated 35 times and then the
5 reaction mixture was further heated at 72°C for 10 minutes.

The PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and then digested with HindIII and BamHI. The product from the L chain V region was cloned into the HEF expression vector, HEF-κ and the product from
10 the H chain V region was cloned into the HEF expression vector, HEF-γ. After DNA sequencing, plasmids containing a DNA fragment with a correct DNA sequence are designated as HEF-M1L and HEF-M1H, respectively.

4.2 Preparation of vectors expressing chimera MABL-2 15 antibodies

Modification and cloning of cDNA were performed in the same manner described in Example 4.1 except for using pGEM-M2L and pGEM-M2H as template DNA instead of pGEM-M1L and pGEM-M1H. After DNA sequencing, plasmids containing DNA
20 fragments with correct DNA sequences are designated as HEF-M2L and HEF-M2H, respectively.

4.3 Transfection to COS7 cells

The aforementioned expression vectors were tested in COS7 cells to observe the transient expression of the
25 chimera MABL-1 and MABL-2 antibodies.

(1) Transfection with genes for the chimera MABL-1 antibody

COS7 cells were co-transformed with the HEF-M1L and HEF-M1H vectors by electroporation using the Gene Pulser apparatus (BioRad). Each DNA (10 µg) and 0.8 ml of PBS with 1×10^7 cells/ml were added to a cuvette. The mixture was
5 treated with pulse at 1.5 kV, 25 µF of electric capacity.

After the restoration for 10 minutes at a room temperature, the electroporated cells were transferred into DMEM culture medium (GIBCO BRL) containing 10% γ-globulin-free fetal bovine serum. After culturing for 72 hours, the
10 supernatant was collected, centrifuged to remove cell fragments and recovered.

(2) Transfection with genes coding for the chimera MABL-2 antibody

The co-transfection to COS7 cells with the genes
15 coding for the chimera MABL-2 antibody was carried out in the same manner as described in Example 4.3-(1) except for using the HEF-M2L and HEF-M2H vectors instead of the HEF-M1L and HEF-M1H vectors. The supernatant was recovered in the same manner.

20 4.4 Flow cytometry

Flow cytometry was performed using the
aforementioned culture supernatant of COS7 cells to measure
binding to the antigen. The culture supernatant of the COS7
cells expressing the chimera MABL-1 antibody or the COS7
25 cells expressing the chimera MABL-2 antibody, or human IgG
antibody (SIGMA) as a control was added to 4×10^5 cells of
mouse leukemia cell line L1210 expressing human IAP and

incubated on ice. After washing, the FITC-labeled anti-human IgG antibody (Cappel) was added thereto. After incubating and washing, the fluorescence intensity thereof was measured using the FACScan apparatus (BECTON DICKINSON).

5 Since the chimera MABL-1 and MABL-2 antibodies were specifically bound to L1210 cells expressing human IAP, it is confirmed that these chimera antibodies have proper structures of the V regions of the mouse monoclonal antibodies MABL-1 and MABL-2, respectively (Figs. 1-3).

10

Example 5 (Preparation of reconstructed Single chain Fv (scFv) of the antibody MABL-1 and antibody MABL-2)

5.1 Preparation of reconstructed single chain Fv of antibody MABL-1

15

The reconstructed single chain Fv of antibody MABL-1 was prepared as follows. The H chain V region and the L chain V of antibody MABL-1, and a linker were respectively amplified by the PCR method and were connected to produce the reconstructed single chain Fv of antibody MABL-1. The production method is illustrated in Fig. 4. Six primers (A-F) were employed for the production of the single chain Fv of antibody MABL-1. Primers A, C and E have a sense sequence and primers B, D and F have an antisense sequence.

20

The forward primer VHS for the H chain V region (Primer A, SEQ ID No. 13) was designed to hybridize to a DNA encoding the N-terminal of the H chain V region and to contain NcoI restriction enzyme recognition site. The

25

reverse primer VHAS for H chain V region (Primer B, SEQ ID No. 14) was designed to hybridize to a DNA coding the C-terminal of the H chain V region and to overlap with the linker.

5 The forward primer LS for the linker (Primer C, SEQ ID No. 15) was designed to hybridize to a DNA encoding the N-terminal of the linker and to overlap with a DNA encoding the C-terminal of the H chain V region. The reverse primer LAS for the linker (Primer D, SEQ ID No. 16) was
10 designed to hybridize to a DNA encoding the C-terminal of the linker and to overlap with a DNA encoding the N-terminal of the L chain V region.

 The forward primer VLS for the L chain V region (Primer E, SEQ ID No. 17) was designed to hybridize to a DNA
15 encoding the C-terminal of the linker and to overlap with a DNA encoding the N-terminal of the L chain V region. The reverse primer VLAS-FLAG for L chain V region (Primer F, SEQ ID No. 18) was designed to hybridize to a DNA encoding the
20 C-terminal of the L chain V region and to have a sequence encoding the FLAG peptide (Hopp. T. P. et al., Bio/Technology, 6, 1204-1210, 1988), two stop codons and EcoRI restriction enzyme recognition site.

 In the first PCR step, three reactions, A-B, C-D and E-F, were carried out and PCR products thereof were
25 purified. Three PCR products obtained from the first PCR step were assembled by their complementarity. Then, the primers A and F were added and the full length DNA encoding

the reconstructed single chain Fv of antibody MABL-1 was amplified (Second PCR). In the first PCR, the plasmid pGEM-M1H encoding the H chain V region of antibody MABL-1 (see Example 2), a plasmid pSC-DP1 which comprises a DNA sequence encoding a linker region comprising: Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser (SEQ ID No. 19) (Huston, J.S., et al., Proc. Natl. Acad. Sci. USA, 85, 5879-5883, 1988) and the plasmid pGEM-M1L encoding the L chain V region of antibody MABL-1 (see Example 2) were employed as template, respectively.

50 μ l of the solution for the first PCR step comprises 5 μ l of 10 \times PCR Buffer II, 2 mM MgCl₂, 0.16 mM dNTPs, 2.5 units of DNA polymerase, AmpliTaq Gold (PERKIN ELMER), 0.4 μ M each of primers and 5 ng each of template DNA. The PCR solution was preheated at 94°C of the initial temperature for 9 minutes and then heated at 94°C for 1 minute, at 65°C for 1 minute and at 72°C for 1 minute and 20 seconds in order. This temperature cycle was repeated 35 times and then the reaction mixture was further heated at 72°C for 7 minutes.

The PCR products A-B (371bp), C-D (63bp) and E-F (384bp) were purified using the QIAquick PCR Purification Kit (QIAGEN) and were assembled in the second PCR. In the second PCR, 98 μ l of a PCR solution comprising 120 ng of the first PCR product A-B, 20 ng of the PCR product C-D and 120 ng of the PCR product E-F, 10 μ l of 10 \times PCR Buffer II, 2mM MgCl₂, 0.16 mM dNTPs, 5 units of DNA polymerase AmpliTaq

Gold (PERKIN ELMER) was preheated at 94°C of the initial temperature for 8 minutes and then heated at 94°C for 2 minutes, at 65°C for 2 minutes and at 72°C for 2 minutes in order. This temperature cycle was repeated twice and then
5 0.4 μ M each of primers A and F were added into the reaction, respectively. The mixture was preheated at 94°C of the initial temperature for 1 minutes and then heated at 94°C for 1 minute, at 65°C for 1 minute and at 72°C for 1 minute and 20 seconds in order. This temperature cycle was repeated
10 35 times and then the reaction mixture was further heated at 72°C for 7 minutes.

A DNA fragment of 843 bp produced by the second PCR was purified and digested by NcoI and EcoRI. The resultant DNA fragment was cloned into pSCFVT7 vector. The
15 expression vector pSCFVT7 contains a pelB signal sequence suitable for *E. coli* periplasmic expression system (Lei, S.P., et al., J. Bacteriology, 169, 4379-4383, 1987). After the DNA sequencing, the plasmid containing the DNA fragment encoding correct amino acid sequence of the reconstructed
20 single chain Fv of antibody MABL-1 is designated as "pscM1" (see Fig. 5). The nucleotide sequence and the amino acid sequence of the reconstructed single chain Fv of antibody MABL-1 contained in the plasmid pscM1 are shown in SEQ ID No. 20.

25 The pscM1 vector was modified by the PCR method to prepare a vector expressing the reconstructed single chain FV of antibody MABL-1 in mammalian cells. The resultant DNA

fragment was introduced into pCHO1 expression vector. This expression vector, pCHO1, was constructed by digesting DHFR- Δ E-rvH-PM1-f (WO92/19759) with EcoRI and SmaI to eliminate the antibody gene and connecting the EcoRI-NotI-BamHI Adapter (Takara Shuzo) thereto.

As a forward primer for PCR, Sal-VHS primer shown in SEQ ID No. 21 was designed to hybridize to a DNA encoding the N-terminal of the H chain V region and to contain SalI restriction enzyme recognition site. As a reverse primer for PCR, FRH1anti primer shown in SEQ ID No. 22 was designed to hybridize to a DNA encoding the end of the first framework sequence.

100 μ l of PCR solution comprising 10 μ l of 10 \times PCR Buffer II, 2 mM MgCl₂, 0.16 mM dNTPs, 5 units of the DNA polymerase, AmpliTaq Gold, 0.4 μ l M each of primer and 8 ng of the template DNA (pscM1) was preheated at 95°C of the initial temperature for 9 minutes and then heated at 95°C for 1 minute, at 60°C for 1 minute and at 72°C for 1 minute and 20 seconds in order. This temperature cycle was repeated 35 times and then the reaction mixture was further heated at 72°C for 7 minutes.

The PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and digested by SalI and MboII to obtain a DNA fragment encoding the N-terminal of the reconstructed single chain Fv of antibody MABL-1. The pscM1 vector was digested by MboII and EcoRI to obtain a DNA fragment encoding the C-terminal of the reconstructed single

chain Fv of antibody MABL-1. The SalI-MboII DNA fragment and the MboII-EcoRI DNA fragment were cloned into pCH01-Igs vector. After DNA sequencing, the plasmid comprising the desired DNA sequence was designated as "pCHOM1" (see Fig.

5 6). The expression vector, pCH01-Igs, contains a mouse IgG1 signal sequence suitable for the secretion-expression system in mammalian cells (Nature, 322, 323-327, 1988). The nucleotide sequence and the amino acid sequence of the reconstructed single chain Fv of antibody MABL-1 contained
10 in the plasmid pCHOM1 are shown in SEQ ID No. 23.

5.2 Preparation of reconstructed single chain Fv of antibody MABL-2

The reconstructed single chain Fv of antibody MABL-2 was prepared in accordance with the aforementioned
15 Example 5.1. Employed in the first PCR step were plasmid pGEM-M2H encoding the H chain V region of MABL-2 (see Example 2) instead of pGEM-M1H and plasmid pGEM-M2L encoding the L chain V region of MABL-2 (see Example 2) instead of pGEM-M1L, to obtain a plasmid pscM2 which comprises a DNA
20 fragment encoding the desired amino acid sequence of the single chain Fv of antibody MABL-2. The nucleotide sequence and the amino acid sequence of the reconstructed single chain Fv of antibody MABL-2 contained in the plasmid pscM2 are shown in SEQ ID No. 24.

25 The pscM2 vector was modified by the PCR method to prepare a vector, pCHOM2, for the expression in mammalian cells which contains the DNA fragment encoding the correct

amino acid sequence of reconstructed the single chain Fv of antibody MABL-2. The nucleotide sequence and the amino acid sequence of the reconstructed single chain Fv of antibody MABL-2 contained in the plasmid pCHOM2 are shown in SEQ ID
5 No. 25.

5.3 Transfection to COS7 cells

The pCHOM2 vector was tested in COS7 cells to observe the transient expression of the reconstructed single chain Fv of antibody MABL-2.

10 The COS7 cells were transformed with the pCHOM2 vector by electroporation using the Gene Pulser apparatus (BioRad). The DNA (10 µg) and 0.8 ml of PBS with 1×10^7 cells/ml were added to a cuvette. The mixture was treated with pulse at 1.5 kV, 25 µF of electric capacity.

15 After the restoration for 10 minutes at a room temperature, the electroporated cells were transferred into IMDM culture medium (GIBCO BRL) containing 10% fetal bovine serum. After culturing for 72 hours, the supernatant was collected, centrifuged to remove cell fragments and
20 recovered.

5.4 Detection of the reconstructed single chain Fv of antibody MABL-2 in culture supernatant of COS7 cells

25 The existence of the single chain Fv of antibody MABL-2 in the culture supernatant of COS7 cells which had been transfected with the pCHOM2 vector was confirmed by the Western Blotting method.

The culture supernatant of COS7 cells transfected with the pCHOM2 vector and the culture supernatant of COS7 cells transfected with the pCH01 as a control were subjected to SDS electrophoresis and transferred to REINFORCED NC
5 membrane (Schleicher & Schuell). The membrane was blocked with 5% skim milk (Morinaga Nyu-gyo), washed with 0.05% Tween 20-PBS and mixed with an anti-FLAG antibody (SIGMA). The membrane was incubated at room temperature, washed and mixed with alkaline phosphatase-conjugated mouse IgG
10 antibody (Zymed). After incubating and washing at room temperature, the substrate solution (Kirkegaard Perry Laboratories) was added to develop color (Fig. 7).

A FLAG-peptide-specific protein was detected only in the culture supernatant of the pCHOM2 vector-introduced
15 COS7 cells and thus it is confirmed that the reconstructed single chain Fv of antibody MABL-2 was secreted in this culture supernatant.

5.5 Flow cytometry

Flow cytometry was performed using the
20 aforementioned COS7 cells culture supernatant to measure the binding to the antigen. The culture supernatant of the COS7 cells expressing the reconstructed single chain Fv of antibody MABL-2 or the culture supernatant of COS7 cells transformed with pCH01 vector as a control was added to $2 \times$
25 10^5 cells of the mouse leukemia cell line L1210 expressing human Integrin Associated Protein (IAP) or the cell line L1210 transformed with pCOS1 as a control. After incubating

on ice and washing, the mouse anti-FLAG antibody (SIGMA) was added. Then the cells were incubated and washed. Then, the FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was added thereto and the cells were incubated and washed again. Subsequently, the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

Since the single chain Fv of antibody MABL-2 was specifically bound to L1210 cells expressing human IAP, it is confirmed that the reconstructed single chain Fv of antibody MABL-2 has an affinity to human Integrin Associated Protein (IAP) (see Figs. 8-11).

5.6 Competitive ELISA

The binding activity of the reconstructed single chain Fv of antibody MABL-2 was measured based on the inhibiting activity against the binding of mouse monoclonal antibodies to the antigen.

The anti-FLAG antibody adjusted to 1 $\mu\text{g/ml}$ was added to each well on 96-well plate and incubated at 37°C for 2 hours. After washing, blocking was performed with 1% BSA-PBS. After incubating and washing at a room temperature, the culture supernatant of COS7 cells into which the secretion-type human IAP antigen gene (SEQ ID No. 26) had been introduced was diluted with PBS into twofold volume and added to each well. After incubating and washing at a room temperature, a mixture of 50 μl of the biotinized MABL-2 antibody adjusted to 100 ng/ml and 50 μl of sequentially diluted supernatant of the COS7 cells expressing the

reconstructed single chain Fv of antibody MABL-2 were added into each well. After incubating and washing at a room temperature, the alkaline phosphatase-conjugated streptoavidin (Zymed) was added into each well. After
5 incubating and washing at a room temperature, the substrate solution (SIGMA) was added and absorbance of the reaction mixture in each well was measured at 405 nm.

The results revealed that the reconstructed single chain Fv of antibody MABL-2 (MABL2-scFv) evidently inhibited
10 concentration-dependently the binding of the mouse antibody MABL-2 to human IAP antigen in comparison with the culture supernatant of the PCHO1-introduced COS7 cells as a control. (Fig. 12). Accordingly, it is suggested that the
15 reconstructed single chain Fv of antibody MABL-2 has the correct structure of each of the V regions from the mouse monoclonal antibody MABL-2.

5.7 Apoptosis-inducing Effect in vitro

An apoptosis-inducing action of the reconstructed single chain Fv of antibody MABL-2 was examined by Annexin-V
20 staining (Boehringer Mannheim) using the L1210 cells transfected with human IAP gene, the L1210 cells transfected with the pCOS1 vector as a control and CCRF-CEM cells.

To each 1×10^5 cells of the above cells was added the culture supernatant of the COS7 cells expressing the
25 reconstructed single chain Fv of antibody MABL-2 or the culture supernatant of COS7 cells transfected with the pCHO1 vector as a control at 50% final concentration and the

mixtures were cultured for 24 hours. Then, the Annexin-V staining was performed and the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

Results of the Annexin-V staining are shown in Figs. 13-18, respectively. Dots in the left-lower region represent living cells and dots in the right-lower region represent cells at the early stage of apoptosis and dots in the right-upper region represent cells at the late stage of apoptosis. The results show that the reconstructed single chain Fv of antibody MABL-2 (MABL2-scFv) remarkably induced cell death of L1210 cells specific to human IAP antigen (Figs. 13-16) and that the reconstructed single chain Fv also induced remarkable cell death of CCRF-CEM cells in comparison with the control (Figs. 17-18).

5.8 Expression of MABL-2 derived single chain Fv in CHO cells

CHO cells were transfected with the pCHOM2 vector to establish a CHO cell line which constantly expresses the single chain Fv (polypeptide) derived from the antibody MABL-2.

CHO cells were transformed with the pCHOM2 vector by the electroporation using the Gene Pulser apparatus (BioRad). A mixture of DNA (10 μ g) and 0.7 ml of PBS with CHO cells (1×10^7 cells/ml) was added to a cuvette. The mixture was treated with pulse at 1.5 kV, 25 μ F of electric capacity. After the restoration for 10 minutes at a room temperature, the electroporated cells were transferred into

nucleic acid free α -MEM medium (GIBCO BRL) containing 10% fetal bovine serum and cultured. The expression of desired protein in the resultant clones was confirmed by SDS-PAGE and a clone with a high expression level was selected as a cell line producing the single chain Fv derived from the antibody MABL-2. The cell line was cultured in serum-free medium CHO-S-SFM II (GIBCO BRL) containing 10 nM methotrexate (SIGMA). Then, the culture supernatant was collected, centrifuged to remove cell fragments and recovered.

5.9 Purification of MABL-2 derived single chain Fv produced in CHO cells

The culture supernatant of the CHO cell line expressing the single chain Fv obtained in Example 5.8 was concentrated up to twenty times using a cartridge for the artificial dialysis (PAN130SF, ASAHI MEDICALS). The concentrated solution was stored at -20°C and thawed on purification.

Purification of the single chain Fv from the culture supernatant of the CHO cells was performed using three kinds of chromatography, i.e., Blue-sepharose, a hydroxyapatite and a gel filtration.

(1) Blue-sepharose column chromatography

The concentrated supernatant was diluted to ten times with 20 mM acetate buffer (pH 6.0) and centrifuged to remove insoluble materials (10000 \times rpm, 30 minutes). The supernatant was applied onto a Blue-sepharose column (20 ml)

equilibrated with the same buffer. After washing the column with the same buffer, proteins adsorbed in the column were eluted by a stepwise gradient of NaCl in the same buffer, 0.1, 0.2, 0.3, 0.5 and up to 1.0 M. The pass-through fraction and each eluted fraction were analyzed by SDS-PAGE. The fractions in which the single chain Fv were confirmed (the fractions eluted at 0.1 to 0.3M NaCl) were pooled and concentrated up to approximately 20 times using CentriPrep-10 (AMICON).

10 (2) Hydroxyapatite

The concentrated solution obtained in (1) was diluted to 10 times with 10 mM phosphate buffer (pH 7.0) and applied onto the hydroxyapatite column (20 ml, BIORAD). The column was washed with 60 ml of 10 mM phosphate buffer (pH 7.0). Then, proteins adsorbed in the column were eluted by a linear gradient of sodium phosphate buffer up to 200 mM (see Fig. 19). The analysis of each fraction by SDS-PAGE confirmed the single chain Fv in fraction A and fraction B.

(3) Gel filtration

20 Each of fractions A and B in (2) was separately concentrated with CentriPrep-10 and applied onto TSKgel G3000SWG column (21.5 x 600 mm) equilibrated with 20 mM acetate buffer (pH 6.0) containing 0.15 M NaCl. Chromatograms are shown in Fig. 20. The analysis of the fractions by SDS-PAGE confirmed that both major peaks (AI and BI) are of desired single chain Fv. In the gel
25 filtration analysis, the fraction A was eluted at 36 kDa of

2002210917 10 Mar 2006

apparent molecular weight and the fraction B was eluted at 76 kDa. The purified single chain Fvs (AI, BI) were analyzed with 15% SDS polyacrylamide gel. Samples were treated in the absence or presence of a reductant and the electrophoresis was carried out in accordance with the Laemmli's method. Then the protein was stained with Coomassie Brilliant Blue. As shown in Fig. 21, both AI and BI gave a single band at 35 kDa of apparent molecular weight, regardless of the absence or presence of the reductant. From the above, it is concluded that AI is a monomer of the single chain Fv and BI is a non-covalently bound dimer of the single chain Fv. The gel filtration analysis of the fractions AI and BI with TSKgel G3000SW column (7.5 x 60 mm) revealed that a peak of the monomer is detected only in the fraction AI and a peak of the dimer is detected only in the fraction BI (Fig. 22). The dimer fraction (fraction BI) accounted for 4 percent (%) of total single chain Fvs. More than 90% of the dimer in the dimer fraction was stably preserved for more than a month at 4°C.

5.10 Construction of vector expressing single chain Fv derived from antibody MABL-2 in E. coli cell

The pscM2 vector was modified by the PCR method to prepare a vector effectively expressing the single chain Fv from the antibody MABL-2 in E. coli cells. The resultant DNA fragment was introduced into pSCFVT7 expression vector.

As a forward primer for PCR, Nde-VHSm02 primer shown in SEQ ID No. 27 was designed to hybridize to a DNA

encoding the N-terminal of the H chain V region and to contain a start codon and NdeI restriction enzyme recognition site. As a reverse primer for PCR, VLAS primer shown in SEQ ID No. 28 was designed to hybridize to a DNA
5 encoding the C-terminal of the L chain V region and to contain two stop codons and EcoRI restriction enzyme recognition site. The forward primer, Nde-VHSm02, comprises five point mutations in the part hybridizing to the DNA encoding the N-terminal of the H chain V region for the
10 effective expression in E. coli.

100 μ l of a PCR solution comprising 10 μ l of 10 x PCR Buffer #1, 1 mM MgCl₂, 0.2 mM dNTPs, 5 units of KOD DNA polymerase (all from TOYOBO), 1 μ M of each primer and 100 ng of a template DNA (pscM2) was heated at 98°C for 15 seconds,
15 at 65°C for 2 seconds and at 74°C for 30 seconds in order. This temperature cycle was repeated 25 times.

The PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and digested by NdeI and EcoRI, and then the resulting DNA fragment was cloned into
20 pSCFVT7 vector, from which pelB signal sequence had been eliminated by the digestion with NdeI and EcoRI. After DNA sequencing, the resulting plasmid comprising a DNA fragment with the desired DNA sequence is designated as "pscM2DEm02" (see Fig. 23). The nucleotide sequence and the amino acid
25 sequence of the single chain Fv derived from the antibody MABL-2 contained in the plasmid pscM2DEm02 are shown in SEQ ID No. 29.

5.11 Expression of single chain Fv derived from antibody
MABL-2 in E. coli cells

E. coli BL21(DE3)pLysS (STRATAGENE) was transformed with pscM2DEm02 vector to obtain a strain of E. coli expressing the single chain Fv derived from antibody MABL-2. The resulting clones were examined for the expression of the desired protein using SDS-PAGE, and a clone with a high expression level was selected as a strain producing the single chain Fv derived from antibody MABL-2.

5.12 Purification of single chain Fv derived from antibody
MABL-2 produced in E.coli

A single colony of E. coli obtained by the transformation was cultured in 3 ml of LB medium at 28°C for 7 hours and then in 70 ml of LB medium at 28°C overnight. This pre-culture was transplanted to 7 L of LB medium and cultured at 28°C with stirring at 300 rpm using the Jar-fermenter. When an absorbance of the medium reached O.D.=1.5, the bacteria were induced with 1 mM IPTG and then cultured for 3 hours.

The culture medium was centrifuged (10000 x g, 10 minutes) and the precipitated bacteria were recovered. To the bacteria was added 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM EDTA, 0.1 M NaCl and 1% Triton X-100 and the bacteria were disrupted by ultrasonication (out put: 4, duty cycle: 70%, 1 minute x 10 times). The suspension of disrupted bacteria was centrifuged (12000 x g, 10 minutes) to precipitate inclusion body. Isolated inclusion body was

mixed with 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM EDTA, 0.1 M NaCl and 4% Triton X-100, treated by ultrasonication (out put: 4, duty cycle: 50%, 30 seconds x 2 times) again and centrifuged (12000 x g, 10 minutes) to isolate the desired protein as precipitate and to remove containment proteins included in the supernatant.

The inclusion body comprising the desired protein was lysed in 50 mM Tris-HCl buffer (pH 8.0) containing 6 M Urea, 5 mM EDTA and 0.1 M NaCl and applied onto Sephacryl S-300 gel filtration column (5 x 90 cm, Amersham Pharmacia) equilibrated with 50 mM Tris-HCl buffer (pH 8.0) containing 4M Urea, 5 mM EDTA, 0.1 M NaCl and 10 mM mercaptoethanol at a flow rate of 5 ml/minutes to remove associated single chain Fvs with high-molecular weight. The obtained fractions were analyzed with SDS-PAGE and the fractions with high purity of the protein were diluted with the buffer used in the gel filtration up to $O.D_{280}=0.25$. Then, the fractions were dialyzed three times against 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM EDTA, 0.1 M NaCl, 0.5 M Arg, 2 mM glutathione in the reduced form and 0.2 mM glutathione in the oxidized form in order for the protein to be refolded. Further, the fraction was dialyzed three times against 20 mM acetate buffer (pH 6.0) containing 0.15 M NaCl to exchange the buffer.

The dialysate product was applied onto Superdex 200 pg gel filtration column (2.6 x 60 cm, Amersham Pharmacia) equilibrated with 20 mM acetate buffer (pH 6.0)

containing 0.15 M NaCl to remove a small amount of high molecular weight protein which was intermolecularly crosslinked by S-S bonds. As shown in Fig. 24, two peaks, major and sub peaks, were eluted after broad peaks which are expectedly attributed to an aggregate with a high molecular weight. The analysis by SDS-PAGE (see Fig. 21) and the elution positions of the two peaks in the gel filtration analysis suggest that the major peak is of the monomer of the single chain Fv and the sub peak is of the non-covalently bound dimer of the single chain Fv. The non-covalently bound dimer accounted for 4 percent of total single chain Fvs.

5.13 Apoptosis-inducing activity in vitro of single chain Fv derived from antibody MABL-2

An apoptosis-inducing action of the single chain Fv from antibody MABL-2 (MABL2-scFv) produced by the CHO cells and *E. coli* was examined according to two protocols by Annexin-V staining (Boehringer Mannheim) using the L1210 cells (hIAP/L1210) into which human IAP gene had been introduced.

In the first protocol sample antibodies at the final concentration of 3 µg/ml were added to 5×10^4 cells of hIAP/L1210 cell line and cultured for 24 hours. Sample antibodies, i.e., the monomer and the dimer of the single chain Fv of MABL-2 from the CHO cells obtained in Example 5.9, the monomer and the dimer of the single chain Fv of MABL-2 from *E. coli* obtained in Example 5.12, and the mouse

IgG antibody as a control were analyzed. After culturing, the Annexin-V staining was carried out and the fluorescence intensity thereof was measured using the FACScan apparatus (BECTON DICKINSON).

5 In the second protocol sample antibodies at the final concentration of 3 $\mu\text{g/ml}$ were added to 5×10^4 cells of hIAP/L1210 cell line, cultured for 2 hours and mixed with anti-FLAG antibody (SIGMA) at the final concentration of 15 $\mu\text{g/ml}$ and further cultured for 22 hours. Sample antibodies
10 of the monomer of the single chain Fv of MABL-2 from the CHO cells obtained in Example 5.9 and the mouse IgG antibody as a control were analyzed. After culturing, the Annexin-V staining was carried out and the fluorescence intensity thereof was measured using the FACScan apparatus.

15 Results of the analysis by the Annexin-V staining are shown in Figs. 25-31. The results show that the dimers of the single chain Fv polypeptide of MABL-2 produced in the CHO cells and E. coli remarkably induced cell death (Figs. 26, 27) in comparison with the control (Fig. 25), while no
20 apoptosis-inducing action was observed in the monomers of the single chain Fv polypeptide of MABL-2 produced in the CHO cells and E. coli (Figs. 28, 29). When anti-FLAG antibody was used together, the monomer of the single chain Fv polypeptide derived from antibody MABL-2 produced in the
25 CHO cells induced remarkably cell death (Fig. 31) in comparison with the control (Fig. 30).

5.14 Antitumor effect of the monomer and the dimer of
scFv/CHO polypeptide with a model mouse of human myeloma

(1) Quantitative measurement of human IgG in mouse serum

Measurement of human IgG (M protein) produced by
5 human myeloma cell and contained in mouse serum was carried
out by the following ELISA. 100 μ L of goat anti-human IgG
antibody (BIOSOURCE, Lot#7902) diluted to 1 μ g/mL with 0.1%
bicarbonate buffer (pH 9.6) was added to each well on 96
wells plate (Nunc) and incubated at 4°C overnight so that
10 the antibody was immobilized. After blocking, 100 μ L of the
stepwisely diluted mouse serum or human IgG (CAPPEL,
Lot#00915) as a standard was added to each well and
incubated for 2 hours at a room temperature. After washing,
100 μ L of alkaline phosphatase-labeled anti-human IgG
15 antibody (BIOSOURCE, Lot#6202) which had been diluted to
5000 times was added, and incubation was carried out for 1
hour at a room temperature. After washing, a substrate
solution was added. After incubation, absorbance at 405 nm
was measured using the MICROPLATE READER Model 3550
20 (BioRad). The concentration of human IgG in the mouse serum
was calculated based on the calibration curve obtained from
the absorbance values of human IgG as the standard.

(2) Preparation of antibodies for administration

The monomer and the dimer of the scFv/CHO
25 polypeptide were respectively diluted to 0.4 mg/mL or 0.25
mg/mL with sterile filtered PBS(-) on the day of
administration to prepare samples for the administration.

(3) Preparation of a mouse model of human myeloma

A mouse model of human myeloma was prepared as follows. KPMM2 cells passaged in vivo (JP-Appl. 7-236475) by SCID mouse (Japan Clare) were suspended in RPMI1640 medium
5 (GIBCO-BRL) containing 10% fetal bovine serum (GIBCO-BRL) and adjusted to 3×10^7 cells/mL. 200 μ L of the KPMM2 cell suspension (6×10^6 cells/mouse) was transplanted to the SCID mouse (male, 6 week-old) via caudal vein thereof, which had been subcutaneously injected with the asialo GM1
10 antibody (WAKO JUNYAKU, 1 vial dissolved in 5 mL) a day before the transplantation.

(4) Administration of antibodies

The samples of the antibodies prepared in (2), the monomer (250 μ L) and the dimer (400 μ L), were administered
15 to the model mice of human myeloma prepared in (3) via caudal vein thereof. The administration was started from three days after the transplantation of KPMM2 cells and was carried out twice a day for three days. As a control, 200 μ L of sterile filtered PBS(-) was likewise administered twice a
20 day for three days via caudal vein. Each group consisted of seven mice.

(5) Evaluation of antitumor effect of the monomer and the dimer of scFv/CHO polypeptide with the model mouse of human myeloma

25 The antitumor effect of the monomer and the dimer of scFv/CHO polypeptide with the model mice of human myeloma was evaluated in terms of the change of human IgG (M

protein) concentration in the mouse serum and survival time of the mice. The change of human IgG concentration was determined by measuring it in the mouse serum collected at 24 days after the transplantation of KPMM2 cells by ELISA described in the above (1). The amount of serum human IgG (M protein) in the serum of the PBS(-)-administered group (control) increased to about 8500 $\mu\text{g/mL}$, whereas the amount of human IgG of the scFv/CHO dimer-administered group was remarkably low, that is, as low as one-tenth or less than that of the control group. Thus, the results show that the dimer of scFv/CHO strongly inhibits the growth of the KPMM2 cells (Fig. 32). As shown in Fig. 33, a remarkable elongation of the survival time was observed in the scFv/CHO dimer-administered group in comparison with the PBS(-)-administered group.

From the above, it is confirmed that the dimer of scFv/CHO has an antitumor effect for the human myeloma model mice. It is considered that the antitumor effect of the dimer of scFv/CHO, the modified antibody of the invention, results from the apoptosis-inducing action of the modified antibody.

5.15 Hemagglutination Test

Hemagglutination test and determination of hemagglutination were carried out in accordance with "Immuno-Biochemical Investigation", Zoku-Seikagaku Jikken Koza, edited by the Biochemical Society of Japan, published by Tokyo Kagaku Dojin.

Blood was taken from a healthy donor using heparin-treated syringes and washed with PBS(-) three times, and then erythrocyte suspension with a final concentration of 2% in PBS(-) was prepared. Test samples were the antibody MABL-2, the monomer and the dimer of the single chain Fv polypeptide produced by the CHO cells, and the monomer and the dimer of the single chain Fv polypeptide produced by E. coli, and the control was mouse IgG (ZYMED). For the investigation of the hemagglutination effect, round bottom 96-well plates available from Falcon were used. 50 μ L per well of the aforementioned antibody samples and 50 μ L of the 2% erythrocyte suspension were added and mixed in the well. After incubation for 2 hours at 37°C, the reaction mixtures were stored at 4°C overnight and the hemagglutination thereof was determined. As a control, 50 μ L per well of PBS(-) was used and the hemagglutination test was carried out in the same manner. The mouse IgG and antibody MABL-2 were employed at 0.01, 0.1, 1.0, 10.0 or 100.0 μ g/mL of the final concentration of the antibodies. The single chain Fvs were employed at 0.004, 0.04, 0.4, 4.0, 40.0 or 80.0 μ g/mL of the final concentration and further at 160.0 μ g/mL only in the case of the dimer of the polypeptide produced by E. coli. Results are shown in the Table 2. In the case of antibody MABL-2, the hemagglutination was observed at a concentration of more than 0.1 μ g/mL, whereas no hemagglutination was observed for both the monomer and the dimer of the single chain Fv.

Table 2 Hemagglutination Test

	Control	0.01	0.1	1	10	100	$\mu\text{g/mL}$		
mIgG	-	-	-	-	-	-			
MABL-2 (intact)	-	-	+	+++	+++	++			
	Control	0.004	0.04	0.4	4	40	80	$\mu\text{g/mL}$	
scFv/CHO monomer	-	-	-	-	-	-	-		
scFv/CHO dimer	-	-	-	-	-	-	-		
	Control	0.004	0.04	0.4	4	40	80	160	$\mu\text{g/mL}$
scFv/E.coli monomer	-	-	-	-	-	-	-	-	
scFv/E.coli dimer	-	-	-	-	-	-	-	-	

Example 6 Modified antibody $\text{sc}(\text{Fv})_2$ comprising two H chain V regions and two L chain V regions and antibody MABL-2 scFvs having linkers with different length

6.1 Construction of plasmid expressing antibody MABL-2

sc(Fv)₂

For the preparation of a plasmid expressing the modified antibody [$\text{sc}(\text{Fv})_2$] which comprises two H chain V regions and two L chain V regions derived from the antibody MABL-2, the aforementioned pCHOM2, which comprises the DNA encoding scFv derived from the MABL-2 described above, was modified by the PCR method as mentioned below and the resulting DNA fragment was introduced into pCHOM2.

Primers employed for the PCR are EF1 primer (SEQ ID NO: 30) as a sense primer, which is designed to hybridize to a DNA encoding EF1 α , and an antisense primer (SEQ ID NO: 19), which is designed to hybridize to the DNA encoding C-terminal of the L chain V region and to contain a DNA

sequence coding for a linker region, and VLLAS primer containing Sall restriction enzyme recognition site (SEQ ID NO 31).

100 μ l of the PCR solution comprises 10 μ l of 10 x
5 PCR Buffer #1, 1 mM MgCl₂, 0.2 mM dNTPs (dATP, dGTP, dCTP and dTTP), 5 units of KOD DNA polymerase (Toyobo, Inc.), 1 μ M of each primer and 100 ng of the template DNA (pCHOM2). The PCR solution was heated at 94°C for 30 seconds, at 50°C for 30 seconds and at 74°C for 1 minute in order. This
10 temperature cycle was repeated 30 times.

The PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and digested by Sall. The resultant DNA fragment was cloned into pBluescript KS⁺ vector (Toyobo, Inc.). After DNA sequencing, a plasmid
15 comprising the desired DNA sequence was digested by Sall and the obtained DNA fragment was connected using Rapid DNA Ligation Kit (BOEHRINGER MANNHEIM) to pCHOM2 digested by Sall. After DNA sequencing, a plasmid comprising the desired DNA sequence is designated as "pCHOM2(Fv)₂" (see Fig. 34).
20 The nucleotide sequence and the amino acid sequence of the antibody MABL-2 sc(Fv)₂ region contained in the plasmid pCHOM2(Fv)₂ are shown in SEQ ID No. 32.

6.2 Preparation of Plasmid expressing antibody MABL-2 scFvs having linkers with various length

25 The scFvs containing linkers with different length and the V regions which are designed in the order of [H chain]-[L chain] (hereinafter "HL") or [L chain]-[H chain]

(hereinafter "LH") were prepared using, as a template, cDNAs encoding the H chain and the L chain derived from the MABL-2 as mentioned below.

To construct HL type scFv the PCR procedure was carried out using pCHOM2(Fv)₂ as a template. In the PCR step, a pair of CFHL-F1 primer (SEQ ID NO: 33) and CFHL-R2 primer (SEQ ID NO: 34) or a pair of CFHL-F2 primer (SEQ ID NO: 35) and CFHL-R1 primer (SEQ ID NO: 36) and KOD polymerase were employed. The PCR procedure was carried out by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order to produce a cDNA for the H chain containing a leader sequence at 5'-end or a cDNA for the L chain containing FLAG sequence at 3'-end thereof. The resultant cDNAs for the H chain and the L chain were mixed and PCR was carried out by repeating 5 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order using the mixture as templates and the KOD polymerase. To the reaction mixture were added CFHL-F1 and CFHL-R1 primers and then the PCR reaction was performed by repeating 30 times of the aforementioned temperature cycle to produce a cDNA for HL-0 type without a linker.

To construct LH type scFv, the PCR reaction was carried out using, as a template, pGEM-M2L and pGEM-M2H which contain cDNAs encoding the L chain V region and the H chain V region from the antibody MABL-2, respectively (see

JP- Appl. 11-63557). A pair of T7 primer (SEQ ID NO: 37) and CFLH-R2 primer (SEQ ID NO: 38) or a pair of CFLH-F2 primer (SEQ ID NO: 39) and CFLH-R1 (SEQ ID NO: 40) and the KOD polymerase (Toyobo Inc.) were employed. The PCR reaction was performed by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in sequential order to produce a cDNA of an L chain containing a leader sequence at 5'-end or a cDNA of an H chain containing FLAG sequence at 3'-end thereof.

The resultant cDNAs of the L chain and the H chain were mixed and PCR was carried out using this mixture as templates and the KOD polymerase by repeating 5 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order. To the reaction mixture were added T7 and CFLH-R1 primers and the reaction was performed by repeating 30 times of the aforementioned temperature cycle. The reaction product was used as a template and PCR was carried out using a pair of CFLH-F4 primer (SEQ ID NO: 41) and CFLH-R1 primer by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order to produce a cDNA of LH-0 type without a linker.

The resultant cDNAs of LH-0 and HL-0 types were digested by EcoRI and BamHI restriction enzymes (Takara Shuzo) and the digested cDNAs were introduced into an expression plasmid INPEP4 for mammalian cells using Ligation High (Toyobo Inc.), respectively. Competent E. coli JM109

(Nippon Gene) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using QIAGEN Plasmid Maxi Kit (QUIAGEN). Thus plasmids pCF2LH-0 and pCF2HL-0 were prepared.

5 To construct the expression plasmids of HL type containing linkers with different size, pCF2HL-0, as a template, and CFHL-X3 (SEQ ID NO: 42), CFHL-X4 (SEQ ID NO: 43), CFHL-X5 (SEQ ID NO: 44), CFHL-X6 (SEQ ID NO: 45) or CFHL-X7 (SEQ ID NO: 46), as a sense primer, and BGH-1 (SEQ
10 ID NO: 47) primer, as an antisense primer, which is complementary with the vector sequence were employed. PCR reaction was carried out using the KOD polymerase by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in
15 order and the reaction products were digested by restriction enzymes XhoI and BamHI (Takara Shuzo). The digested fragments were introduced between XhoI and BamHI sites in the pCF2HL-0 using Ligation High (Toyobo Inc.), respectively. Competent E. coli JM109 was transformed with
20 each plasmid and the desired plasmids were isolated from the transformed E. coli by using Qiagen Plasmid Maxi kit. Thus expression plasmids pCF2HL-3, pCF2HL-4, pCF2HL-5, pCF2HL-6 and pCF2HL-7 were prepared.

25 To construct expression plasmid for the transient expression in COS7 cells the plasmids pCF2HL-0, pCF2HL-3, pCF2HL-4, pCF2HL-5, pCF2HL-6 and pCF2HL-7 were digested by restriction enzymes EcoRI and BamHI (Takara Shuzo) and the

resultant fragments of approximately 800 bp were purified with agarose gel electrophoresis. The obtained fragments were introduced between EcoRI and BamHI sites in an expression plasmid pCOS1 for the expression in mammalian cells by using Ligation High (Toyobo Inc.), respectively. Competent E. coli DH5 α (Toyobo Inc.) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using Qiagen Plasmid Maxi kit. Thus the expression plasmids CF2HL-0/pCOS1, CF2HL-3/pCOS1, CF2HL-4/pCOS1, CF2HL-5/pCOS1, CF2HL-6/pCOS1 and CF2HL-7/pCOS1 were prepared.

As a typical example of these plasmids, the construction of the plasmid CF2HL-0/pCOS1 is illustrated in Fig. 35 and the nucleotide sequence and the amino acid sequence of MABL2-scFv <HL-0> contained in the plasmid are shown in SEQ ID No. 48. Nucleotide sequences and amino acid sequences of the linker regions in these plasmids are also shown in Fig. 36.

To construct the expression plasmids of LH type containing linkers with different size, pCF2LH-0, as a template, and CFLH-X3 (SEQ ID NO: 49), CFLH-X4 (SEQ ID NO: 50), CFLH-X5 (SEQ ID NO: 51), CFLH-X6 (SEQ ID NO: 52) or CFLH-X7 (SEQ ID NO: 53), as a sense primer, and BGH-1 primer, as an antisense primer, which is complementary with the vector sequence were employed. PCR reaction was carried out using the KOD polymerase by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C

for 30 seconds and 72°C for 1 minute in order and the reaction products were digested by restriction enzymes XhoI and BamHI. The digested fragments were introduced into the pCF2LH-0 between XhoI and BamHI sites using Ligation High, respectively. Competent E. coli DH5α (Toyobo Inc.) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using Qiagen Plasmid Maxi kit. Thus expression plasmids pCF2LH-3, pCF2LH-4, pCF2LH-5, pCF2LH-6 and pCF2LH-7 were prepared.

To construct expression plasmid for the transient expression in COS7 cells the plasmids pCF2LH-0, pCF2LH-3, pCF2LH-4, pCF2LH-5, pCF2LH-6 and pCF2LH-7 were digested by restriction enzymes EcoRI and BamHI (Takara Shuzo) and the resultant fragments of approximately 800 bp were purified with agarose gel electrophoresis. The obtained fragments were introduced between XhoI and BamHI sites in an expression plasmid pCOS1 for the expression in mammalian cells by using the Ligation High, respectively. Competent E. coli DH5α (Toyobo Inc.) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using the Qiagen Plasmid Maxi kit. Consequently, the expression plasmids CF2LH-0/pCOS1, CF2LH-3/pCOS1, CF2LH-4/pCOS1, CF2LH-5/pCOS1, CF2LH-6/pCOS1 and CF2LH-7/pCOS1 were prepared.

As a typical example of these plasmids, the construction of the plasmid CF2LH-0/pCOS1 is illustrated in Fig. 37 and the nucleotide sequence and the amino acid

sequence of MABL2-scFv <LH-0> contained in the plasmid are shown in SEQ ID No. 54. Nucleotide sequences and amino acid sequences of the linker regions in these plasmids are also shown in Fig. 38.

5 6.3 Expression of scFvs and sc(Fv)₂ in COS7 cells

(1) Preparation of culture supernatant using serum-containing culture medium

10 The HL type and LH type of scFvs and sc(Fv)₂ were transiently expressed in COS7 cells (JCRB9127, Japan Health Sciences Foundation). COS7 cells were subcultured in DMEM media (GIBCO BRL) containing 10% fetal bovine serum (HyClone) at 37°C in carbon dioxide atmosphere incubator. The COS7 cells were transfected with CF2HL-0, 3 ~ 7/pCOS1, or CF2LH-0, 3 ~ 7/pCOS1 prepared in Example 6.2 or
15 pCHOM2(Fv)₂ vectors by electroporation using the Gene Pulser apparatus (BioRad). The DNA (10 µg) and 0.25 ml of 2 × 10⁷ cells/ml in DMEM culture medium containing 10% FBS and 5 mM BES (SIGMA) were added to a cuvette. After standing for 10 minutes the mixtures were treated with pulse at 0.17kV,
20 950µF of electric capacity. After the restoration for 10 minutes at room temperature, the electroporated cells were transferred into the DMEM culture medium (10%FBS) in 75 cm³ flask. After culturing for 72 hours, the culture supernatant was collected and centrifuged to remove cell fragments. The
25 culture supernatant was subjected to the filtration using 0.22 µm bottle top filter (FALCON) to obtain the culture supernatant (hereinafter "CM").

(2) Preparation of culture supernatant using serum-free culture medium

Cells transfected in the same manner as (1) were transferred to the DMEM medium (10% FBS) in 75 cm³ flask and cultured overnight. After the culture, the supernatant was discarded and the cells were washed with PBS and then added to CHO-S-SFM II medium (GIBCO BRL). After culturing for 72 hours, the culture supernatant was collected, centrifuged to remove cell fragments and filtered using 0.22 µm bottle top filter (FALCON) to obtain CM.

6.4 Detection of scFvs and sc(Fv)₂ in CM of COS7

The various MABL2-scFVs and sc(Fv)₂ in CM of COS7 prepared in the aforementioned Example 6.3 (2) were detected by Western Blotting method.

Each CM of COS7 was subjected to SDS-PAGE electrophoresis and transferred to REINFORCED NC membrane (Schleicher & Schuell). The membrane was blocked with 5% skim milk (Morinaga Nyu-gyo) and washed with TBS. Then an anti-FLAG antibody (SIGMA) was added thereto. The membrane was incubated at room temperature and washed. A peroxidase labeled mouse IgG antibody (Jackson Immuno Research) was added. After incubating and washing at room temperature, the substrate solution (Kirkegaard Perry Laboratories) was added to develop color (Fig. 39).

6.5 Flow cytometry

Flow cytometry was performed using the culture supernatants of COS7 cells prepared in Example 6.3 (1) to

measure the binding of the MABL2-scFVs and sc(Fv)₂ to human Integrin Associated Protein (IAP) antigen. The culture supernatants to be tested or a culture supernatant of COS7 cells as a control was added to 2×10^5 cells of the mouse leukemia cell line L1210 expressing human IAP. After
5 incubating on ice and washing, 10 µg/mL of the mouse anti-FLAG antibody (SIGMA) was added and then the cells were incubated and washed. Then, the FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was added thereto and the cells
10 were incubated and washed again. The fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON). The results of the flow cytometry show that the MABL2-scFvs having linkers with different length and the sc(Fv)₂ in the culture supernatants of COS7 have high affinity to human IAP
15 (see Figs. 40a and 40b).

6.6 Apoptosis-inducing Effect in vitro

An apoptosis-inducing action of the culture supernatants of COS7 prepared in Example 6.3 (1) was examined by Annexin-V staining (Boehringer Mannheim) using
20 the L1210 cells transfected with human IAP gene (hIAP/L1210).

To 5×10^4 cells of the hIAP/L1210 cells were added the culture supernatants of COS7 cells transfected with each vectors or a culture supernatant of COS7 cells as
25 a control at 10% of the final concentration and the mixtures were cultured for 24 hours. Then, the Annexin-V/PI staining was performed and the fluorescence intensity was measured

using the FACScan apparatus (BECTON DICKINSON). The results revealed that scFvs <HL3, 4, 6, 7, LH3, 4, 6, 7> and sc(Fv)₂ in CM of COS7 induced remarkable cell death of hIAP/L1210 cells. These results are shown in Fig. 41.

5 6.7 Construction of vectors for the expression of scFvs and sc(Fv)₂ in CHO cells

To isolate and purify MABL2-scFvs and sc(Fv)₂ from culture supernatant, the expression vectors for expressing in CHO cells were constructed as below.

10 The EcoRI-BamHI fragments of pCF2HL-0, 3 ~ 7, and pCF2LH-0, 3 ~ 7 prepared in Example 6.2 were introduced between EcoRI and BamHI sites in an expression vector pCHO1 for CHO cells using the Ligation High. Competent E. coli DH5α was transformed with them. The plasmids were isolated from the transformed E. coli using QIAGEN Plasmid Midi kit (QIAGEN) to prepare expression plasmids pCHOM2HL-0, 3 ~ 7, and pCHOM2LH-0, 3 ~ 7.

15 6.8 Production of CHO cells expressing MABL2-scFvs <HL-0, 3 ~ 7>, MABL2-scFvs <LH-0, 3 ~ 7> and sc(Fv)₂ and preparation of the culture supernatants thereof

20 CHO cells were transformed with each of the expression plasmids pCHOM2HL-0, 3 ~ 7, and pCHOM2LH-0, 3 ~ 7, constructed in Example 6.7 and pCHOM2(Fv)₂ vector to prepare the CHO cells constantly expressing each modified antibody. As a typical example thereof, the production of the CHO cells constantly expressing MABL2-scFv <HL-5> or sc(Fv)₂ is illustrated as follows.

25

The expression plasmids pCHOM2HL-5 and pCHOM2(Fv)₂ were linearized by digesting with a restriction enzyme PvuI and subjected to transfection to CHO cells by electroporation using Gene Pulser apparatus (BioRad). The DNA (10 µg) and 0.75 ml of PBS with 1 × 10⁷ cells/ml were added to a cuvette and treated with pulse at 1.5 kV, 25 µF of electric capacity. After the restoration for 10 minutes at room temperature, the electroporated cells were transferred into nucleic acid-containing α-MEM culture medium (GIBCO BRL) containing 10% fetal bovine serum and cultured. After culturing overnight, the supernatant was discarded. The cells were washed with PBS and added to nucleic acid-free α-MEM culture medium (GIBCO BRL) containing 10% fetal bovine serum. After culturing for two weeks, the cells were cultured in a medium containing 10 nM (final concentration) methotrexate (SIGMA), then 50 nM and 100 nM methotrexate. The resultant cells were cultured in serum-free CHO-S-SFM II medium (GIBCO BRL) in a roller bottle. The culture supernatant was collected, centrifuged to remove cell fragments and filtered using a filter with 0.22 µm of pore size to obtain CM, respectively.

According to the above, CHO cells which constantly express MABL2-scFvs <HL-0, -3, -4, -6, -7> and <LH-0, -3, -4, -5, -6, -7> and CMs thereof were obtained.

6.9 Purification of dimer of MABL2-scFv <HL-5> and sc(Fv)₂

The MABL2-scFv <HL-5> and the sc(Fv)₂ were purified from CMs prepared in Example 6.8 by two types of purification method as below.

<Purification Method 1>

5 HL-5 and sc(Fv)₂ were purified by the anti-FLAG antibody affinity column chromatography utilizing the FLAG sequence located at C-terminal of the polypeptides and by gel filtration. One liter of CM as obtained in 6.8 was applied onto a column (7.9ml) prepared with anti-FLAG M2 Affinity gel (SIGMA) equilibrated with 50 mM Tris-HCl buffer 10 (TBS, pH 7.5) containing 150 mM NaCl. After washing the column with TBS, the scFv was eluted by 0.1 M glycine-HCl buffer, pH 3.5. The resultant fractions were analyzed by SDS-PAGE and the elution of the scFv was confirmed. The scFv 15 fraction was mixed with Tween 20 up to 0.01% of the final concentration and concentrated using Centricon-10 (MILIPORE). The concentrate was applied onto TSKgel G3000SWG column (7.5 x 600 mm) equilibrated with 20 mM acetate buffer (pH 6.0) containing 150 mM NaCl and 0.01% Tween 20. At 0.4 20 mL/minute of the flow rate, the scFv was detected by the absorption at 280 nm. The HL-5 was eluted as the major fraction in the position of the dimer and the sc(Fv)₂ was eluted in the position of the monomer.

<Purification Method 2>

25 HL-5 and sc(Fv)₂ were purified using three steps comprising ion exchange chromatography, hydroxyapatite and gel filtration. In the ion exchange chromatography, Q

sepharose fast flow column (Pharmacia) was employed for HL-5 and SP-sepharose fast flow column was employed for $sc(Fv)_2$. In and after the second step, HL-5 and $sc(Fv)_2$ were processed by the same procedure.

5 First step for HL-5

CM of HL-5 was diluted to two times with 20 mM Tris-HCl buffer (pH 9.0) containing 0.02% Tween 20 and then the pH was adjusted to 9.0 with 1 M Tris. The solution was applied onto Q Sepharose fast flow column equilibrated with 10 20 mM Tris-HCl buffer (pH 8.5) containing 0.02% Tween 20. A polypeptide adsorbed to the column was eluted by a linear gradient of NaCl in the same buffer, from 0.1 to 0.55 M. Monitoring the eluted fractions by SDS-PAGE, the fractions containing HL-5 were collected and subjected to 15 hydroxyapatite of the second step.

First step for $sc(Fv)_2$

CM of the $sc(Fv)_2$ was diluted to two times with 20mM acetate buffer (pH 5.5) containing 0.02% Tween 20 and its pH was adjusted to 5.5 with 1 M acetic acid. The 20 solution was applied onto a SP-Sepharose fast flow column equilibrated with 20 mM acetate buffer (pH 5.5) containing 0.02% Tween 20. A polypeptide adsorbed to the column was eluted by a linear gradient of NaCl in the buffer, from 0 to 0.5 M. Monitoring the eluted fractions by SDS-PAGE, the 25 fractions containing the $sc(Fv)_2$ were collected and subjected to hydroxyapatite of the second step.

Second step: Hydroxyapatite chromatography of HL-5 and sc(Fv)₂

The fractions of HL-5 and sc(Fv)₂ obtained in the first step were separately applied onto the hydroxyapatite column (Type I, BIORAD) equilibrated with 10 mM phosphate buffer containing 0.02% Tween 20, pH 7.0. After washing the column with the same buffer, polypeptides adsorbed to the column were eluted by a linear gradient of the phosphate buffer up to 0.5 M. Monitoring the eluted fractions by SDS-PAGE, the fractions containing the desired polypeptides were collected.

Third step: Gel filtration of HL-5 and sc(Fv)₂

Each fraction obtained at the second step was separately concentrated with CentriPrep-10 (MILIPORE) and applied onto a Superdex 200 column (2.6 x 60 cm, Pharmacia) equilibrated with 20 mM acetate buffer (pH 6.0) containing 0.02% Tween 20 and 0.15 M NaCl. HL-5 was eluted in the position of the dimer, and sc(Fv)HL-5 and sc(Fv)₂ were eluted in the position of the monomer as a major peak respectively.

Since the monomer of HL-5 was hardly detected by both purification methods, it is proved that the dimers of single chain Fvs are formed in high yields when the linker for the single chain Fv contains around 5 amino acids. Furthermore, the dimer of HL-5 and the sc(Fv)₂ were stably preserved for a month at 4°C after the purification.

6.10 Evaluation of the binding activity of purified dimer of scFv <HL-5> and sc(Fv)₂ against antigen

Flow cytometry was performed using the purified dimer of MABL2-scFv <HL-5> and the purified sc(Fv)₂ in order to evaluate the binding to human Integrin Associated Protein (IAP) antigen. 10µg/ml of the purified dimer of MABL2-scFv <HL-5>, the purified sc(Fv)₂, the antibody MABL-2 as a positive control or a mouse IgG (Zymed) as a negative control was added to 2 × 10⁵ cells of the mouse leukemia cell line L1210 expressing human IAP (hIAP/L1210) or the cell line L1210 transformed with pCOS1 (pCOS1/L1210) as a control. After incubating on ice and washing, 10µg/mL of the mouse anti-FLAG antibody (SIGMA) was added and then the cells were incubated and washed. FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was added thereto and the cells were incubated and washed again. Then the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

Since the purified dimer of MABL2-scFv <HL-5> and the purified sc(Fv)₂ were specifically bound to hIAP/L1210 cells, it is confirmed that the dimer of scFv <HL-5> and the sc(Fv)₂ have high affinity to human IAP (see Fig. 42).

6.11 Apoptosis-inducing activity in vitro of purified dimer of scFv <HL-5> and sc(Fv)₂

An apoptosis-inducing action of the purified dimer of MABL2-scFv <HL-5> and the purified sc(Fv)₂ were examined by Annexin-V staining (Boehringer Mannheim) using the L1210

cells (hIAP/L1210) in which human IAP gene had been introduced and cells of human leukemic cell line CCRF-CEM.

Different concentrations of the purified dimer of MABL2-scFv <HL-5>, the purified MABL2-sc(Fv)₂, the antibody MABL-2 as a positive control or a mouse IgG as a negative control were added to 5 × 10⁴ cells of hIAP/L1210 cell line or 1 × 10⁵ cells of CCRF-CEM cell line. After culturing for 24 hours, the Annexin-V staining was carried out and the fluorescence intensity thereof was measured using the FACScan apparatus (BECTON DICKINSON). As a result the dimer of MABL2-scFv <HL-5> and the MABL2-sc(Fv)₂ remarkably induced cell death of hIAP/L1210 and CCRF-CEM in concentration-dependent manner (see Fig. 43). As a result it was shown that the dimer of MABL2-scFv <HL-5> and MABL2-sc(Fv)₂ had improved efficacy of inducing apoptosis compared with original antibody MABL-2.

6.12 Hemagglutination Test of the purified dimer of scFv <HL-5> and the sc(Fv)₂

Hemagglutination test was carried out using different concentrations of the purified dimer of scFv <HL-5> and the purified sc(Fv)₂ in accordance with Example 5.15.

The hemagglutination was observed with the antibody MABL-2 as a positive control, whereas no hemagglutination was observed with both the single chain antibody MABL2-sc(Fv)₂ and the MABL2-scFv <HL-5>. Further, there was no substantial difference in the hemagglutination

between two buffers employed with the antibody MABL-2. These results are shown in Table 3.

Hemagglutination Test

TABLE 3

Diluent : PBS

(μ g/ml)

	cont	28.9	14.45	7.225	3.6125	1.8063	0.9031	0.4516	0.2258	0.1129	0.0564	0.0282	0.0141	0.0071	0.0035	0.0018
MABL2-sc(Fv) ₂	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	cont	28.0	14.0	7.0	3.5	1.75	0.875	0.4375	0.2188	0.1094	0.0547	0.0273	0.0137	0.0068	0.0034	0.0017
MABL2-sc(Fv)<HLS>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	cont	80	40	20	10	5	2.5	1.25	0.625	0.3125	0.1563	0.0781	0.0391	0.0195	0.0098	0.0049
MABL2 (Intact)	-	+	+	+	+	+	+	+	+	+	±	-	-	-	-	-
mIgG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Diluent : Acetate Buffer															
	cont	80	40	20	10	5	2.5	1.25	0.625	0.3125	0.1563	0.0781	0.0391	0.0195	0.0098	0.0049
MABL2 (Intact)	-	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-

6.13 Antitumor effect of the purified dimer of scFv <HL-5>
and the sc(Fv)₂ for a model mouse of human myeloma

The antitumor effects were tested for the dimer of scFv <HL-5> and the sc(Fv)₂ prepared and purified in
5 Examples 6.8 and 6.9. The test was performed by using the mouse model for human myeloma produced in Example 5.1 and determining the amount of M protein produced by human myeloma cells in the mouse serum using ELISA and examining survival time of the mice. Then, the antitumor effects of
10 the dimer of scFv <HL-5> and the sc(Fv)₂ were evaluated in terms of the change of the amount of M protein in the mouse serum and the survival time of the mice.

In the test, the HL-5 and the sc(Fv)₂ were employed as a solution at 0.01, 0.1 or 1 mg/mL in vehicle
15 consisting of 150 mM NaCl, 0.02% Tween and 20 mM acetate buffer, pH 6.0 and administered to the mice at 0.1, 1 or 10 mg/kg of dosage. Control group of mice were administered only with the vehicle.

The mouse serum was gathered 26 days after the
20 transplantation of the human myeloma cells and the amount of M protein in the serum was measured using ELISA according to Example 5.14. As a result, the amount of M protein in the serum of both mice groups administered with HL-5, the dimer and the sc(Fv)₂ decreased in dose-dependent manner (see Fig.
25 44). Furthermore, a significant elongation of the survival time was observed in both groups administered with the HL-5 (Fig. 45) and with the sc(Fv)₂ (Fig. 46) in comparison with

the control group administered with the vehicle. These results show that the HL-5 and the sc(Fv)₂ of the invention have excellent antitumor effect in vivo.

Example 7

5 Single chain Fv comprising H chain V region and L chain V region of human antibody 12B5 against human MPL

A DNA encoding V regions of human monoclonal antibody 12B5 against human MPL was constructed as follows:

7.1 Construction of a gene encoding H chain V region of 12B5

10 The gene encoding H chain V region of human antibody 12B5 binding to human MPL was designed by connecting the nucleotide sequence of the gene thereof (SEQ ID NO: 55) at the 5'-end to the leader sequence (SEQ ID NO: 56) originated from human antibody gene (Eur. J. Immunol. 1996; 26: 63-69).

15 The designed nucleotide sequence was divided into four oligonucleotides having overlapping sequences of 15 bp each (12B5VH-1, 12B5VH-2, 12B5VH-3, 12B5VH-4). 12B5VH-1 (SEQ ID NO: 57) and 12B5VH-3 (SEQ ID NO: 59) were synthesized in the sense direction, and 12B5VH-2 (SEQ ID NO: 58) and 12B5VH-4

20 (SEQ ID NO: 60) in the antisense direction, respectively. After assembling each synthesized oligonucleotide by respective complementarity, the outside primers (12B5VH-S and 12B5VH-A) were added to amplify the full length of the gene. 12B5VH-S (SEQ ID NO: 61) was designed to hybridize to

25 5'-end of the leader sequence by the forward primer and to have Hind III restriction enzyme recognition site and Kozak sequence, and 12B5VH-A (SEQ ID NO: 62) was designed to

hybridize to the nucleotide sequence encoding C-terminal of H chain V region by the reverse primer and to have a splice donor sequence and BamHI restriction enzyme recognition site, respectively.

5 100 μ l of the PCR solution containing 10 μ l of 10 x PCR Gold Buffer II, 1.5mM MgCl₂, 0.08mM dNTPs (dATP, dGTP, dCTP, dTTP), 5 units of DNA-polymerase AmpliTaq Gold (all by PERKIN ELMER) and each 2.5 p mole of each synthesized oligonucleotide (12B5VH-1 to -4) was heated at 94°C of the
10 initial temperature for 9 minutes, at 94°C for 2 minutes, at 55°C for 2 minutes and 72°C for 2 minutes. After repeating the cycle two times each 100 pmole of external primer 12B5VH-S and 12B5VH-A was added. The mixture was subjected to the cycle consisting of at 94°C for 30 seconds, at 55°C
15 for 30 seconds and 72°C for 1 minute 35 times and heated at 72°C for further 5 minutes.

 The PCR product was purified by 1.5% low-melting-temperature agarose gel (Sigma), digested by restriction enzymes BamHI and Hind III, and cloned into expression
20 vector HEF-gyl for human H chain. After determining the DNA sequence the plasmid containing the correct DNA sequence was named HEF-12B5H-gyl.

 The HEF-12B5H-gyl was digested by restriction enzymes EcoRI and BamHI to produce the gene encoding 12B5VH which
25 was then cloned into an expression vector pCOS-Fd for human Fab H chain to produce pFd-12B5H. The expression vector for human Fab H chain was constructed by amplifying the DNA (SEQ

ID NO: 63) containing the intron region existing between the genes encoding human antibody H chain V region and the constant region, and the gene encoding a part of the constant region of human H chain by PCR, and inserting the PCR product into animal cell expression vector pCOS1. The human H chain constant region was amplified for the gene under the same conditions mentioned above using as the template HEF-gyl, as the forward primer G1CH1-S (SEQ ID NO: 64) which was designed to hybridize to 5'-end sequence of intron 1 and to have restriction enzyme recognition sites EcoRI and BamHI and as the reverse primer G1CH1-A (SEQ ID NO: 65) which was designed to hybridize to 3'-end DNA of human H chain constant region CH1 domain and to have a sequence encoding a part of hinge region, two stop codons and restriction enzyme recognition site Bgl II.

The nucleotide sequence and amino acid sequence of the reconstructed 12B5H chain variable region which were included in plasmids HEF-12B5H-gyl and pFd-12B5H are shown in SEQ ID NO: 66.

7.2 Construction of the gene encoding 12B5 L chain V region

The gene encoding L chain V region of human antibody 12B5 binding to human MPL was designed by connecting the nucleotide sequence of gene (SEQ ID NO: 67) at the 5'-end to the leader sequence (SEQ ID NO: 68) originated from human antibody gene 3D6 (Nuc. Acid Res. 1990: 18; 4927). In the same way as mentioned above the designed nucleotide sequence was divided into four oligonucleotides having overlapping

sequences of 15 bp each (12B5VL-1, 12B5VL-2, 12B5VL-3, 12B5VL-4) and synthesized respectively. 12B5VL-1 (SEQ ID NO: 69) and 12B5VL-3 (SEQ ID NO: 71) had sense sequences, and 12B5VL-2 (SEQ ID NO: 70) and 12B5VL-4 (SEQ ID NO: 72) had antisense sequences, respectively. Each of the synthesized oligonucleotides was assembled by respective complementarity and mixed with the external primer (12B5VL-S and 12B5VL-A) to amplify the full length of the gene. 12B5VL-S (SEQ ID NO: 73) was designed to hybridize to 5'-end of the leader sequence by the forward primer and to have Hind III restriction enzyme recognition site and Kozak sequence. 12B5VL-A (SEQ ID NO: 74) was designed to hybridize to the nucleotide sequence encoding C-terminal of L chain V region by the reverse primer and to have a splice donor sequence and BamHI restriction enzyme recognition site.

Performing the PCR as mentioned above, the PCR product was purified by 1.5% low-melting-temperature agarose gel (Sigma), digested by restriction enzymes BamHI and Hind III, and cloned into an expression vector HEF-gk for human L chain. After determining the DNA sequence the plasmid containing the correct DNA sequence was named HEF-12B5L-gk. The nucleotide sequence and amino acid sequence of the reconstructed 12B5 L chain V region which were included in plasmid HEF-12B5L-gk are shown in SEQ ID NO:75.

7.3 Production of reconstructed 12B5 single chain Fv (scFv)

The reconstructed 12B5 antibody single chain Fv was designed to be in the order of 12B5VH-linker-12B5VL and to

have FLAG sequence (SEQ ID NO: 76) at C-terminal to facilitate the detection and purification. The reconstructed 12B5 single chain Fv (sc12B5) was constructed using a linker sequence consisting of 15 amino acids represented by (Gly₄Ser)₃.

5 (1) Production of the reconstructed 12B5 single chain Fv using the linker sequence consisting of 15 amino acids

The gene encoding the reconstructed 12B5 antibody single chain Fv, which contained the linker sequence consisting of 15 amino acids, was constructed by connecting 10 12B5 H chain V region, linker region and 12B5 L chain V region which was amplified by PCR respectively. This method is schematically shown in Fig. 47. Six PCR primers (A-F) were used for production of the reconstructed 12B5 single chain Fv. Primers A, C, and E had sense sequences, and 15 primers B, D, and F had antisense sequences.

The forward primer 12B5-S (Primer A, SEQ ID NO: 77) for H chain V region was designed to hybridize to 5'-end of H chain leader sequence and to have EcoRI restriction enzyme recognition site. The reverse primer HuVHJ3 (Primer B, SEQ 20 ID NO: 78) for H chain V region was designed to hybridize to DNA encoding C-terminal of H chain V region.

The forward primer RHuJH3 (Primer C, SEQ ID NO: 79) for the linker was designed to hybridize to DNA encoding the 25 N-terminal of the linker and to overlap DNA encoding the C-terminal of H chain V region. The reverse primer RHuVK1 (Primer D, SEQ ID NO: 80) for the linker was designed to

hybridize to DNA encoding the C-terminal of the linker and overlap DNA encoding the N-terminal of L chain V region.

The forward primer HuVK1.2 (Primer E, SEQ ID NO: 81) for L chain V region was designed to hybridize to DNA encoding the N-terminal of L chain V region. The reverse primer 12B5F-A for L chain V region (Primer F, SEQ ID NO: 82) was designed to hybridize to DNA encoding C-terminal of L chain V region and to have the sequence encoding FLAG peptide (Hopp, T. P. et al., *Bio/Technology*, 6, 1204-1210, 1988), two transcription stop codons and NotI restriction enzyme recognition site.

In the first PCR step, three reactions A-B, C-D, and E-F were performed, and the three PCR products obtained from the first step PCR were assembled by respective complementarity. After adding primers A and F the full length DNA encoding the reconstructed 12B5 single chain Fv having the linker consisting of 15 amino acids was amplified (the second PCR). In the first step PCR, the plasmid HEF-12B5H-gyl (see Example 7. 1) encoding the reconstructed 12B5 H chain V region, pSCFVT7-hM21 (humanized ONS-M21 antibody) (Ohtomo et al., *Anticancer Res.* 18 (1998), 4311-4316) containing DNA (SEQ ID NO: 83) encoding the linker region consisting of Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser (Huston et al., *Proc. Natl. Acad. Sci. USA*, 85, 5879-5883, 1988) and the plasmid HEF-12B5L-gκ (see Example 7. 2) encoding the reconstructed 12B5 L chain V region were used as templates, respectively.

50 μ l of PCR solution for the first step contained 5 μ l of 10 x PCR Gold Buffer II, 1.5mM MgCl₂, 0.08mM dNTPs, 5 units of DNA polymerase AmpliTaq Gold (all by PERKIN ELMER), each 100 pmole of each primer and 100ng of each template DNA.

5 The PCR solution was heated at 94°C of the initial temperature for 9 minutes, at 94 for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute. After repeating the cycle 35 times the reaction mixture was further heated 72°C for 5 minutes.

10 The PCR products A-B, C-D, and E-F were assembled by the second PCR. PCR mixture solution for the second step of 98 μ l containing as the template 1 μ l of the first PCR product A-B, 0.5 μ l of PCR product C-D and 1 μ l of PCR product E-F, 10 μ l of 10 x PCR Gold Buffer II, 1.5mM MgCl₂, 0.08mM dNTPs, 15 5 units of DNA polymerase AmpliTaq Gold (all by PERKIN ELMER) was heated at 94°C of the initial temperature for 9 minutes, at 94°C for 2 minutes, at 65°C for 2 minutes and 72°C for 2 minutes. After repeating the cycle two times, each 100 pmole of each of primers A and F were added. After 20 repeating the cycle consisting of at 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute 35 times, the reaction mixture was heated at 72°C for 5 minutes.

The DNA fragments produced by the second PCR were purified using 1.5% low-melting-temperature agarose gel, 25 digested by EcoRI and NotI, and cloned into pCHO1 vector and pCOS1 vector (Japanese Patent Application No. 8-255196). The expression vector pCHO1 was a vector constructed by

deleting the antibody gene from DHFR- Δ E-rvH-PM1-f (see W092/19759) by EcoRI and SmaI digestion, and connecting to EcoRI-NotI-BamHI Adaptor (TAKARA SHUZO). After determining the DNA sequence the plasmids containing the DNA fragment encoding the correct amino acid sequence of reconstructed 12B5 single chain Fv were named pCHO-scl2B5 and pCOS-scl2B5. The nucleotide sequence and amino acid sequence of the reconstructed 12B5 single chain Fv included in the plasmids pCHO-scl2B5 and pCOS-scl2B5 are shown in SEQ ID NO: 84.

7.4 Expression of antibody 12B5 (IgG, Fab) and single chain Fv polypeptide by animal cell

Antibody 12B5 (IgG, Fab) and single chain Fv derived from antibody 12B5 were expressed by using COS-7 cells or CHO cells.

The transient expression using COS-7 cells was performed as follows. The transfection was performed by electroporation method using Gene Pulser equipment (BioRad). For the expression of antibody 12B5 (IgG) each 10 μ g of the above-mentioned expression vector HEF-12B5H-gy1 and HEF-12B5L-g κ were added, for the expression of 12B5Fab fragment each 10 μ g of pFd-12B5H and HEF-12B5L-g κ were added and for the expression of single chain Fv 10 μ g of pCOS-scl2B5 was added to COS-7 cells (1×10^7 cells/ml) suspended in 0.8ml of PBS. The mixture kept in a cuvette was treated by pulse at the capacity of 1.5kV, 25 μ FD. After recovering for 10 minutes in a room temperature the electroporated cells were added to DMEM culture medium (GIBCO BRL) containing 10%

bovine fetal serum cultivated. After cultivating overnight the cells were washed once by PBS, added to serum-free medium CHO-S-SFM II and cultivated for 2 days. The culture medium was centrifuged to remove cell debris and filtered with 0.22 μ m filter to prepare the culture supernatant.

To establish a stable expression CHO cell line for the single chain Fv (polypeptide) derived from antibody 12B5, the expression vector pCHO-scl2B5 was introduced into CHO cells as follows.

The expression vector was introduced into CHO cells by electroporation method using Gene Pulser equipment (BioRad). Linearized DNA (100 μ g) obtained by digestion with restriction enzyme PvuI and CHO cells (1×10^7 cells /ml) suspended in 0.8 ml of PBS were mixed in a cuvette, left stationary on ice for 10 minutes and treated with pulse at the capacity of 1.5kV, 25 μ FD. After recovering for 10 minutes at a room temperature the electroporated cells were added to CHO-S-SFM II (GIBCO BRL) containing 10% bovine fetal serum and cultivated. After cultivating for 2 days the cultivation was continued in CHO-S-SFM II (GIBCO BRL) containing 5nM methotrexate (SIGMA) and 10% bovine fetal serum. From thus obtained clones a clone with high expression rate was selected as the production cell line for 12B5 single chain Fv. After cultivating in serum-free medium CHO-S-SFM II (GIBCO BRL) containing 5nM methotrexate (SIGMA), the culture supernatant was obtained by centrifugal separation of cell debris.

7.5 Purification of single chain Fv derived from 12B5
produced by CHO cells

The culture supernatant of CHO cell line expressing
12B5 single chain Fv obtained in 7.4 was purified by anti-
5 FLAG antibody column and gel filtration column.

(1) Anti-FLAG antibody column

The culture supernatant was added to anti-FLAG M2 affinity
gel (SIGMA) equilibrated by PBS. After washing the column
by the same buffer the proteins adsorbed to the column were
10 eluted by 0.1M glycine-HCl buffer (pH 3.5). The eluted
fractions were immediately neutralized by adding 1M Tris-HCl
buffer (pH 8.0). The eluted fractions were analyzed by SDS-
PAGE and the fraction which was confirmed to contain the
single chain Fv was concentrated using Centricon-10
15 (MILLIPORE).

(2) Gel filtration

The concentrated solution obtained in (1) was added to
Superdex200 column (10x300mm, AMERSHAM PHARMACIA)
equilibrated by PBS containing 0.01% Tween20.

20 The product sc12B5 was eluted in two peaks (A, B) (see Fig.
48). The fractions A and B were analyzed using the 14%-SDS-
polyacrylamide gel. The sample was processed by
electrophoresis in the presence and absence of a reducing
agent according to Laemmli method, and stained by Coomassie
25 Brilliant Blue after the electrophoresis. As shown in Fig.
49 the fractions A and B, regardless of the presence of the
reducing agent or its absence, produced a single band having

an apparent molecular weight of about 31 kD. When the fractions A and B were analyzed by gel filtration using Superdex200 PC 3.2/30 (3.2x300mm, AMERSHAM PHARMACIA), the fraction A produced an eluted product at an apparent
5 molecular weight of about 44 kD and the fraction B produced at 22kD (see Fig. 50a and b). The results show that the fraction A is the non-covalent bond dimer of sc12B5 single chain Fv, and B is the monomer.

10 7.6 Measurement of TPO-like agonist activity of various single chain Fvs

The TPO-like activity of anti-MPL single chain antibody was evaluated by measuring the proliferation activity to Ba/F3 cells (BaF/mpl) expressing human TPO receptor (MPL). After washing BaF/Mpl cells two times by RPMI1640 culture medium
15 (GIBCO) containing 10% bovine fetal serum (GIBCO), the cells were suspended in the culture medium at cell density of 5×10^5 cells/ml. The anti-MPL single chain antibody and human TPO (R&D Systems) was diluted with the culture medium, respectively. 50 μ l of the cell suspension and 50 μ l of the
20 diluted antibody or human TPO were added in 96-well microplate (flat bottom) (Falcon), and cultivated in CO₂ incubator (CO₂ concentration: 5%) for 24 hours. After the incubation 10 μ l of WST-8 reagent (reagent for measuring the number of raw cells SF: Nacalai Tesque) was added and the
25 absorbance was immediately measured at measurement wavelength of 450nm and at reference wavelength of 620nm using fluorescence absorbency photometer SPECTRA Fluor

(TECAN). After incubating in CO₂ incubator (CO₂ concentration: 5%) for 2 hours, the absorbance at 450nm of measurement wavelength and 620nm of reference wavelength was again measured using SPECTRA Fluor. Since WST-8 reagent developed the color reaction depending upon the number of live cells at wavelength of 450nm, the proliferation activity of BaF/Mpl based on the change of absorbance in 2 hours was evaluated by ED 50 calculated as follows. In the proliferation reaction curve wherein the absorbance was plotted on the ordinate against the antibody concentration on the abscissa, the absorbance at the plateau was set 100% reaction rate. Obtaining an approximation formula by straight line approximation method based on the plotted values close to 50% reaction rate, the antibody concentration of 50% reaction rate was calculated and adopted as ED 50.

The results of the agonist activity to MPL measured by using culture supernatants of COS-7 cells expressing various 12B5 antibody molecules showed as illustrated in Fig. 51 that 12B5IgG having bivalent antigen-binding site increased the absorbance in concentration-dependent manner and had TPO-like agonist activity (ED50; 29nM), while the agonist activity of 12B5Fab having monovalent antigen-binding site was very weak (ED50; 34,724nM). On the contrary the single chain Fv (sc12B5) having monovalent antigen-binding site like Fab showed strong agonist activity at a level that ED50 was 75nM. However it has been known that variable regions

of H chain and L chain of the single chain Fv are associated through non-covalent bond and, therefore, each variable region is dissociated in a solution and can be associated with variable region of other molecule to form multimers like dimers. When the molecular weight of scl2B5 purified by gel filtration was measured, it was confirmed that there were molecules recognized to be monomer and dimer (see Fig. 48). Then monomer scl2B5 and dimer scl2B5 were isolated (see Fig. 50) and measured for the agonist activity to MPL. As shown in Figs. 51 and 52, ED50 of scl2B5 monomer was 4438.7nM, which confirmed that the agonist activity was reduced compared with the result using culture supernatant of COS-7 cells. On the contrary single chain Fv (scl2B5 dimer) having bivalent antigen-binding site showed about 400-fold stronger agonist activity (ED50; 10.1nM) compared with monovalent scl2B5. Furthermore, the bivalent single chain Fv showed the agonist activity equivalent to or higher than the agonist activity of human TPO and 12B5IgG.

Example 8

Construction of a gene encoding the variable region of human antibody 12E10 against human MPL

A DNA encoding variable region of human monoclonal antibody 12E10 against human MPL was constructed as follows:

8.1 Construction of a gene encoding 12E10 H chain V region

The nucleotide sequence SEQ ID NO:86 was designed as a gene encoding H chain V region of human antibody 12E10 binding to human MPL on the basis of the amino acid sequence

described in W099/10494 (SEQ ID NO:85). The full length of nucleotide sequence was designed by connecting to its 5'-end the leader sequence (SEQ ID NO:87) derived from human antibody gene (GenBank accession No. AF062252). The designed nucleotide sequence was divided into four oligonucleotides having overlapping sequences of 15 bp each (12E10VH1, 12E10VH2, 12E10VH3, 12E10VH4). 12E10VH1 (SEQ ID NO: 88) and 12E10VH3 (SEQ ID NO: 90) were synthesized in the sense direction, and 12E10VH2 (SEQ ID NO: 89) and 12E10VH4 (SEQ ID NO: 91) in the antisense direction, respectively. After assembling each synthesized oligonucleotide by respective complementarity, the external primers (12E10VHS and 12E10VHA) were added to amplify the full length of the gene. 12E10VHS (SEQ ID NO: 92) was designed to hybridize to 5'-end of the leader sequence by the forward primer and to have Hind III restriction enzyme recognition site and Kozak sequence, and 12E10VHA (SEQ ID NO: 93) was designed to hybridize to the nucleotide sequence encoding C-terminal of H chain V region by the reverse primer and to have a splice donor sequence and BamHI restriction enzyme recognition site, respectively.

100 μ l of the PCR solution containing 10 μ l of 10 x PCR Gold Buffer II, 1.5mM MgCl₂, 0.08mM dNTPs (dATP, dGTP, dCTP, dTTP), 5 units of DNA-polymerase AmpliTaq Gold (all by PERKIN ELMER) and each 2.5pmole of each synthesized oligonucleotide (12E5VH-1 to -4) was heated at 94°C of the initial temperature for 9 minutes, at 94°C for 2 minutes, at

55°C for 2 minutes and 72°C for 2 minutes. After repeating the cycle two times each 100 pmole of external primer 12E10VHS and 12E10VHA were added. The mixture was subjected to the cycle consisting of at 94°C for 30 seconds, at 55°C
5 for 30 seconds and 72°C for 1 minute 35 times and heated at 72°C for further 5 minutes.

The PCR product was purified by 1.5% low-melting-temperature agarose gel (Sigma), digested by restriction enzymes BamHI and Hind III, and cloned into a human H chain
10 expression vector HEF-gyl. After determining the DNA sequence the plasmid containing the correct DNA sequence was named HEF-12E10H-gyl.

The HEF-12E10H-gyl was digested by restriction enzymes EcoRI and BamHI to produce the gene encoding 12E10VH and
15 then cloned into a human Fab H chain expression vector pCOS-Fd to produce pFd-12E10H. The human Fab H chain expression vector was constructed by amplifying the DNA (SEQ ID NO: 63) containing the intron region existing between the genes encoding human antibody H chain V region and the constant
20 region, and the gene encoding a part of the human H chain constant region by PCR, and inserting the PCR product into animal cell expression vector pCOS1. The human H chain constant region was amplified for the gene under the same conditions mentioned above using as the template HEF-gyl, as
25 the forward primer G1CH1-S (SEQ ID NO: 64) which was designed to hybridize to 5'-end sequence of intron 1 and to have restriction enzyme recognition sites EcoRI and BamHI

and as the reverse primer G1CH1-A (SEQ ID NO: 65) which was designed to hybridize to 3'-end DNA of human H chain constant region CH1 domain and to have a sequence encoding a part of hinge region, two stop codons and restriction enzyme recognition site Bgl II.

The nucleotide sequence and amino acid sequence of the reconstructed 12E10 H chain variable region which were included in plasmids HEF-12E10H-gyl and pFd-12E10H are shown in SEQ ID NO: 94.

10 8.2 Construction of a gene encoding 12E10 L chain V region

The nucleotide sequence SEQ ID NO:96 was designed as a gene encoding L chain V region of human antibody 12E10 binding to human MPL on the basis of the amino acid sequence described in WO99/10494 (SEQ ID NO:95). It was further designed by connecting to its 5'-end the leader sequence (SEQ ID NO: 97) derived from human antibody gene (Mol. Immunol. 1992; 29: 1515-1518). In the same way as mentioned above the designed nucleotide sequence was divided into four oligonucleotides having overlapping sequences of 15 bp each (12E10VL1, 12E10VL2, 12E10VL3, 12E10VL4) and synthesized respectively. 12E10VL1 (SEQ ID NO: 98) and 12E10VL3 (SEQ ID NO: 100) had sense sequences, and 12E10VL2 (SEQ ID NO: 99) and 12E10VL4 (SEQ ID NO: 101) had antisense sequences, respectively. Each of the synthesized oligonucleotides was assembled by respective complementarity and mixed with the external primers (12E10VLS and 12E10VLA) to amplify the full length of the gene. 12E10VLS (SEQ ID NO: 102) was designed

to hybridize to 5'-end of the leader sequence by the forward primer and to have EcoRI restriction enzyme recognition site and Kozak sequence. 12E10VLA (SEQ ID NO: 103) was designed to hybridize to the nucleotide sequence encoding C-terminal
5 of L chain V region by the reverse primer and to have a BlnI restriction enzyme recognition site.

Performing the PCR as mentioned above, the PCR product was purified by 1.5% low-melting-temperature agarose gel (Sigma), digested by restriction enzymes EcoRI and BlnI, and
10 cloned into pUC19 containing a gene for human lambda chain constant region. After determining the DNA sequence the plasmid containing the correct DNA sequence was digested by EcoRI to produce a gene encoding 12E10 L chain V region and human lambda chain constant region and then inserted in
15 expression vector pCOS1. The plasmid having 12E10 L chain gene (SEQ ID NO: 104) was named pCOS-12E10L

8.3 Production of reconstructed 12E10 single chain Fv

The reconstructed 12E10 antibody single chain Fv was designed to be in the order of 12E10VH-linker-12E10VL and to
20 have FLAG sequence (SEQ ID NO: 105) at C-terminal to facilitate the detection and purification. The reconstructed 12E10 chain Fvs (scl2E10 and dbl2E10) were constructed using a linker sequence consisting of 15 amino acids represented by (Gly₄Ser)₃ or 5 amino acids represented by (Gly₄Ser)₁.

25 (1) Production of the reconstructed 12E10 single chain Fv using the linker sequence consisting of 5 amino acids

The gene encoding the reconstructed 12E10 single chain Fv, which contained the linker sequence consisting of 5 amino acids, was constructed by introducing the nucleotide sequence for the linker (Gly₄Ser)₁ to 3'-end of the gene encoding 12E10 H chain V region and to 5'-end of the gene encoding 12E10 L chain V region, amplifying thus obtained respective gene by PCR and connecting the amplified genes. Four PCR primers (A-D) were used to produce the reconstructed 12E10 single chain Fv. Primers A and C had sense sequences, and primers B and D had antisense sequences.

The forward primer for H chain V region was 12E10S (Primer A, SEQ ID NO: 106). The reverse primer DB2 (Primer B, SEQ ID NO: 107) for H chain V region was designed to hybridize to DNA encoding C-terminal of H chain V region and to have the nucleotide sequence encoding the linker (Gly₄Ser)₁ and the nucleotide sequence encoding N-terminal of L chain V region.

The forward primer DB1 (Primer C, SEQ ID NO: 108) for L chain V region was designed to hybridize to DNA encoding the N-terminal of L chain V region and to have the nucleotide sequence encoding the linker (Gly₄Ser)₁ and the nucleotide sequence encoding C-terminal of H chain V region. The reverse primer 12E10FA (Primer D, SEQ ID NO: 109) for L chain V region was designed to hybridize to DNA encoding the C-terminal of L chain V region and to have the nucleotide sequence encoding FLAG and NotI restriction enzyme recognition site.

In the first PCR step, two reactions A-B and C-D were performed, and the two PCR products obtained from the first step PCR were assembled by respective complementarity.

After adding primers A and D the full length DNA encoding the reconstructed 12E10 single chain Fv having the linker consisting of 5 amino acids was amplified (the second PCR).

In the first step PCR, the plasmid HEF-12E10H-gyl (see Example 8. 1) encoding the reconstructed 12E10 H chain V region and pCOS-12E10L (see Example 8.2) encoding the reconstructed 12E10 L chain V region were used as templates, respectively.

50 μ l of the first step PCR solution contained 5 μ l of 10 x PCR Gold Buffer II, 1.5mM MgCl₂, 0.08mM dNTPs, 5 units of DNA polymerase AmpliTaq Gold (by PERKIN ELMER), each 100 pmole of each primer and 100ng of each template DNA. The PCR solution was heated at 94 $^{\circ}$ C of the initial temperature for 9 minutes, at 94 for 30 seconds, 55 $^{\circ}$ C for 30 seconds and 72 $^{\circ}$ C for 1 minute. After repeating the cycle 35 times the reaction mixture was further heated at 72 $^{\circ}$ C for 5 minutes.

The PCR products A-B (429bp) and C-D (395bp) were assembled by the second PCR. The second step PCR mixture solution (98 μ l) containing 1 μ l each of the first PCR product A-B and C-D as templates, 100 pmole each of each primer, 10 μ l of 10 x PCR Gold Buffer II, 1.5mM MgCl₂, 0.08mM dNTPs and 5 units of DNA polymerase AmpliTaq Gold (by PERKIN ELMER) was reacted under the same conditions as mentioned above.

The DNA fragment of 795bp produced by the second PCR was purified using 1.5% low-melting-temperature agarose gel, digested by EcoRI and NotI, and cloned into pCHO1 vector or pCOS1 vector. The expression vector pCHO1 was a vector
5 constructed by deleting the antibody gene from DHFR- Δ E-RVH-PM1-f (see WO92/19759) by EcoRI and SmaI digestion, and connecting to EcoRI-NotI-BamHI Adaptor (TAKARA SHUZO). After determining the DNA sequence the plasmids containing the DNA fragment encoding the correct amino acid sequence of
10 reconstructed 12E10 single chain Fv were named pCHO-db12E10 and pCOS-db12E10. The nucleotide sequence and amino acid sequence of the reconstructed 12E10 single chain Fv included in the plasmids pCHO-db12E10 and pCOS-db12E10 are shown in SEQ ID NO: 110.

15 (2) Production of the reconstructed 12E10 single chain Fv using the linker sequence consisting of 15 amino acids

The gene encoding the reconstructed 12E10 antibody single chain Fv, which contained the linker sequence consisting of 15 amino acids, was constructed by introducing
20 the nucleotide sequence for the linker (Gly₄Ser)₃ to 3'-end of the gene encoding 12E10 H chain V region and to 5'-end of the gene encoding 12E10 L chain V region, amplifying thus obtained respective gene by PCR and connecting the amplified genes. Four PCR primers (A-D) were used for production of
25 the reconstructed 12E10 single chain Fv. Primers A and C had sense sequences, and primers B and D had antisense sequences.

The forward primer for H chain V region was 12E10S (Primer A, SEQ ID NO: 106). The reverse primer sc4.3 (Primer B, SEQ ID NO: 111) for H chain V region was designed to hybridize to DNA encoding C-terminal of H chain V region and to have the nucleotide sequence encoding the linker (Gly₄Ser)₃ and the nucleotide sequence encoding N-terminal of L chain V region.

The forward primer scl.3 (Primer C, SEQ ID NO: 112) for L chain V region was designed to hybridize to DNA encoding the N-terminal of L chain V region and to have the nucleotide sequence encoding the linker (Gly₄Ser)₃ and the nucleotide sequence encoding C-terminal of H chain V region. The reverse primer 12E10FA (Primer D, SEQ ID NO: 109) for L chain V region was designed to hybridize to DNA encoding the C-terminal of L chain V region and to have the nucleotide sequence encoding FLAG and NotI restriction enzyme recognition site.

In the first PCR step, two reactions A-B and C-D were performed, and the two PCR products obtained from the first step PCR were assembled by respective complementarity. After adding primers A and D the full length DNA encoding the reconstructed 12E10 single chain Fv having the linker consisting of 15 amino acids was amplified (the second PCR). In the first step PCR, the plasmid pCOS-dbl2E10 (see Example 8. 3(1)) encoding the reconstructed 12E10 single chain Fv was used as template.

50 μ l of the first step PCR solution contained 5 μ l of 10 x ExTaq Buffer, 0.4mM dNTPs, 2.5 units of DNA polymerase TaKaRa ExTaq (by TAKARA), each 100 pmole of each primer and 10ng of each template DNA. The PCR solution was heated at 94°C of the initial temperature for 30 seconds, at 94 for 15 seconds and 72°C for 2 minute, and the cycle was repeated 5 times. After repeating 28 times the cycle of at 94°C for 15 seconds and at 70°C for 2 minutes, the reaction mixture was further heated at 72°C for 5 minutes.

The PCR products A-B (477bp) and C-D (447bp) were assembled by the second PCR. The second step PCR mixture solution (98 μ l) containing 1 μ l each of the first PCR products A-B and C-D as templates, 100 pmole each of each primer A and D, 5 μ l of 10 x ExTaq Buffer, 0.4mM dNTPs, 2.5 units of DNA polymerase TaKaRa ExTaq (by TAKARA) was reacted under the same conditions as mentioned above.

The DNA fragment of 825bp produced by the second PCR was purified using 1.0% low-melting-temperature agarose gel, digested by EcoRI and NotI. Thus obtained DNA fragment was cloned into pCHO1 vector or pCOS1 vector. After determining the DNA sequence the plasmids containing the DNA fragment encoding the correct amino acid sequence of reconstructed 12E10 single chain Fv were named pCHO-scl2E10 and pCOS-scl2E10. The nucleotide sequence and amino acid sequence of the reconstructed 12E10 single chain Fv included in the plasmids pCHO-scl2E10 and pCOS-scl2E10 are shown in SEQ ID NO: 113.

8.4 Expression of antibody 12E10 (IgG, Fab) and single chain Fv polypeptide by animal cell

Antibody 12E10 (IgG, Fab) and single chain Fv derived from antibody 12E10 (linker sequence 5 amino acids, 15 amino acids) were expressed by using COS-7 cells or CHO cells.

The transient expression using COS-7 cells was performed as follows. The transfection was performed by electroporation method using Gene Pulser II equipment (BioRad). For the expression of antibody 12E10 (IgG) each 10µg of the above-mentioned expression vector HEF-12E10H-gy1 and pCOS-12E10L were added, for the expression of 12E10Fab fragment each 10µg of pFd-12E10H and pCOS-12E10L were added and for the expression of single chain Fv of pCOS-scl2E10 (10µg) or pCOS-db12E10 (10µg) was added to COS-7 cells (1×10⁷ cells/ml) suspended in 0.8ml of PBS. The mixture kept in a cuvette was treated by pulse at the capacity of 1.5kV, 25µFD. After recovering for 10 minutes in a room temperature the electroporated cells were added to DMEM medium (GIBCO BRL) containing 10% bovine fetal serum and cultivated. After cultivating overnight the cells were washed once by PBS, added to serum-free medium CHO-S-SFM II (GIBCO BRL) and cultivated for 3 days. The culture supernatant was centrifuged to remove cell debris and filtered with 0.22µm filter.

To establish a stable expression CHO cell line for the single chain Fv (polypeptide) derived from antibody 12E10,

the expression vector pCHO-scl2E10 or pCHO-dsl2E10 was introduced into CHO cells respectively.

Each expression vector was introduced into CHO cells by electroporation method using Gene Pulser II equipment (BioRad). Linearized DNA (100µg) obtained by digestion with restriction enzyme PvuI and CHO cells (1×10^7 cells /ml) suspended in 0.8 ml of PBS were mixed in a cuvette, left stationary on ice for 10 minutes and treated with pulse at the capacity of 1.5kV, 25µFD. After recovering for 10 minutes at a room temperature the electroporated cells were added to CHO-S-SFM II medium (GIBCO BRL) containing 10% dialyzed bovine fetal serum and nucleic acid and cultivated. After cultivating for 2 days the cultivation was continued in nucleic acid-free CHO-S-SFM II medium (GIBCO BRL) containing 10% dialyzed bovine fetal serum. From thus obtained clones a clone with high expression rate was selected as the production cell line for 12E10 single chain Fv. After cultivating in serum-free CHO-S-SFM II medium (GIBCO BRL), the culture supernatant was centrifuged to remove cell debris and filtered with 0.22µm filter.

8.5 Purification of single chain Fv derived from 12E10 produced by CHO cells

The culture supernatants produced by CHO cell lines expressing 12E10 single chain Fvs (scl2E10, dbl2E10) obtained in Example 8.4 were purified by anti-FLAG antibody column and gel filtration column respectively to produce purified single chain Fvs.

(1) Purification with anti-FLAG antibody column

Each culture supernatant (sc12E10, db12E10) was added to anti-FLAG M2 affinity gel column (SIGMA) equilibrated by 50mM Tris-HCl buffer (pH7.4) containing 150mM NaCl. After
5 washing the column by the same buffer the proteins adsorbed to the column were eluted by 100mM glycine buffer (pH 3.5). The eluted fractions were immediately neutralized by adding 1M Tris-HCl buffer (pH 8.0) and analyzed by SDS-PAGE. The
10 fraction which was confirmed to contain the single chain Fv was pooled and concentrated about 20-fold using Centricon-10 (AMICON).

(2) Gel filtration

The concentrated solution obtained in (1) was added to Superdex200 column HR (10x300mm, AMERSHAM PHARMACIA)
15 equilibrated by PBS containing 0.01% Tween20. Chromatograms were shown in Fig. 53 and 54. The product sc12E10 was eluted in two peaks (A, B) (see Fig. 53). The product db12E10 was eluted in two peaks (C, D) (see Fig. 54). Each peak
20 fraction was collected, treated in the presence and absence of a reducing agent, processed by electrophoresis according to Laemmli method and stained by Coomassie Brilliant Blue after the electrophoresis. As shown in Fig. 55 the all of
25 fractions A, B, C and D, regardless of the presence or absence of the reducing agent, produced a single band having an apparent molecular weight of about 31 kD. When these fractions were analyzed by gel filtration using Superdex200 HR, the fraction A produced a product eluted at an apparent

molecular weight of about 42 kD, the fraction B at 20kD (see Fig. 56), fraction C at 69kD and fraction D at 41kD (see Fig. 57). The results suggest that scl2E10-derived fraction A is the non-covalent bond dimer of single chain Fv and the fraction B is the monomer of single chain Fv, and the db12E10-derived fraction C is the non-covalent bond trimer of single chain Fv and D is non-covalent bond dimer of single chain Fv.

8.6 Measurement of TPO-like agonist activity of various single chain Fvs

The TPO-like activity of anti-mpl single chain antibody was evaluated by measuring the proliferation activity to Ba/F3 cells (BaF/mpl) expressing human TPO receptor (MPL).

After washing BaF/mpl cells two times by RPMI1640 medium (GIBCO) containing 1% bovine fetal serum (GIBCO), the cells were suspended in the medium at cell density of 5×10^5 cells/mL. The anti-MPL single chain antibody or human TPO (R&D Systems) was diluted with the medium, respectively. 50 μ l of the cell suspension and 50 μ l of the diluted antibody or human TPO were added in 96-well microplate (flat bottom) (Corning), and cultivated in CO₂ incubator (CO₂ concentration: 5%) for 24 hours. After the incubation 10 μ l of WST-8 reagent (reagent for measuring the number of raw cells SF: Nacalai Tesque) was added and the absorbance was immediately measured at measurement wavelength of 450nm and at reference wavelength of 655nm using absorbency photometer

Benchmark Plus (BioRad). After incubating in CO₂ incubator (CO₂ concentration: 5%) for 2 hours, the absorbance at 450nm of measurement wavelength and 655nm of reference wavelength was again measured using Benchmark Plus. Since WST-8 reagent developed the color reaction depending upon the number of live cells at wavelength of 450nm, the proliferation activity of BaF/mpl was evaluated based on the change of absorbance in 2 hours.

The agonist activity to MPL measured by using culture supernatants of COS-7 cells expressing various 12E10 antibody molecules are shown in Fig. 58. Single chain Fvs having the 5-amino-acid-linker (ds12E10) and the 15-amino-acid-linker (sc12E10) increased the absorbance in concentration-dependent manner, showing TPO-like agonist activity (ED₅₀; 9pM and 51pM respectively), while 12E10IgG and 12E10Fab had no activity.

It has been known that H chain and L chain of the single chain Fv are associated not only within a molecule but also between molecules to form multimers such as dimer. When the culture supernatants of CHO cells expressing single chain Fvs of 12E10 were gel filtrated and tested for agonist activity on MPL. The results were shown in Fig. 59. The dimer, which was contained in sc12E10 in a small amount, showed about 5000-fold stronger TPO-like agonist activity (sc12E10 dimer, ED₅₀; 1.9pM) compared with the monomer (sc12E10 monomer, ED₅₀; >10nM). The activity was higher than that of TPO (ED₅₀; 27pM). The dimer of db12E10 (db12E10

dimer, ED50;2.0pM) showed strong activity comparable to that of scl2E10 dimer. db12E10 trimer (ED50; 7.4pM), which was presumed to be a trimer from molecular weight obtained by gel filtration, showed a high activity which is lower than that of db12E10 dimer. Those results suggest that it is important for the activity of agonist antibody 12E10 that the antigen-binding site is bivalent (dimer). Considering the fact that 12E10 IgG had no activity, other factors than being bivalent are presumed to be important such as the location of antigen-binding site, the distance or the angle.

EXPLANATION OF DRAWINGS

Fig. 1 shows the result of flow cytometry, illustrating that human IgG antibody does not bind to L1210 cells expressing human IAP (hIAP/L1210).

Fig. 2 shows the result of flow cytometry, illustrating that the chimera MABL-1 antibody specifically binds to L1210 cells expressing human IAP (hIAP/L1210).

Fig. 3 shows the result of flow cytometry, illustrating that the chimera MABL-2 antibody specifically binds to L1210 cells expressing human IAP (hIAP/L1210).

Fig. 4 schematically illustrates the process for producing the single chain Fv according to the present invention.

Fig. 5 illustrates a structure of an expression plasmid which can be used to express a DNA encoding the single chain Fv of the invention in E. coli.

Fig. 6 illustrates a structure of an expression plasmid which is used to express a DNA encoding the single chain Fv of the invention in mammalian cells.

5 Fig. 7 shows the result of western blotting in Example 5.4. From the left, a molecular weight marker (which indicates 97.4, 66, 45, 31, 21.5 and 14.5 kDa from the top), the culture supernatant of pCH01-introduced COS7 cells and the culture supernatant of pCHOM2-introduced COS7 cells. It illustrates that the reconstructed single chain Fv of the
10 antibody MABL-2 (arrow) is contained in the culture supernatant of the pCHOM2-introduced cells.

Fig. 8 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of pCH01/COS7 cell as a control does not bind to pCOS1/L1210
15 cell as a control.

Fig. 9 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of MABL2-scFv/COS7 cells does not bind to pCOS1/L1210 cells as
a control.

20 Fig. 10 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of pCOS1/COS7 cells as a control does not bind to hIAP/L1210 cells.

25 Fig. 11 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of MABL2-scFv/COS7 cells specifically binds to hIAP/L1210 cells.

Fig. 12 shows the result of the competitive ELISA in Example 5.6, wherein the binding activity of the single chain Fv of the invention (MABL2-scFv) to the antigen is demonstrated in terms of the inhibition of binding of the mouse monoclonal antibody MABL-2 to the antigen as an index, in comparison with the culture supernatant of pCHO1/COS7 cells as a control.

Fig. 13 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of pCHO1/COS7 cells as a control does not induce the apoptosis of pCOS1/L1210 cells as a control.

Fig. 14 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of MABL2-scFv/COS7 cells does not induce apoptosis of pCOS1/L1210 cells as a control.

Fig. 15 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of pCHO1/COS7 cells as a control does not induce apoptosis of hIAP/L1210 cells.

Fig. 16 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of MABL2-scFv/COS7 cells specifically induces apoptosis of hIAP/L1210 cells.

Fig. 17 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of pCHO1/COS7 cells as a

control does not induce apoptosis of CCRF-CEM cells (at 50% of the final concentration).

Fig. 18 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of MABL2-scFv/COS7 cells specifically induces apoptosis of CCRF-CEM cells (at 50% of the final concentration).

Fig. 19 shows the chromatogram obtained in the purification of the single chain Fv derived from the antibody MABL-2 produced by the CHO cells in Example 5.9, illustrating that fraction A and fraction B were obtained as the major peaks when the fraction from Blue-sepharose column was purified with hydroxyapatite column.

Fig. 20 shows the results of purification by gel filtration of fraction A and fraction B obtained in Example 5.9-(2), illustrating that the major peaks (AI and BI, respectively) were eluted from fraction A at approximately 36 kD of the apparent molecular weight and from fraction B at approximately 76 kD.

Fig. 21 is the analysis on SDS-PAGE of the fractions obtained in the purification of the single chain Fv derived from the antibody MABL-2 produced by the CHO cells in Example 5.9, illustrating that a single band of approximately 35 kD of molecular weight was observed in both fractions.

Fig. 22 shows the results of analysis of fractions AI and BI obtained by gel filtration in the purification of

the single chain Fv derived from the antibody MABL-2 produced by the CHO cells, wherein fraction AI comprises monomer and fraction BI comprises dimer.

5 Fig. 23 illustrates a structure of an expression plasmid which can be used to express a DNA encoding the single chain Fv of the invention in E. coli.

10 Fig. 24 shows the results of purification on the gel filtration column of crude products of the single chain Fv polypeptide derived from the antibody MABL-2 produced by E. coli obtained in Example 5.12, wherein each peak indicates monomer or dimer, respectively, of the single chain Fv produced by E. coli.

15 Fig. 25 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that mouse IgG antibody as a control does not induce apoptosis of hIAP/L1210 cells (the final concentration of 3 $\mu\text{g/ml}$).

20 Fig. 26 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that the dimer of MABL2-scFv produced by the CHO cells remarkably induces apoptosis of hIAP/L1210 cells (the final concentration of 3 $\mu\text{g/ml}$).

25 Fig. 27 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that the dimer of MABL2-scFv produced by E. coli remarkably induces apoptosis of hIAP/L1210 cells (the final concentration of 3 $\mu\text{g/ml}$).

Fig. 28 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that apoptosis induction to hIAP/L1210 cells by the MABL2-scFv monomer produced by the CHO cells is the same level as that of the control (the final concentration of 3 $\mu\text{g/ml}$).

Fig. 29 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that apoptosis induction to hIAP/L1210 cells of the MABL2-scFv monomer produced by E. coli is the same level as that of control (the final concentration of 3 $\mu\text{g/ml}$).

Fig. 30 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that mouse IgG antibody used as a control does not induce apoptosis of hIAP/L1210 cells even when anti-FLAG antibody is added (the final concentration of 3 $\mu\text{g/ml}$).

Fig. 31 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that MABL2-scFv monomer produced by the CHO cells remarkably induces apoptosis of hIAP/L1210 cells when anti-FLAG antibody is added (the final concentration of 3 $\mu\text{g/ml}$).

Fig. 32 shows the results of quantitative measurement of human IgG in the serum of a human myeloma cell line KPMM2-transplanted mouse, indicating amounts of human IgG produced by the human myeloma cells in the mouse. It illustrates that the dimer of scFv/CHO remarkably inhibited growth of the KPMM2 cells.

Fig. 33 shows the survival time of the mouse after the transplantation of tumor, illustrating that the scFv/CHO dimer-administered group elongated remarkably the survival time.

5 Fig. 34 illustrates a structure of an expression plasmid which expresses a modified antibody [sc(Fv)₂] comprising two H chain V regions and two L chain V regions derived from the antibody MABL-2.

10 Fig. 35 illustrates a structure of a plasmid which expresses a scFv (HL type) wherein the V regions are linked in the manner of [H chain]-[L chain] without a peptide linker.

Fig. 36 illustrates a structure of the HL-type polypeptide and amino acid sequences of peptide linkers.

15 Fig. 37 illustrates a structure of a plasmid which expresses a scFv (LH type) wherein the V regions are linked in the manner of [L chain]-[H chain] without a peptide linker.

20 Fig. 38 illustrates a structure of the LH-type polypeptide and amino acid sequences of peptide linkers.

Fig. 39 shows the results of the western blotting in Example 6.4, illustrating that the modified antibody sc(Fv)₂ comprising two H chain V regions and two L chain V regions, and the MABL2-scFv having peptide linkers with
25 different length are expressed.

Figs. 40a and 40b show the results of flow cytometry using the culture supernatant of COS7 cells

prepared in Example 6.3 (1), illustrating that the MABL2-scFv and sc(Fv)₂ having peptide linkers with different length have high affinities against human IAP.

5 Fig. 41a and 41b shows the results of the apoptosis-inducing effect in Example 6.6, illustrating that the scFv <HL3, 4, 6, 7, LH3, 4, 6 and 7> and the sc(Fv)₂ remarkably induce cell death of hIAP/L1210 cells.

10 Fig. 42 shows the results of the evaluation of antigen binding capacity in Example 6.10, illustrating that the dimer of scFv <HL5> and sc(Fv)₂ have high affinities against human IAP.

15 Fig. 43 shows the results of the in vitro apoptosis-inducing effect in Example 6.11, illustrating that the dimer of scFv <HL5> and the sc(Fv)₂ induce apoptosis of hIAP/L1210 cells and CCRF-CEM cells in concentration-dependent manner.

20 Fig. 44 shows the results of the quantitative measurement of M protein produced by a human myeloma cell line KPMM2 in the serum of the human myeloma cell-transplanted mouse. It illustrates that the dimer of scFv <HL5> and the sc(Fv)₂ remarkably inhibited growth of the KPMM2 cells.

25 Fig. 45 shows the survival time (days) of mice after the transplantation of tumor, illustrating that the survival time of the scFv <HL5> administrated-group was remarkably prolonged.

Fig. 46 shows the survival time (days) of mice after the transplantation of tumor, illustrating that the survival time of the sc(Fv)₂ administrated-group was remarkably prolonged.

5 Fig. 47 is a scheme showing the method for constructing DNA fragment encoding the reconstructed 12B5 single chain Fv containing the linker sequence consisting of 15 amino acids and the structure thereof.

10 Fig. 48 shows the purification result of each 12B5 single chain Fv by gel filtration obtained in Example 7. 5 (1), illustrating that scl2B5 was divided into two peaks (fractions A and B).

Fig. 49 shows the analytical result of each fraction A and B by SDS-PAGE performed in Example 7. 5 (2).

15 Fig. 50 shows the analytical result of each fraction A and B by Superdex200 column performed in Example 7. 5 (2), illustrating that the major peak of fraction A was eluted at an apparent molecular weight of about 44 kD shown in (a) and that the major peak of fraction B was eluted at
20 an apparent molecular weight of about 22kD shown in (b).

Fig. 51 shows the measurement result of the TPO-like agonist activity of scl2B5 and antibody 12B5 (IgG, Fab), illustrating that 12B5IgG and monovalent single chain Fv (scl2B5) showed TPO-like agonist activity in concentration-
25 dependent manner.

Fig. 52 shows the measurement result of TOP-like agonist activity of scl2B5 monomer and dimer, illustrating

that single chain Fv (sc12B5 dimer) having bivalent antigen-binding site had agonist activity about 400-fold higher than monovalent sc12B5 and that the efficacy is equivalent to or higher than human TPO.

5 Fig. 53 shows the purification result of obtained sc12E10 single chain antibody by gel filtration chromatography using Superdex200HR column, illustrating that sc12E10 was divided into two peaks (fractions A and B).

10 Fig. 54 shows the purification result of obtained db12E10 single chain antibody by gel filtration chromatography using Superdex200HR column, illustrating that db12E10 was divided into peaks (fractions C and D).

15 Fig. 55 shows SDS-PAGE analysis of fractions A and B (sc12E10) and fractions C and D (db12E10) under the reductive or non-reductive condition.

20 Fig. 56 shows the analytical result of fractions A and B by gel filtration chromatography using Superdex200HR column, illustrating (1) the major peak of fraction A was eluted at an apparent molecular weight of about 42 kD and (2) the major peak of fraction B was eluted at an apparent molecular weight of about 20kD.

25 Fig. 57 shows the analytical result of fractions C and D by gel filtration chromatography using Superdex200HR column, illustrating (1) the major peak of fraction C was eluted at an apparent molecular weight of about 69 kD and (2) the major peak of fraction D was eluted at an apparent molecular weight of about 41kD.

Fig. 58 is a graph showing the agonist activity of various 12E10 antibody molecules on MPL, illustrating that single chain Fvs (sc12E10, db12E10) showed TPO-like agonist activity while 12E10 IgG and 12E10 Fab did not.

5 Fig. 59 is a graph showing the agonist activity of monomer and dimer of sc12E10 and dimer and trimer of db12E10 on MPL, illustrating that dimer of sc12E10 and dimer and trimer of db12E10 showed higher TPO-like agonist activity than TPO.

10

INDUSTRIAL APPLICABILITY

The modified antibodies of the invention have an agonist action capable of transducing a signal into cells by crosslinking a cell surface molecule(s) and are advantageous in that the permeability to tissues and tumors is high due to the lowered molecular size compared with antibody molecule (whole IgG). This invention provides the modified antibodies with an agonist activity remarkably higher than TPO or parent antibodies (whole IgG). Especially even parent antibodies without agonist activity can be altered into the modified antibodies with an agonist activity higher than TPO. Therefore the modified antibodies can be used as signal-transducing agonists. The modification of antibody molecule results in the reduction of side effects caused by intercellular crosslinking and provides novel medicines inducing only required action by crosslinking a cell surface molecule(s). Medical preparations containing as active

15
20
25

2002210917 10 Mar 2006

ingredient the modified antibodies of the invention are useful as preventives and/or remedies for platelet-related-blood diseases, thrombocytopenia caused by chemotherapy for cancers or leukemia and the like.

5 In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense,
10 i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

 It is to be understood that a reference herein to a prior art document does not constitute an admission that
15 the document forms part of the common general knowledge in the art in Australia or any other country.

CLAIMS

1. A modified antibody comprising two or more H chain V
5 regions and two or more L chain V regions of antibody and
showing TPO agonist action by crosslinking TPO receptor,
wherein the modified antibody is:
- (i) a multimer of single chain Fv comprising an H
chain V region and an L chain V region; or
 - 10 (ii) a single chain polypeptide comprising two or
more H chain V regions and two or more L chain V regions.
2. The modified antibody of claim 1, wherein the H chain
V region and the L chain V region are connected through a
15 linker.
3. The modified antibody of claim 2, wherein the linker
is a peptide linker comprising at least one amino acid.
- 20 4. The modified antibody of any one of claims 1 to 3,
wherein the modified antibody is composed of tetramer,
trimer or dimer of single chain Fv.
5. The modified antibody of claim 4, wherein the
25 modified antibody is composed of dimer of single chain Fv.
6. The modified antibody of any one of claims 1 to 5,
wherein the H chain V region and the L chain V region
existing in the same chain are not associated to form an
30 antigen-binding site.
7. The modified antibody of any one of claims 1 to 3,
wherein the modified antibody is a single chain

2002210917 10 Mar 2006

2002210917 10 Mar 2006

- 121 -

polypeptide comprising two H chain V regions and two L chain V regions.

8. The modified antibody of any one of claims 1 to 7,
5 wherein the modified antibody further comprises an amino acid sequence(s) for peptide purification.

9. The modified antibody of any one of claims 1 to 8,
10 wherein the modified antibody has been purified.

10. The modified antibody of any one of claims 1 to 9,
wherein H chain V region and/or L chain V region is H chain V region and/or L chain V region derived from a human antibody.

15 11. The modified antibody of any one of claims 1 to 9, wherein H chain V region and/or L chain V region is humanized H chain V region and/or L chain V region.

20 12. The modified antibody of any one of claims 1 to 11, wherein the modified antibody is mono-specific modified antibody.

25 13. The modified antibody of any one of claims 1 to 11, wherein the modified antibody is multi-specific modified antibody.

14. The modified antibody of claim 13, wherein the modified antibody is bi-specific modified antibody.

30 15. The modified antibody of claim 12, wherein the L chain V region and the H chain V region are from the same monoclonal antibody.

2002210917 10 Mar 2006

- 5 16. The modified antibody of any one of claims 1 to 15 which shows an equivalent or better agonist action (ED50) compared with the parent monoclonal antibody.
17. The modified antibody of claim 16 which shows at least 2-fold agonist action (ED50) compared with the parent monoclonal antibody.
- 10 18. The modified antibody of claim 17 which shows at least 10-fold agonist action (ED50) compared with the parent monoclonal antibody.
- 15 19. The modified antibody of any one of claims 1 to 15 which is derived from a parent antibody having substantially no agonist action.
- 20 20. A compound comprising two or more H chain V regions and two or more L chain V regions of monoclonal antibody and showing an equivalent or better agonist action (ED50) compared with thrombopoietin (TPO).
- 25 21. The compound of claim 20 which shows at least 2-fold agonist action (ED50) compared with TPO.
22. The compound of claim 21 which shows at least 10-fold agonist action (ED50) compared with TPO.
- 30 23. The modified antibody or compound of any one of claims 1-22 which has ED50 of TPO agonist activity not more than 20pM.
24. The modified antibody or compound of claim 23 which

has ED50 of TPO agonist activity not more than 10 pM.

25. The modified antibody or compound of claim 24 which has ED50 of TPO agonist activity not more than 2pM.

5

26. The modified antibody or compound of any one of claims 1 to 25 which has intercellular adhesion action (ED50) not more than 1/10 compared with the parent antibody.

10

27. The modified antibody or compound of any one of claims 1 to 25 which has substantially no intercellular adhesion action.

15

28. A DNA which encodes the modified antibody or compound of any one of claims 1 to 27.

29. An animal cell which produces the modified antibody or compound of any one of claims 1 to 27.

20

30. A microorganism which produces the modified antibody or compound of any one of claims 1 to 27.

31. Use of the modified antibody or compound of any one of claims 1 to 27 as TPO agonist.

25

32. A method of causing an agonist action to cells by crosslinking TPO receptor using the modified antibody or compound of any one of claims 1 to 27 thereby transducing a signal into cells.

30

33. The method of claim 32 wherein the agonist action is proliferation, differentiation-induction or growth

2002210917 10 Mar 2006

- 124 -

stimulation of megakaryocytes, platelet production or phosphorylation of TPO receptor protein.

34. A medicine comprising as active ingredient the
5 modified antibody or compound of any one of claims 1 to 27.

35. The medicine of claim 34 which is for the treatment
10 of thrombocytopenia.

36. Use of the modified antibody or compound of any one
of claims 1 to 27 as medicine.

37. A method of screening a modified antibody comprising
15 two or more H chain V regions and two or more L chain V regions of antibody and showing an agonist action by crosslinking TPO receptor, wherein the modified antibody is:

(i) a multimer of single chain Fv comprising an H chain V
20 region and an L chain V region; or

(ii) a single chain polypeptide comprising two or more H chain V regions and two or more L chain V regions, which comprises the steps

(1) to produce a modified antibody comprising two or more
25 H chain V regions and two or more L chain V regions of antibody and binding specifically to TPO receptor,

(2) to subject cells expressing said TPO receptor to react with the modified antibody and

(3) to measure TPO agonist action in the cells caused by
30 crosslinking TPO receptor.

38. A method of measuring an agonist action of a modified antibody comprising two or more H chain V regions and two

or more L chain V regions of antibody and showing an agonist action by crosslinking TPO receptor, wherein the modified antibody is:

- 5 (i) a multimer of single chain Fv comprising an H chain V region and an L chain V region; or
- (ii) a single chain polypeptide comprising two or more H chain V regions and two or more L chain V regions, which comprises the steps
 - 10 (1) to produce a modified antibody comprising two or more H chain V regions and two or more L chain V regions of antibody and binding specifically to TPO receptor,
 - (2) to subject cells expressing said TPO receptor to react with the modified antibody and
 - 15 (3) to measure TPO agonist action in the cells caused by crosslinking TPO receptor.

39. A modified antibody according to claim 1 substantially as hereinbefore described with reference to any one of the Examples.

20 40. A compound according to claim 20 substantially as hereinbefore described with reference to any one of the Examples.

25 41. A DNA according to claim 28 substantially as hereinbefore described with reference to any one of the Examples.

30 42. An animal cell according to claim 29 substantially as hereinbefore described with reference to any one of the Examples.

43. A microorganism according to claim 30 substantially

2002210917 10 Mar 2006

- 126 -

as hereinbefore described with reference to any one of the Examples.

5 44. A use according to claim 31, substantially as hereinbefore described with reference to any one of the Examples.

10 45. A method according to claim 32 substantially as hereinbefore described with reference to any one of the Examples.

15 46. A medicine according to claim 34 substantially as hereinbefore described with reference to any one of the Examples.

47. A use according to claim 36, substantially as hereinbefore described with reference to any one of the Examples.

20 48. A method according to claim 37 substantially as hereinbefore described with reference to any one of the Examples.

25 49. A method according to claim 38 substantially as hereinbefore described with reference to any one of the Examples.

Dated this 9th day of March 2006

CHUGAI SEIYAKU KABUSHIKI KAISHA

30 By Their Patent Attorneys

GRIFFITH HACK

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20





Fig. 21

SDS-PAGE analysis of MABL2-scFv



TSK gel G3000SW

20 mM Acetate buffer, 0.15 M NaCl, pH 6.0




Fig. 23




Fig. 24




Fig. 25




Fig. 26




Fig. 27




Fig. 28




Fig. 29




Fig. 30




Fig. 31





Fig. 32


*Effect of MABL-2 (scFv) on serum hlgG
in KPMM2 i.v. SCID mice*



** : p<0.01

Fig. 33

Effect of MABL-2 (scFv) on survival of KPMM2 i.v. SCID mice



** ; P<0.01 by t-test

Fig. 34




Fig. 35





Fig. 36

Base Sequence and Amino Acid Sequence of Linker for HL Type



Plasmid	Number of	
	linker amino acid	linker
CF2HL-0/pCOS1	0	gtc tcg agt gac gtc gtg V S S D V V
CF2HL-3/pCOS1	3	gtc tcg agt ggt ggt tcc gac gtc gtg V S S G G S D V V
CF2HL-4/pCOS1	4	gtc tcg agt ggt ggt ggt tcc gac gtc gtg V S S G G G S D V V
CF2HL-5/pCOS1	5	gtc tcg agt ggt ggt ggt ggt tcc gac gtc gtg V S S G G G G S D V V
CF2HL-6/pCOS1	6	gtc tcg agt gt ggt ggt ggt ggt tcc gac gtc gtg V S S G G G G G S D V V
CF2HL-7/pCOS1	7	gtc tcg agt ggt ggt ggt ggt ggt ggt tcc gac gtc gtg V S S G G G G G G S D V V

Fig. 37





Fig. 38

Base Sequence and Amino Acid Sequence of Linker for LH Type



Plasmid	Number of	
	linker amino acid	linker
CF2LH-0/pCOS1	0	gag ata aaa E I K
CF2LH-3/pCOS1	3	gag ata aaa tcc gga ggc E I K S G G
CF2LH-4/pCOS1	4	gag ata aaa tcc gga ggt ggc E I K S G G G
CF2LH-5/pCOS1	5	gag ata aaa tcc gga ggt ggt ggc E I K S G G G G
CF2LH-6/pCOS1	6	gag ata aaa tcc gga ggt ggt ggt ggc E I K S G G G G G
CF2LH-7/pCOS1	7	gag ata aaa tcc gga ggt ggt ggt ggt ggc E I K S G G G G G G

Fig. 39




Fig. 40a









Fig. 40b









Fig. 41a




Fig. 41b




Fig. 43




Fig. 44




Fig. 45




Fig. 46




Fig. 47




Fig. 48





Fig. 49



M: MW marker
1: sc12B5 fraction A
2: sc12B5 fraction B

Fig. 50




Fig. 51




Fig. 52




Fig. 53




Fig. 54





Fig. 56

sc3 peak A



sc3 peak B




Fig. 57





Fig. 5 8





Fig. 5 9



SEQUENCE LISTING

<110> CHUGAI SEIYAKU KABUSHIKI KAISHA

<120> DEGRADED AGONIST ANTIBODY _____

<130> FP1033

<141> 2001-10-22

<150> JP2000-321821

<151> 2000-10-20

<150> PCT/JP01/03288

<151> 2001-04-17

<150> JP2001-277314

<151> 2001-09-12

<160> 113

<210> 1

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 1

ccatcctaat acgactcact atagggc 27

<210> 2

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 2

ggatcccggg tggatggtgg gaagatg 27

<210> 3

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 3

ggatcccggg ccagtggata gacagatg 28

<210> 4

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 4

ggatcccggg agtggataga ccgatg 26

<210> 5

<211> 394

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (393)

<223> pGEM-MIL. 1-57;signal peptide, 58-394;mature peptide

<400> 5

```

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct gcg 48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
  1           5           10           15
tcc agc agt gat gtt gtg atg acc caa act cca ctc tcc ctg cct gtc 96
Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val
          20           25           30
agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag agc ctt 144
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
          35           40           45
cta cac agt aaa gga aac acc tat tta caa tgg tac cta cag aag cca 192
Leu His Ser Lys Gly Asn Thr Tyr Leu Gln Trp Tyr Leu Gln Lys Pro
          50           55           60
ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc aac cga ttt tct 240
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
          65           70           75           80
ggg gtc cca gac agg ttc agt ggc agt gga tca ggg aca gat ttc aca 288
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
          85           90           95
ctc aag atc agc aga gtg gag gct gag gat ctg gga gtt tat ttc tgc 336
Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
          100          105          110
tct caa agt aca cat gtt ccg tac acg tcc gga ggg ggg acc aag ctg 384
Ser Gln Ser Thr His Val Pro Tyr Thr Ser Gly Gly Gly Thr Lys Leu
          115          120          125

```


gaa ata aaa c

394

Glu Ile Lys

130

<210> 6

<211> 409

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (408)

<223> pGEM-M1H. 1-57;signal peptide, 58-409;mature peptide

<400> 6

atg gaa tgg agc tgg ata ttt ctc ttc ctc ctg tca gga act gca ggt 48

Met Glu Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly

1

5

10

15

gtc cac tcc cag gtc cag ctg cag cag tct gga cct gac ctg gta aag 96

Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys

20

25

30

cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc 144

Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35

40

45

gtt aac cat gtt atg cac tgg gtg aag cag aag cca ggg cag ggc ctt 192

Val Asn His Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu

50

55

60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tac aat 240

Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn

65

70

75

80

gag aag ttc aag ggc aag gcc aca ctg act tca gag aaa tcc tcc agc 288
 Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Glu Lys Ser Ser Ser
 85 90 95
 gca gcc tac atg gag ctc agc agc ctg gcc tct gag gac tct gcg gtc 336
 Ala Ala Tyr Met Glu Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val
 100 105 110
 tac tac tgt gca aga ggg ggt tac tat agt tac gac gac tgg ggc caa 384
 Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Ser Tyr Asp Asp Trp Gly Gln
 115 120 125
 ggc acc act ctc aca gtc tcc tca g 409
 Gly Thr Thr Leu Thr Val Ser Ser
 130 135

<210> 7

<211> 394

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (393)

<223> pGEM-M2L. 1-57;signal peptide, 58-394;mature peptide

<400> 7

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct ggt 48
 Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Gly
 1 5 10 15
 tcc agc agt gat gtt gtg atg acc caa agt cca ctc tcc ctg cct gtc 96
 Ser Ser Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val
 20 25 30

agt ctt gga gat caa gcc tcc atc tct tgo aga tca agt cag agc ctt 144
 Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
 35 40 45
 gtg cac agt aat gga aag acc tat tta cat tgg tac ctg cag aag cca 192
 Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro
 50 55 60
 ggc cag tct cca aaa ctc ctg atc tac aaa gtt tcc aac cga ttt tct 240
 Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
 65 70 75 80
 ggg gtc cca gac agg ttc agt ggc agt gga tca gtg aca gat ttc aca 288
 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val Thr Asp Phe Thr
 85 90 95
 ctc atg atc agc aga gtg gag gct gag gat ctg gga gtt tat ttc tgc 336
 Leu Met Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
 100 105 110
 tct caa agt aca cat gtt ccg tac acg ttc gga ggg ggg acc aag ctg 384
 Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
 115 120 125
 gaa ata aaa c 394
 Glu Ile Lys
 130

<210> 8

<211> 409

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (408)

<223> pGEM-M2H. 1-57:signal peptide, 58-409:mature peptide

<400> 8

atg gaa tgg agc tgg ata ttt ctc ttc ctc ctg tca gga act gca ggt 48

Met Glu Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly

1 5 10 15

gtc cac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag 96

Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys

20 25 30

cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc 144

Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

gct aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt 192

Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tat aat 240

Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn

65 70 75 80

gag aag ttc aag gac aag gcc act ctg act tca gac aaa tcc tcc acc 288

Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr

85 90 95

aca gcc tac atg gac ctc agc agc ctg gcc tct gag gac tct gcg gtc 336

Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val

100 105 110

tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa 384

Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gln

115 120 125

ggc acc act ctc aca gtc tcc tca g 409

Gly Thr Thr Leu Thr Val Ser Ser

130

135

<210> 9

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 9

cccaagcttc caccatgaag ttgctgtta gg 32

<210> 10

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 10

cccaagcttc caccatggaa tggagctgga ta 32

<210> 11

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 11

9/74

cgcgatcca ctcacgtttt atttccagct tggt 34

<210> 12

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 12

cgcgatcca ctcacctgag gagactgtga gagt 34

<210> 13

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 13

catgcatgg cgcaggtcca gctgcagcag 30

<210> 14

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 14

accaccacct gaggagactg tgagagt 27

10/74

<210> 15

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 15

gtctcctcag gtggtggtgg ttcggg 27

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 16

cacaacatcc gatccgccac caccgga 27

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 17

ggcggatcgg atgttgtgat gacccaa 27

11/74

<210> 18

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 18

ccggaattct cattatttat cgtcatcgtc tttgtagtct tttatttcca gcttggt 57

<210> 19

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Linker amino acid sequence and nucleotide sequence

<400> 19

ggt ggt ggt ggt tcg ggt ggt ggt ggt tcg ggt ggt ggc gga tcg 45

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

5

10

15

<210> 20

<211> 828

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (822)

<223> pscM1. MABL1-scFv

<400> 20

atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc gct 48
 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
 1 5 10 15
 gcc caa cca gcc atg gcg cag gtc cag ctg cag cag tct gga cct gac 96
 Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Gln Ser Gly Pro Asp
 20 25 30
 ctg gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga 144
 Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly
 35 40 45
 tac acc ttc gtt aac cat gtt atg cac tgg gtg aag cag aag cca ggg 192
 Tyr Thr Phe Val Asn His Val Met His Trp Val Lys Gln Lys Pro Gly
 50 55 60
 cag ggc ctt gag tgg att gga tat att tat cct tac aat gat ggt act 240
 Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr
 65 70 75 80
 aag tac aat gag aag ttc aag ggc aag gcc aca ctg act tca gag aaa 288
 Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Glu Lys
 85 90 95
 tcc tcc agc gca gcc tac atg gag ctc agc agc ctg gcc tct gag gac 336
 Ser Ser Ser Ala Ala Tyr Met Glu Leu Ser Ser Leu Ala Ser Glu Asp
 100 105 110
 tct gcg gtc tac tac tgt gca aga ggg ggt tac tat agt tac gac gac 384
 Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Ser Tyr Asp Asp
 115 120 125
 tgg ggc caa ggc acc act ctc aca gtc tcc tca ggt ggt ggt ggt tcg 432
 Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser
 130 135 140

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 21

acgcgtcgac tcccaggtcc agctgcagca g 31

<210> 22

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 22

gaaggtgtat ccagaagc 18

<210> 23

<211> 819

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (813)

<223> pCHOM1. MABL1-scFv

<400> 23

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca ggt 48

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

1	5	10	15	
gtc gac tcc cag gtc cag ctg cag cag tct gga cct gac ctg gta aag				96
Val Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys				
	20	25	30	
cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc				144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe				
	35	40	45	
gtt aac cat gtt atg cac tgg gtg aag cag aag cca ggg cag ggc ctt				192
Val Asn His Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu				
	50	55	60	
gag tgg att gga tat att tat cct tac aat gat ggt act aag tac aat				240
Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn				
	65	70	75	80
gag aag ttc aag ggc aag gcc aca ctg act tca gag aaa tcc tcc agc				288
Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Glu Lys Ser Ser Ser				
	85	90	95	
gca gcc tac atg gag ctc agc agc ctg gcc tct gag gac tct gcg gtc				336
Ala Ala Tyr Met Glu Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val				
	100	105	110	
tac tac tgt gca aga ggg ggt tac tat agt tac gac gac tgg ggc caa				384
Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Ser Tyr Asp Asp Trp Gly Gln				
	115	120	125	
ggc acc act ctc aca gtc tcc tca ggt ggt ggt ggt tcg ggt ggt ggt				432
Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly				
	130	135	140	
ggt tcg ggt ggt ggc gga tcg gat gtt gtg atg acc caa act cca ctc				480
Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Thr Pro Leu				
	145	150	155	160

tcc ctg cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tct 528
 Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser
 165 170 175
 agt cag agc ctt cta cac agt aaa gga aac acc tat tta caa tgg tac 576
 Ser Gln Ser Leu Leu His Ser Lys Gly Asn Thr Tyr Leu Gln Trp Tyr
 180 185 190
 cta cag aag cca ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc 624
 Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser
 195 200 205
 aac cga ttt tet ggg gtc cca gac agg ttc agt ggc agt gga tca ggg 672
 Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly
 210 215 220
 aca gat ttc aca ctc aag atc agc aga gtg gag gct gag gat ctg gga 720
 Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly
 225 230 235 240
 gtt tat ttc tgc tct caa agt aca cat gtt ceg tac acg tcc gga ggg 768
 Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Ser Gly Gly
 245 250 255
 ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat aaa taa 816
 Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp Lys
 260 265 270
 tga 819

<210> 24

<211> 828

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (822)

<223> pscM2. MABL2-scFv

<400> 24

```

atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc gct 48
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
  1           5           10           15
gcc caa cca gcc atg gcg cag gtc cag ctg cag cag tct gga cct gaa 96
Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Gln Ser Gly Pro Glu
          20           25           30
ctg gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga 144
Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly
          35           40           45
tac acc ttc gct aac cat gtt att cac tgg gtg aag cag aag cca ggg 192
Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro Gly
          50           55           60
cag ggc ctt gag tgg att gga tat att tat cct tac aat gat ggt act 240
Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr
          65           70           75           80
aag tat aat gag aag ttc aag gac aag gcc act ctg act tca gac aaa 288
Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys
          85           90           95
tcc tcc acc aca gcc tac atg gac ctc agc agc ctg gcc tct gag gac 336
Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp
          100          105          110
tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act tac gac gac 384
Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp
          115          120          125

```

tgg ggc caa ggc acc act ctc aca gtc tcc tca ggt ggt ggt ggt tcg 432
 Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser
 130 135 140
 ggt ggt ggt ggt tcg ggt ggt ggc gga tcg gat gtt gtg atg acc caa 480
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln
 145 150 155 160
 agt cca ctc tcc ctg cct gtc agt ctt gga gat caa gcc tcc atc tct 528
 Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser
 165 170 175
 tgc aga tca agt cag agc ctt gtg cac agt aat gga aag acc tat tta 576
 Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Lys Thr Tyr
 180 185 190
 cat tgg tac ctg cag aag cca ggc cag tct cca aaa ctc ctg atc tac 624
 His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr
 195 200 205
 aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt 672
 Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
 210 215 220
 gga tca gtg aca gat ttc aca ctc atg atc agc aga gtg gag gct gag 720
 Gly Ser Val Thr Asp Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu
 225 230 235 240
 gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg 768
 Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr
 245 250 255
 ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac 816
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp
 260 270
 gat aaa taatga 828

Asp Lys

<210> 25

<211> 819

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (813)

<223> pCHOM2. MABL2-scFv

<400> 25

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca ggt 48

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

1 5 10 15

gtc gac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag 96

Val Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys

20 25 30

cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc 144

Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

gct aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt 192

Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tat aat 240

Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn

65 70 75 80

gag aag ttc aag gac aag gcc act ctg act tca gac aaa tcc tcc acc 288

Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr

	85	90	95	
aca gcc tac atg gac ctc agc agc ctg gcc tct gag gac tct gcg gtc				336
Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val				
	100	105	110	
tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa				384
Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gln				
	115	120	125	
ggc acc act ctc aca gtc tcc tca ggt ggt ggt ggt tcc ggt ggt ggt				432
Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly				
	130	135	140	
ggt tcc ggt ggt ggc gga tcc gat gtt gtg atg acc caa agt cca ctc				480
Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Leu				
	145	150	155	160
tcc ctg cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tca				528
Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser				
	165	170	175	
agt cag agc ctt gtg cac agt aat gga aag acc tat tta cat tgg tac				576
Ser Gln Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr				
	180	185	190	
ctg cag aag cca ggc cag tct cca aaa ctc ctg atc tac aaa gtt tcc				624
Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser				
	195	200	205	
aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tca gtg				672
Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val				
	210	215	220	
aca gat ttc aca ctc atg atc agc aga gtg gag gct gag gat ctg gga				720
Thr Asp Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu Asp Leu Gly				
	225	230	235	240

gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga ggg 768
 Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly
 245 250 255
 ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat aaa taa 816
 Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp Lys
 260 265 270
 tga 819

<210> 26

<211> 456

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (450)

<223> pCHO-shIAP. Soluble human IAP

<400> 26

atg tgg ccc ctg gta gcg gcg ctg ttg ctg ggc tcg gcg tgc tgc gga 48
 Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly
 1 5 10 15
 tca gct cag cta cta ttt aat aaa aca aaa tct gta gaa ttc acg ttt 96
 Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
 20 25 30
 tgt aat gac act gtc gtc att cca tgc ttt gtt act aat atg gag gca 144
 Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
 35 40 45
 caa aac act act gaa gta tac gta aag tgg aaa ttt aaa gga aga gat 192
 Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp

50	55	60	
att tac acc ttt gat gga gct cta aac aag tcc act gtc ccc act gac	240		
Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp			
65	70	75	80
ttt agt agt gca aaa att gaa gtc tca caa tta cta aaa gga gat gcc	288		
Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala			
	85	90	95
tct ttg aag atg gat aag agt gat gct gtc tca cac aca gga aac tac	336		
Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr			
	100	105	110
act tgt gaa gta aca gaa tta acc aga gaa ggt gaa acg atc atc gag	384		
Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu			
	115	120	125
cta aaa tat cgt gtt gtt tca tgg ttt tct cca aat gaa aat gac tac	432		
Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Asp Tyr			
	130	135	140
aag gac gac gat gac aag tgatag	456		
Lys Asp Asp Asp Asp Lys			
145	150		

<210> 27

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 27

ggaattccat atgcaagtgc aacttcaaca gtctggacct gaactg 46

<210> 28

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 28

ggaattctca ttattttatt tccagcttgg t 31

<210> 29

<211> 741

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (735)

<223> pscM2DEm02. MABL2-scFv

<400> 29

atg caa gtg caa ett caa cag tct gga cct gaa ctg gta aag cct ggg 48

Met Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly

1 5 10 15

gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc gct aac 96

Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asn

20 25 30

cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt gag tgg 144

His Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp

35 40 45

att gga tat att tat cct tac aat gat ggt act aag tat aat gag aag 192
 Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys
 50 55 60

ttc aag-gac aag gcc act ctg act tca gac aaa tcc tcc acc aca gcc 240
 Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala
 65 70 75 80

tac atg gac ctc agc agc ctg gcc tct gag gac tct gcg gtc tat tac 288
 Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr
 85 90 95

tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa ggc acc 336
 Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr
 100 105 110

act ctc aca gtc tcc tca ggt ggt ggt ggt tcg ggt ggt ggt ggt tcg 384
 Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 115 120 125

ggt ggt ggc gga tcg gat gtt gtg atg acc caa agt cca ctc tcc ctg 432
 Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu
 130 135 140

cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tca agt cag 480
 Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln
 145 150 155 160

agc ctt gtg cac agt aat gga aag acc tat tta cat tgg tac ctg cag 528
 Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln
 165 170 175

aag cca ggc cag tct cca aaa ctc ctg atc tac aaa gtt tcc aac cga 576
 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg
 180 185 190

ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tca gtg aca gat 624

Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val Thr Asp
 195 200 205
 ttc aca ctc atg atc agc aga gtg gag gct gag gat ctg gga gtt tat 672
 Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr
 210 215 220
 ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga ggg ggg acc 720
 Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr
 225 230 235 240
 aag ctg gaa ata aaa taatga 741
 Lys Leu Glu Ile Lys
 245

<210> 30

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 30

cagacagtgg ttcaaagt 18

<210> 31

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 31

cgcgctcgacc gatccgccac caccogaacc accaccaccc gaaccaccac cacctttat 60
 ttccagcttg gt 72

<210> 32

<211> 1605

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (1599)

<223> pCHOM2(Fv)2. MABL2-sc(Fv)2

<400> 32

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca ggt 48
 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15
 gtc gac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag 96
 Val Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
 20 25 30
 cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc 144
 Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45
 gct aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt 192
 Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu
 50 55 60
 gag tgg att gga tat att tat cct tac aat gat ggt act aag tat aat 240
 Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn
 65 70 75 80
 gag aag ttc aag gac aag gcc act ctg act tca gac aaa tcc tcc acc 288

225	230	235	240	
ggt tat ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga ggg				768
Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly				
	245	250	255	
ggg acc aag ctg gaa ata aaa ggt ggt ggt ggt tcg ggt ggt ggt ggt				816
Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly				
	260	265	270	
tcg ggt ggt ggc gga tcg gtc gac tcc cag gtc cag ctg cag cag tct				864
Ser Gly Gly Gly Gly Ser Val Asp Ser Gln Val Gln Leu Gln Gln Ser				
	275	280	285	
gga cct gaa ctg gta aag cct ggg gct tca gtg aag atg tcc tgc aag				912
Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys				
	290	295	300	
gct tct gga tac acc ttc gct aac cat gtt att cac tgg gtg aag cag				960
Ala Ser Gly Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln				
	305	310	315	320
aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat				1008
Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn				
	325	330	335	
gat ggt act aag tat aat gag aag ttc aag gac aag gcc act ctg act				1056
Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr				
	340	345	350	
tca gac aaa tcc tcc acc aca gcc tac atg gac ctc agc agc ctg gcc				1104
Ser Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala				
	355	360	365	
tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act				1152
Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr				
	370	375	380	

tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcc tca ggt ggt 1200
 Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly
 385 390 395 400
 ggt ggt tcg ggt ggt ggt ggt tcg ggt ggt ggc gga tcg gat gtt gtg 1248
 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val
 405 410 415
 atg acc caa agt cca ctc tcc ctg cct gtc agt ctt gga gat caa gcc 1296
 Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala
 420 425 430
 tcc atc tct tgc aga tca agt cag agc ctt gtg cac agt aat gga aag 1344
 Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Lys
 435 440 445
 acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca aaa ctc 1392
 Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu
 450 455 460
 ctg atc tac aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg ttc 1440
 Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe
 465 470 475 480
 agt ggc agt gga tca gtg aca gat ttc aca ctc atg atc agc aga gtg 1488
 Ser Gly Ser Gly Ser Val Thr Asp Phe Thr Leu Met Ile Ser Arg Val
 485 490 495
 gag gct gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt 1536
 Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val
 500 505 510
 ccg tac acg ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa 1584
 Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys
 515 520 525
 gac gat gac gat aaa taatga 1605

Asp Asp Asp Asp Lys

530

<210> 33

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 33

tgaggaattc ccaccatggg atg 33

<210> 34

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 34

cacgacgtca ctcgagactg tgagagtggg gccttggecc 40

<210> 35

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 35

31/74

agtctcgagt gacgtcgtga tgacccaaag tccactctcc 40

<210> 36

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 36

gactgatcc tcattattta tcgtcatcgt c 31

<210> 37

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 37

cgcgtaatac gactcactat ag 22

<210> 38

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 38

gcaattggac ctgtttatc tcgagcttgg tccccctcc gaacgt 46

<210> 39

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 39

gctcgagata aaacaggtcc aattgcagca gtctggacct gaact 45

<210> 40

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 40

gactggatcc tcattattta tcgtcatcgt cttgtagtc tgaggagact gtgagagtgg 60

<210> 41

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 41

gactgaattc ccaccatgaa gttgcctggt ag 32

<210> 42

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 42

cagtctcgag tggtagttcc gacgtcgtga tgacccaaag 40

<210> 43

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 43

cagtctcgag tggtagtggt tccgacgtcg tgatgacca aag 43

<210> 44

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 44

cagtctcgag tggtagtggt gttccgacg tcgtgatgac ccaaag 46

<210> 45

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 45

cagtctcgag tgggtggtggt ggtggttccg acgtcgtgat gacccaaag 49

<210> 46

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 46

cagtctcgag tgggtggtggt ggtggtggtt cgcacgtcgt gatgacccaa ag 52

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 47

ggccgcatgt tgtcacgaat 20

<210> 48

<211> 780

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (768)

<223> CF2HL-0/pCOS1. MABL2-scFv<HL-0>

<400> 48

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca ggt gtc 51

MET Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val

5

10

15

gac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag cct ggg 102

Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly

20

25

30

gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc gct aac cat 153

Ala Ser Val Lys MET Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asn His

35

40

45

50

gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt gag tgg att gga 204

Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly

55

60

65

tat att tat cct tac aat gat ggt act aag tat aat gag aag ttc aag gac 255

Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp

70

75

80

85

aag gcc act ctg act tca gac aaa tcc tcc acc aca gcc tac atg gac ctc 306

Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala Tyr MET Asp Leu

90

95

100

agc agc ctg gcc tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt 357

Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly

105

110

115

tac tat act tac gac gac tgg ggc caa ggc acc act ctc aca gtc tgc agt 408
 Tyr Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
 120 125 130 135
 gac gtc gtg atg acc caa agt cca ctc tcc ctg cct gtc agt ctt gga gat 459
 Asp Val Val MET Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp
 140 145 150
 caa gcc tcc atc tct tgc aga tca agt cag agc ctt gtg cac agt aat gga 510
 Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly
 155 160 165 170
 aag acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca aaa ctc 561
 Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu
 175 180 185
 ctg atc tac aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg ttc agt 612
 Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser
 190 195 200
 ggc agt gga tca gtg aca gat ttc aca ctc atg atc agc aga gtg gag gct 663
 Gly Ser Gly Ser Val Thr Asp Phe Thr Leu MET Ile Ser Arg Val Glu Ala
 205 210 215 220
 gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg 714
 Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr
 225 230 235
 ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat 765
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp
 240 245 250 255
 aaa taa tga gga tcc 780
 Lys

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 49

caagctcgag ataaaatccg gaggccaggt ccaattgcag cagtc 45

<210> 50

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 50

caagctcgag ataaaatccg gaggtggcca ggtccaattg cagcagtc 48

<210> 51

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 51

caagctcgag ataaaatccg gaggtggtgg ccaggtccaa ttgcagcagt c 51

<210> 52

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 52

caagctcgag ataaaatccg gaggtggtgg tggccaggtc caattgcagc agtc 54

<210> 53

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 53

caagctcgag ataaaatccg gaggtggtgg tggggccag gtccaattgc agcagtc 57

<210> 54

<211> 780

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (768)

<223> CF2LH-0/pCOS1. MABL2-scFv<LH-0>

<400> 54

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct ggt tcc 51

MET Lys Leu Pro Val Arg Leu Leu Val Leu MET Phe Trp Ile Pro Gly Ser

5

10

15

agc agt gat gtt gtg atg acc caa agt cca ctc tcc ctg cct gtc agt ctt 102
 Ser Ser Asp Val Val MET Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu
 20 25 30
 gga gat caa gcc tcc atc tct tgc aga tca agt cag agc ctt gtg cac agt 153
 Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 35 40 45 50
 aat gga aag acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca 204
 Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro
 55 60 65
 aaa ctc ctg atc tac aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg 255
 Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg
 70 75 80 85
 ttc agt ggc agt gga tca gtg aca gat ttc aca ctc atg atc agc aga gtg 306
 Phe Ser Gly Ser Gly Ser Val Thr Asp Phe Thr Leu MET Ile Ser Arg Val
 90 95 100
 gag gct gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt cgg 357
 Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro
 105 110 115
 tac acg ttc gga ggg ggg acc aag ctc gag ata aaa cag gtc caa ttg cag 408
 Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gln Val Gln Leu Gln
 120 125 130 135
 cag tct gga cct gaa ctg gta aag cct ggg gct tca gtg aag atg tcc tgc 459
 Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys MET Ser Cys
 140 145 150
 aag gct tct gga tac acc ttc gct aac cat gtt att cac tgg gtg aag cag 510
 Lys Ala Ser Gly Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln
 155 160 165 170
 aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 561

1	5	10	15	
tcc ctg agt ctc tcc tgt gca gtc tct gga atc acc ctc agg acc tac	96			
Ser Leu Ser Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Arg Thr Tyr				
20	25	30		
ggc atg cac tgg gtc cgc cag gct cca ggc aag ggg ctg gag tgg gtg	144			
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val				
35	40	45		
gca ggt ata tcc ttt gac gga aga agt gaa tac tat gca gac tcc gtg	192			
Ala Gly Ile Ser Phe Asp Gly Arg Ser Glu Tyr Tyr Ala Asp Ser Val				
50	55	60		
cag ggc cga ttc acc atc tcc aga gac agt tcc aag aac acc ctg tat	240			
Gln Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Lys Asn Thr Leu Tyr				
65	70	75	80	
ctg caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt	288			
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys				
85	90	95		
gcg aga gga gca cat tat ggt ttc gat atc tgg ggc caa ggg aca atg	336			
Ala Arg Gly Ala His Tyr Gly Phe Asp Ile Trp Gly Gln Gly Thr Met				
100	105	110		
gtc acc gtc teg agt				351
Val Thr Val Ser Ser				

115

<210> 56

<211> 57

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)... (57)

<223> reader sequence

<400> 56

atg gag ttt ggg ctg agc tgg gtt ttc ctc gtt gct ctt tta aga ggt 48

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly

5

10

15

gtc cag tgt

57

Val Gln Cys

<210> 57

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VH-1

<400> 57

atggagtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag 60

gtgcagctgg tgcagtctgg gggaggcttg gtccggcccg gggggtccct gagtc 115

<210> 58

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VH-2

<400> 58

aaggatatac ctgccacca ctccagcccc ttgctggag cctggcggac ccagtcatg 60
ccgtaggtcc tgagggtgat tccagagact gcacaggaga gactcaggga ccccc 115

<210> 59

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VH-3

<400> 59

ggcaggtata tcctttgacg gaagaagtga atactatgca gactccgtgc agggccgatt 60
caccatctcc agagacagtt ccaagaacac cctgtatctg caaatgaaca gcttg 115

<210> 60

<211> 108

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VH-4

<400> 60

actcgagacg gtgaccattg tccttggcc ccagatatcg aaaccataat gtgctcctct 60
cgcacagtaa tacacagccg tgtcctcggc tctcaggctg ttcatttg 108

<210> 61

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VH-S, PCR primer

<400> 61

ttcaagcttc caccatggag ttgggctga gc 32

<210> 62

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VH-A, PCR primer

<400> 62

ttgggatcca ctcaccactc gagacggtga ccat 34

<210> 63

<211> 588

<212> DNA

<213> Human

<220>

<221> CDS

<222> (236)... (558)

<223> 1-235;intron, 236-558;Human IgG constant region (partial)

<400> 63

gaattcgtga gtggatccca agctagcttt ctggggcagg ccaggcctga ccttgcttt 60

ggggcagga gggggctaag gtgaggcagg tggcgccagc caggtgcaca cccaatgccc 120

atgagcccag aactggacg ctgaacctcg cggacagtta agaaccagg gcctctgcg 180

ccctgggccc agctctgtcc cacaccggg tcacatggca caacctctct tgca gcc 237

Ala

1

tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc 285
 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
 5 10 15
 acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc 333
 Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
 20 25 30
 ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc 381
 Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
 35 40 45
 gtg cac acc ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc 429
 Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
 50 55 60 65
 agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac 477
 Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
 70 75 80
 atc tgc aac gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa 525
 Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
 85 90 95
 gtt gag ccc aaa tct tgt gac aaa act cac aca 558
 Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
 100 105

<210> 64

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> G1CH1-S, PCR primer

<400> 64

tgagaattcg tgagtggatc ccaagct 27

<210> 65

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> G1CH1-A, PCR primer

<400> 65

aaaagatctt tatcatgtgt gagttttgtc acaagatttg ggctcaactt tcttgtccac 60

<210> 66

<211> 432

<212> DNA

<213> Human

<220>

<221> CDS

<222> (12)... (419)

<223> HEF-12B5H-g gamma. 12-419 peptide

<400> 66

aagcttccac c atg gag ttt ggg ctg agc tgg gtt ttc ctc gtt get ctt 50

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu

1

5

10

tta aga ggt gtc cag tgt cag gtg cag ctg gtg cag tct ggg gga ggc 98

Leu Arg Gly Val Gln Cys Gln Val Gln Leu Val Gln Ser Gly Gly Gly

15

20

25

ttg gtc cgg ccc ggg ggg tcc ctg agt ctc tcc tgt gca gtc tct gga 146

Leu Val Arg Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Val Ser Gly
 30 35 40 45
 atc acc ctc agg acc tac ggc atg cac tgg gtc cgc cag gct cca ggc 194
 Ile Thr Leu Arg Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly
 50 55 60
 aag ggg ctg gag tgg gtg gca ggt ata tcc ttt gac gga aga agt gaa 242
 Lys Gly Leu Glu Trp Val Ala Gly Ile Ser Phe Asp Gly Arg Ser Glu
 65 70 75
 tac tat gca gac tcc gtg cag ggc cga ttc acc atc tcc aga gac agt 290
 Tyr Tyr Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Ser
 80 85 90
 tcc aag aac acc ctg tat ctg caa atg aac agc ctg aga gcc gag gac 338
 Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
 95 100 105
 acg gct gtg tat tac tgt gcg aga gga gca cat tat ggt ttc gat atc 386
 Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala His Tyr Gly Phe Asp Ile
 110 115 120 125
 tgg ggc caa ggg aca atg gtc acc gtc tcg agt ggtgagtgga tcc 432
 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 130 135

<210> 67

<211> 321

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)... (321)

<223> 12B5LV. 1-321 peptide

<400> 67

gac atc cag atg acc cag tct cct tcc acc ctg tct gca tct att gga 48

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Ile Gly

1 5 10 15

gac aga gtc acc atc acc tgc cgg gcc agc gag ggt att tat cac tgg 96

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Gly Ile Tyr His Trp

20 25 30

ttg gcc tgg tat cag cag aag cca ggg aaa gcc cct aaa ctc ctg atc 144

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

tat aag gcc tct agt tta gcc agt ggg gcc cca tca agg ttc agc ggc 192

Tyr Lys Ala Ser Ser Leu Ala Ser Gly Ala Pro Ser Arg Phe Ser Gly

50 55 60

agt gga tct ggg aca gat ttc act ctc acc atc agc agc ctg cag cct 240

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

gat gat ttt gca act tat tac tgc caa caa tat agt aat tat ccg ctc 288

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Leu

85 90 95

act ttc ggc gga ggg acc aag ctg gag atc aaa 321

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 68

<211> 66

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)... (66)

<223> reader sequence

<400> 68

atg gac atg agg gtc ccc gct cag ctc ctg ggg ctc ctg ctg ctc tgg 48

MET Asp MET Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp

5

10

15

ctc cca ggt gcc aaa tgt

66

Leu Pro Gly Ala Lys Cys

20

<210> 69

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VL-1

<400> 69

atggacatga gggccccgc tcagctcctg gggctcctgc tgctctggct cccaggtgcc 60

aaatgtgaca tccagatgac ccagtctcct tccacctgt ctgcatctat

110

<210> 70

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VL-2

<400> 70

ggagtttagg ggctttccct ggcttctgct gataccaggc caaccagtga taaataccct 60
cgctggcccc gcaggtgatg gtgactctgt ctccaataga tgcagacagg 110

<210> 71

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VL-3

<400> 71

aagcccctaa actcctgatc tataaggcct ctagttagc cagtggggcc ccatcaaggt 60
tcagcggcag tggatctggg acagatttca ctctacccat cagcagcctg 110

<210> 72

<211> 103

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VL-4

<400> 72

tttgatctcc agcttgggcc ctccgcgaa agtgagcgga taattactat attgttggca 60
gtaataagtt gcaaaatcat caggctgcag gctgctgatg gtg 103

<210> 73

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VL-S, PCR primer

<400> 73

ttcaagcttc caccatggac atgagggtcc cc 32

<210> 74

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5VL-A, PCR primer

<400> 74

tctagatcc actcacgttt gatctccagc ttggt 35

<210> 75

<211> 415

<212> DNA

<213> Human

<220>

<221> CDS

<222> (12)... (398)

<223> HEF-12B5H-g kappa. 12-398 peptide

<400> 75

aagcttcac c atg gac atg agg gtc ccc gct cag ctc ctg ggg ctc ctg 50

Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu

1

5

10

ctg ctc tgg ctc cca ggt gcc aaa tgt gac atc cag atg acc cag tct 98

Leu Leu Trp Leu Pro Gly Ala Lys Cys Asp Ile Gln Met Thr Gln Ser

15	20	25	
cct tcc acc ctg tct gca tct att gga gac aga gtc acc atc acc tgc	146		
Pro Ser Thr Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys			
30	35	40	45
cgg gcc agc gag ggt att tat cac tgg ttg gcc tgg tat cag cag aag	194		
Arg Ala Ser Glu Gly Ile Tyr His Trp Leu Ala Trp Tyr Gln Gln Lys			
	50	55	60
cca ggg aaa gcc cct aaa ctc ctg atc tat aag gcc tct agt tta gcc	242		
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Ala			
	65	70	75
agt ggg gcc cca tca agg ttc agc ggc agt gga tct ggg aca gat ttc	290		
Ser Gly Ala Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe			
	80	85	90
act ctc acc atc agc agc ctg cag cct gat gat ttt gea act tat tac	338		
Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr			
	95	100	105
tgc caa caa tat agt aat tat ccg ctc act ttc ggc gga ggg acc aag	386		
Cys Gln Gln Tyr Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys			
110	115	120	125
ctg gag atc aaa cgtgagtgga tcttaga			415
Leu Glu Ile Lys			

<210> 76

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> FLAG tag sequence

<400> 76

gac tac aag gat gac gac gat aag 24

Asp Tyr Lys Asp Asp Asp Asp Lys

5

<210> 77

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5-S, PCR primer

<400> 77

atagaattcc accatggagt ttggctgag c 31

<210> 78

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> HuVHJ3, PCR primer

<400> 78

tgaagagacg gtgaccattg tccc 24

<210> 79

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> RhuJH3, PCR primer

<400> 79

ggacaatggt caccgtctct tcaggtgg 28

<210> 80

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> RhuVK1, PCR primer

<400> 80

ggagactggg tcacttgat gtccgatccg cc 32

<210> 81

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> HuVK1.2, PCR primer

<400> 81

gacatccaga tgacceagtc tcc 23

<210> 82

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> 12B5F-A, PCR primer

<400> 82

attgcggccg cttatcactt atcgtcgtca tcctttagt ctttgatctc cagcttgg 59

<210> 83

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Linker amino acid sequence and nucleotide sequence

<400> 83

ggt ggt ggt ggt tcg ggt ggt ggt ggt tcg ggt ggt ggc gga tcg 45

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

5

10

15

<210> 84

<211> 823

<212> DNA

<213> Human

<220>

<221> CDS

<222> (12)... (809)

<223> sc12B5, Single chain Fv

<400> 84

aagcttccac c atg gag ttt ggg ctg agc tgg gtt ttc ctc gtt gct ctt 50

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu

1

5

10

tta aga ggt gtc cag tgt cag gtg cag ctg gtg cag tct ggg gga ggc 98

Leu Arg Gly Val Gln Cys Gln Val Gln Leu Val Gln Ser Gly Gly Gly

15	20	25	
ttg gtc cgg ccc ggg ggg tcc ctg agt ctc tcc tgt gca gtc tct gga	146		
Leu Val Arg Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Val Ser Gly			
30	35	40	45
atc acc ctc agg acc tac ggc atg cac tgg gtc cgc cag gct cca ggc	194		
Ile Thr Leu Arg Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly			
	50	55	60
aag ggg ctg gag tgg gtg gca ggt ata tcc ttt gac gga aga agt gaa	242		
Lys Gly Leu Glu Trp Val Ala Gly Ile Ser Phe Asp Gly Arg Ser Glu			
	65	70	75
tac tat gca gac tcc gtg cag ggc cga ttc acc atc tcc aga gac agt	290		
Tyr Tyr Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Ser			
	80	85	90
tcc aag aac acc ctg tat ctg caa atg aac agc ctg aga gcc gag gac	338		
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp			
	95	100	105
acg gct gtg tat tac tgt gcg aga gga gca cat tat ggt ttc gat atc	386		
Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala His Tyr Gly Phe Asp Ile			
110	115	120	125
tgg ggc caa ggg aca atg gtc acc gtc tcg agt ggt ggt ggt ggt tcg	434		
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser			
	130	135	140
ggt ggt ggt ggt tcg ggt ggt ggc gga tcg gac atc cag atg acc cag	482		
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln			
	145	150	155
tct cct tcc acc ctg tct gca tct att gga gac aga gtc acc atc acc	530		
Ser Pro Ser Thr Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr			
	160	165	170

tgc cgg gcc agc gag ggt att tat cac tgg ttg gcc tgg tat cag cag 578
 Cys Arg Ala Ser Glu Gly Ile Tyr His Trp Leu Ala Trp Tyr Gln Gln
 175 180 185
 aag cca ggg aaa gcc cct aaa ctc ctg atc tat aag gcc tct agt tta 626
 Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu
 190 195 200 205
 gcc agt ggg gcc cca tca agg ttc agc ggc agt gga tct ggg aca gat 674
 Ala Ser Gly Ala Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
 210 215 220
 ttc act ctc acc atc agc agc ctg cag cct gat gat ttt gca act tat 722
 Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr
 225 230 235
 TAC TGC CAA CAA TAT AGT AAT TAT CCG CTC ACT TTC GGC GGA GGG ACC 770
 Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr
 240 245 250
 aag ctg gag atc aaa gac tac aag gat gac gac gat aag tgataagcgg c 820
 Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp Lys
 255 260 265
 cgc 823

<210> 85

<211> 114

<212> PRT

<213> Human

<400> 85

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Tyr
 20 25 30
 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60
 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Phe Ser Leu
 65 70 75 80
 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg Gly Thr Met Val Thr Val
 100 105 110
 Ser Ser

<210> 86

<211> 342

<212> DNA

<213> Human

<400> 86

caggtgcagc tgcagcagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
 acctgcactg tctctggtga ctccatcagt agttactact ggagctggat tggcagccc 120
 ccaggaagg gactggagtg gattgggtat atctattaca gtgggagcac caactacaac 180
 cctccctca agagtcgagt caccatatca gtagacacgt ccaagagcca gttctccctg 240
 aagctgagct ctgtgaccgc cgcagacacg gccgtgtatt actgtgcgag agggcggtac 300
 ttogatgtct ggggccgtgg caccatggtc actgtctcct ca 342

<210> 87

<211> 57

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)... (57)

<223> reader sequence

<308> GenBank No. AF062252

<400> 87

atg aaa cat ctg tgg ttc ttc ctt ctc ctg gtg gca gct ccc aga tgg 48

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp

1

5

10

15

gtc ctg tcc

57

Val Leu Ser

<210> 88

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VH1

<400> 88

atgaaacatc tgtggttctt ccttctcctg gtggcagctc ccagatgggt cctgtcccag 60

gtgcagctgc agcagtcggg cccaggactg gtgaagcctt cggagaccct

110

<210> 89

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VH2

<400> 89

acccaatcca ctccagtccc ttcctgggg gctgccgaat ccagctccag tagtaactac 60
tgatggagtc accagagaca gtgcaggtga gggacagggt ctccgaagc 110

<210> 90

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VH3

<400> 90

tggagtggat tgggtatata tattacagtg ggagcaccaa ctacaacccc tccctcaaga 60
gtcagtcac catatcagta gacacgtcca agagccagtt ctcctgaag 110

<210> 91

<211> 114

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VH4

<400> 91

tgaggagaca gtgaccatgg tgccacggcc ccagacatcg aagtaccgcc ctctgcaca 60
gtaatacacg gccgtgtctg cggcggtcac agagctcagc ttcagggaga actg 114

<210> 92

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VHS, PCR primer

<400> 92

ttcaagcttc caccatgaaa catctgtgt tc 32

<210> 93

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VHA, PCR primer

<400> 93

ttgggatcca ctcacctgag gagacagtga ccat 34

<210> 94

<211> 426

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (12)... (417)

<223> 12E10H, H chain V region

<400> 94

aagcttcac c atg aaa cat ctg tgg ttc ttc ctt ctc ctg gtg gca gct 50

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala

<212> PRT

<213> Mus

<400> 95

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
 1 5 10 15
 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
 20 25 30
 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
 35 40 45
 Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
 50 55 60
 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg
 85 90 95
 Ser Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
 100 105 110

<210> 96

<211> 330

<212> DNA

<213> Mus

<400> 96

tcctatgtgc tgactcagcc accctcgggtg tcagggtctc ctggacagtc gatcaccatc 60
 tcttgcaactg gaaccagcag tgacgttggg ggttataact atgtctcctg gtaccaacag 120
 caccaggca aagcccccaa actcatgatt taigagggca gtaaaccgcc ctcaggggtt 180

tctaategct tctctggctc caagtctggc aacaaggcct ccctgaccat ctctgggctc 240
 caggctgagg acgaggctga ttattactgc agtcatata caaccagaag cactcgggtg 300
 ttcggcggag ggaccaagct gaccgtccta 330

<210> 97

<211> 57

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)... (57)

<223> reader sequence

<310>

<400> 97

atg gcc tgg acc gtt ctc ctc ctc ggc ctc ctc tct cac tgc aca ggc 48

Met Ala Trp Thr Val Leu Leu Leu Gly Leu Leu Ser His Cys Thr Gly

1 5 10 15

tct gtg acc 57

Ser Val Thr

<210> 98

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VL1, PCR primer

<400> 98

atggcctgga cgttctct cctcggcctc ctctctcaact gcacaggctc tgtgacctcc 60

tatgtgctga ctcagccacc ctcggtgtca gggctcctg gacagtcgat 110

<210> 99

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VL2, PCR primer

<400> 99

tcatgagttt gggggctttg cctgggtgct gttggtacca ggagacatag ttataaccac 60

caacgtcact gctggttcca gtgcaggaga tggatgacga ctgtccagga 110

<210> 100

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VL3, PCR primer

<400> 100

ccccaaact catgatttat gagggcagta aacggcctc aggggtttct aatcgcttct 60

ctggtccaa gtctggcaac acggcctccc tgaccatctc tgggtccag 110

<210> 101

<211> 102

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VL4, PCR primer

<400> 101

taggacggtc agcttggtcc ctccgccgaa cacccgagtg cttctggttg tatatgagct 60
gcagtaataa tcagcctcgt cctcagcctg gagcccagag at 102

<210> 102

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VLS, PCR primer

<400> 102

atcaagcttc caccatggcc tggaccgttc t 31

<210> 103

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10VLA, PCR primer

<400> 103

ctaggatecg ggctgacctt ggacggtcag cttggt 36

<210> 104

<211> 387

<212> DNA

<213> Mus

<220>

<221> CDS

cta

Leu

<210> 105

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)... (24)

<223> FLAG, reader sequence

<400> 105

gac tac aag gat gac gac gat aag 24

Asp Tyr Lys Asp Asp Asp Asp Lys

<210> 106

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10S, PCR primer

<400> 106

tatgaattcc accatgaaac atctgtggtt 30

<210> 107

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> DB2, PCR primer

<400> 107

taggagctac cgctccacc tgaggagaca gtgacat 38

<210> 108

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> DB1, PCR primer

<400> 108

gtctctcag gtggaggcgg tagctcctat gtctgactc agcc 44

<210> 109

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> 12E10FA, PCR primer

<400> 109

attggggccg cttatcactt atcgtcgtca tcctttagt ctaggacggc cagcttgg 59

<210> 110

<211> 792

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (11)... (778)

<223> 12E10, Single chain Fv

<400> 110

gaattccacc atg aaa cat ctg tgg ttc ttc ctt ctc ctg gtg gca gct 49

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala

1 5 10

ccc aga tgg gtc ctg tcc cag gtg cag ctg cag cag tcg ggc cca gga 97

Pro Arg Trp Val Leu Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Gly

15 20 25

ctg gtg aag cct tcg gag acc ctg tcc ctc acc tgc act gtc tct ggt 145

Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly

30 35 40 45

gac tcc atc agt agt tac tac tgg agc tgg att cgg cag ccc cca ggg 193

Asp Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly

50 55 60

aag gga ctg gag tgg att ggg tat atc tat tac agt ggg agc acc aac 241

Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn

65 70 75

tac aac ccc tcc ctc aag agt cga gtc acc ata tca gta gac acg tcc 289

Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser

80 85 90

aag agc cag ttc tcc ctg aag ctg agc tct gtg acc gcc gca gac acg 337

Lys Ser Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr

95 100 105

gcc gtg tat tac tgt gcg aga ggg cgg tac ttc gat gtc tgg ggc cgt 385

Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg

110 115 120 125

ggc acc atg gtc act gtc tcc tca ggt gga ggc ggt agc tcc tat gtg 433
 Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Ser Ser Tyr Val
 130 135 140
 ctg act cag cca ccc tcg gtg tca ggg tct cct gga cag tcg atc acc 481
 Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr
 145 150 155
 atc tcc tgc act gga acc agc agt gac gtt ggt ggt tat aac tat gtc 529
 Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val
 160 165 170
 tcc tgg tac caa cag cac cca ggc aaa gcc ccc aaa ctc atg att tat 577
 Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr
 175 180 185
 gag ggc agt aaa cgg ccc tca ggg gtt tct aat cgc ttc tct ggc tcc 625
 Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser
 190 195 200 205
 aag tct ggc aac acg gcc tcc ctg acc atc tct ggg ctc cag gct gag 673
 Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu
 210 215 220
 gac gag gct gat tat tac tgc agc tca tat aca acc aga agc act cgg 721
 Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Ser Thr Arg
 225 230 235
 gtg ttc ggc gga ggg acc aag ctg acc gtc cta gac tac aag gat gac 769
 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Asp Tyr Lys Asp Asp
 240 245 250
 gac gat aag tgataagcgg ccgc 792
 Asp Asp Lys
 255

<210> 111

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> sc4.3, PCR primer

<400> 111

ggtggtgag tcagcacata ggacgatccg ccaccacccg aaccaccacc acccgaacca 60

cc

62

<210> 112

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> scl.3, PCR primer

<400> 112

gcaccatggt cactgtctcc tcaggtggtg gtggttcggg tgggtggtgt tcgggtggtg 60

g

61

<210> 113

<211> 822

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (11)... (807)

<223> scl2E10, Single chain Fv

<400> 113

gaattccacc atg aaa cat ctg tgg ttc ttc ctt ctc ctg gtg gca gct 49

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala

1 5 10

ccc aga tgg gtc ctg tcc cag gtg cag ctg cag cag tcg ggc cca gga 97

Pro Arg Trp Val Leu Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Gly

15 20 25

ctg gtg aag cct tcg gag acc ctg tcc ctc acc tgc act gtc tct ggt 145

Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly

30 35 40 45

gac tcc atc agt agt tac tac tgg agc tgg att cgg cag ccc cca ggg 193

Asp Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly

50 55 60

aag gga ctg gag tgg att ggg tat atc tat tac agt ggg agc acc aac 241

Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn

65 70 75

tac aac ccc tcc ctc aag agt cga gtc acc ata tca gta gac acg tcc 289

Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser

80 85 90

aag agc cag ttc tcc ctg aag ctg agc tet gtg acc gcc gca gac acg 337

Lys Ser Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr

95 100 105

gcc gtg tat tac tgt gcg aga ggg cgg tac ttc gat gtc tgg ggc cgt 385

Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg

110 115 120 125

ggc acc atg gtc act gtc tcc tca ggt ggt ggt ggt tcg ggt ggt ggt 433

Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

130 135 140

